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Abstract 
Psoriasis is a common, debilitating systemic inflammatory disorder that is 
characterised by sharply demarcated, thick, erythematous scaly skin 
plaques. Such plaques commonly appear on skin that is subjected to 
repeated tensile trauma, such as elbows, knees and flexures. The 
mechanism by which these inflammatory lesions are spatially restricted is 
not known and yet knowledge of this could be of critical importance for our 
understanding of this disease. Chemokines are the principal regulators of 
leukocyte migration and play a critical role in the initiation and maintenance 
of inflammation. The atypical chemokine receptor ACKR2 (formerly D6) binds 
inflammatory CC-chemokines, but does not signal upon ligand binding; 
instead ACKR2 internalises and helps degrade such chemokines, after which 
it continues to cycle back to the cell surface. ACKR2 acts, through this 
mechanism, as a high-capacity scavenger of chemokines, and plays an 
important role in regulating inflammation. It is known that ACKR2 expression 
is high in unaffected skin of patients with psoriasis (remote from 
inflammatory plaques) and concurrently deficient in the plaques themselves. 
Additionally, human studies have shown that simple skin trauma in psoriasis 
patients causes a reduction in cutaneous ACKR2 expression at the site of 
trauma. However, the functional significance and the molecular mechanism 
by which it occurs are not understood. This thesis explored the role of ACKR2 
in the spatial restriction of psoriasiform inflammation and the molecular 
mechanisms for its differential regulation. Through the use of disease 
relevant mouse models, primary human cell cultures and novel cell migration 
assays, the results presented here show that localised psoriasiform 
inflammation upregulates ACKR2 in remote tissues through the systemic 
release of cytokines. This remotely upregulated ACKR2 expression protects 
tissues from the further spread of inflammation. This protective effect is 
mediated by stromally expressed ACKR2 that acts to control inflammatory T-
cell positioning within the skin. Tensile trauma of keratinocytes however, 
acted to reduce ACKR2 expression in the context of inflammation, which in 
turn provides a novel mechanism for the well-characterised phenomenon 
that occurs in psoriasis (and a range of skin condition) termed 
‘koebnerisation’. Koebnerisation refers to the phenomenon by which 
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relatively simple skin trauma induces the development of disease-specific 
skin lesions. Furthermore, this thesis defines novel disease-relevant 
regulators of ACKR2 expression. In silico analyses identified psoriasis-
associated microRNAs that bound to the 3’-UTR of ACKR2, and reduced its 
expression at transcriptional and protein level. Importantly, trauma of 
keratinocytes induced ACKR2 downregulation concurrent with a substantial 
and significant increase in the expression of the identified ACKR2 targeting 
microRNAs. Together, this thesis defines a novel mechanism by which 
ACKR2-mediated regulation of chemokine function, cutaneous trauma, 
microRNAs and systemic cytokines, co-ordinately modulate the 
predisposition of remote tissue sites to the development of new lesions. 
Importantly, the results presented here have profound implications for how 
spatial restriction is imposed on inflammation. The data also highlight 
therapeutic ACKR2 induction as a plausible novel strategy for the limitation 
and treatment of psoriasiform- and potentially other forms of inflammation. 
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MHC: major histocompatibility complex 
min: minutes 
miR:  microRNA 
miRNA: microRNA 
mm: millimetre 
mRNA:  messenger RNA 
NK:  natural killer cell 
OR:  odds ratio 
PBST:  PBS with added 0.05% Tween 
pDC:  plasmacytoid dendritic cell 
PDE:  phosphodiesterase 
PI3K:  phosphatidylinositol 3-kinase 
PIP3:  phosphatidylinositol 3,4,5-triphophate 
PKC:  protein kinase C 
RBC:  red blood cell 
RNA;  ribonucleic acid 
rRNA:  ribosomal RNA 
s.c  subcutaneously 
SALT: skin-associated lymphoid tissue 
sec: seconds 
SEM: standard error of the mean 
SNP: single nucleotide polymorphism 
TBP:  TATA-binding protein 
TGF:  transforming growth factor 
Th:  T helper cell 
TLR:  toll-like receptor 
TNF:  tumour necrosis factor 
TPA:  12-O-tetradecanoylphorbol-13-acetate 
Treg: regulatory T-cell 
TRM: resident memory T-cell 
tRNA:  transport RNA 
U:  unit 
UTR:  untranslated region 
UV:  ultraviolet 
VEGF:  vascular endothelial growth factor 
WT:  wilt-type 
XMP:  xenotransplantation models of psoriasis 	 	
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1  Introduction 
 
1.1 Chemokines 
 
1.1.1 Chemokines and chemokine receptors: evolution, 
nomenclature and classification 
Chemokines are the principal regulators of leukocyte migration, and key 
regulators of inflammation (Sokol & Luster 2015). Psoriasis is considered to 
be a predominantly T-cell driven inflammatory disease and, unsurprisingly, 
chemokines play a critical role in its pathogenesis with several chemokines 
and chemokine receptors implicated (Singh et al. 2013; Di Meglio et al. 
2011).  
Chemokines are evolutionarily ancient, having first emerged over 650 million 
years ago and appear to be exclusive to vertebrates (DeVries et al. 2005). 
The name chemokine is derived from chemotactic cytokine, and comprises a 
family of over 50 small ~8-10kDa proteins, displaying significant sequence 
homology (Luster 1998; Nomiyama & Yoshie 2015). Chemokines are grouped 
into four subfamilies (summarised in Table 1.1), based on a conserved 
cysteine residue arrangement within their N-terminal; namely CC, CXC, XC, 
and CX3C, that forms the basis for the internationally approved 
nomenclature for this receptor family (DeVries et al. 2005; Zlotnik & Yoshie 
2000; Nomiyama et al. 2013; Murphy et al. 2000). CC and CXC chemokines 
are the most numerous sub-families, functioning as both regulators of 
inflammation as well as homeostasis (Griffith, Sokol & Luster 2014). For 
instance, CCL19/21 play a critical role in T-cell LN homing, whilst CCL2-5 
play a role in recruiting inflammatory cells (including T-cells, and DCs) into 
tissues such as the skin (Griffith, Sokol & Luster 2014). CXCL9/10/11 can be 
produced by inflamed keratinocytes and recruit T-cells into tissues, whereas 
CXCL1-3/5-8 regulate neutrophil trafficking (Flier et al. 2001; Sokol & Luster 
2015) (Table 1.1). 
 
 
  
SHAMS 2016 
	19 
 
 
Table 1.1 Table of chemokine-receptor interactions. 
Generated with data from (Griffith, Sokol & Luster 2014; Mabuchi et al. 
2012). Green; CXC-chemokines, Orange; CC-chemokines, Blue; XC-
chemokines, Red; XC3C-chemokines.  
Chemokine Receptor Main function(s) Suggested role 
in psoriasis 
CXCL1 CXCR2 Neutrophil trafficking Keratinocyte 
hyperproliferation 
CXCL2 CXCR2  
CXCL3 CXCR2  
CXCL4 ? Procoagulant  
CXCL5 CXCR2 Neutrophil trafficking  
CXCL6 CXCR1, CXCR2  
CXCL7 CXCR2  
CXCL8 CXCR1, CXCR2 Keratinocyte 
hyperproliferation 
CXCL9 CXCR3 Th1 response; TH1, CD8+, NK 
trafficking 
Th1/pDC trafficking 
 CXCL10 CXCR3 
CXCL11 CXCR3 
CXCL12 CXCR4 Bone marrow homing  
CXCL13 CXCR5 B cell positioning in LN  
CXCL14 ? Human macrophage skin homing  
CXCL15 ? ? (mouse only)  
CXCL16 CXCR6 NKT/ILC migration and survival Keratinocyte 
hyperproliferation, 
leukocyte trafficking 
CCL1 CCR8 Th2 and Treg migration/survival  
CCL2 CCR2 Monocyte trafficking Monocyte/ 
Macrophage/DC/Th1 
cell trafficking 
CCL3 CCR1, CCR5 Macrophage, NK cell, T-cell 
migration, T-cell-DC interactions 
Th1 cell 
chemotaxis/Monocyte
/DC chemotaxis 
CCL4 CCR5  
CCL5 CCR1, CCR3, CCR5 Th1 cell 
chemotaxis/Monocyte
/DC chemotaxis 
CCL6 ? ? (mouse only)  
CCL7 CCR2, CCR3 Monocyte mobilisation  
CCL8 CCR1, CCR2, CCR3,  
CCR5, (CCR8 mouse) 
Th2 response (skin homing in 
mice) 
 
CCL9/10 ? ?  
CCL11 CCR3 Eosinophil and basophil migration  
CCL12 CCR2 Inflammatory monocyte migration 
(mouse only) 
 
CCL13 CCR2, CCR3, CCR5 Th2 responses  
CCL14 CCR1 ?  
CCL15 CCR1, CCR3 ?  
CCL16 CCR1, CCR2, CCR5 ?  
CCL17 CCR4 Th2 responses, Treg, lung and skin 
homing 
Th1 and Th17 cell 
trafficking 
CCL18 CCR8 Th2 responses, skin homing  
CCL19 CCR7 T cell and DC homing to lymph 
nodes 
 
CCL20 CCR6 Th17 responses Th17 trafficking 
CCL21 CCR6, CCR7 T-cell and DC homing to lymph 
nodes 
 
CCL22 CCR4 Th2 response, Th2 migration, Treg 
migration 
Th1 and Th17 cell 
trafficking 
CCL23 ? ?  
CCL24 CCR3 Eosinophil/Basophil migration  
CCL25 CCR9 T-cell homing to gut, thymocyte 
migration 
 
CCL26 CCR3, CX3CR1 Eosinophil/Basophil migration  
CCL27 CCR10 T-cell homing to skin CD4+/CD8+ 
trafficking 
CCL28 CCR3, CCR10 T-cell and plasma cell homing to 
mucosa 
 
XCL1 XCR1 CD8+ presentation to DCs  
XCL2 XCR1  
CX3CL1 CX3CR1 NK, monocyte and T-cell migration Th1 cell polarisation 	
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Chemokines signal through binding to a family of 7-transmembrane spanning 
G-protein coupled receptors (GPCR). The chemokine receptors share a 
conserved (DRYLAIV) amino acid motif between the third transmembrane 
domain and the second intracellular loop, that appears to be important for 
classical intracellular signalling (Neote et al. 1994; Nibbs & Graham 2013). 
There are currently ten CC- (CCR1-10), eight CXC- (CXCR1-8), one XC- 
(XCR1), and one CX3C- (CX3CR1) known chemokine receptors, and like their 
ligands, they play a role in both inflammation and homeostasis depending on 
the context (Nibbs & Graham 2013). Both chemokine ligand- and receptor 
genes form clusters within the genome, which is in keeping with evolution 
through (at least in part) rapid gene duplications (Zlotnik & Yoshie 2012).  
With a few exceptions (e.g. CCL20 binding only CCR6), there is considerable 
chemokine ligand-receptor binding promiscuity notably amongst 
inflammatory chemokines/receptors (Zlotnik & Yoshie 2012), although 
binding only occurs within one chemokine-receptor subfamily (e.g. CC-
receptors only bind CC-ligands). Typically, one inflammatory chemokine 
binds multiple receptors, and one receptor typically binds several different 
chemokines ligands (Nibbs & Graham 2013). This receptor-ligand binding 
promiscuity allows for a sophisticated and fine-tuned system by which 
leukocyte migration is regulated. Functionally, chemokines are broadly 
either inflammatory (the most numerous grouping) or homeostatic (Luster 
1998; Zlotnik & Yoshie 2012). Chemokines play diverse roles in e.g. 
development, homeostasis, and inflammation (Nomiyama & Yoshie 2015) 
though they are, in the main, collectively considered to be principally 
regulators of leukocyte migration (Thelen 2001). Chemokines and chemokine 
receptors have evolved in parallel (e.g. CXCL12/CXCR4 pair is highly 
conserved and also found in fish). But, the evolution of ligands has been 
more rapid, leading to greater discrepancies in the number of chemokines 
between species as compared to receptors. This difference is particularly 
apparent in lower vertebrates (Bajoghli 2013). Nonetheless, the orthologous 
relationship of chemokines between species have in many cases been 
determined, thus enabling the study of specific chemokine networks in 
animal models (Nomiyama et al. 2013). 
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1.1.2 Chemokines-chemokine receptor interactions: 
intracellular signalling events; PI3K pathways 
Chemokines act on receptors expressed on a range of immune and non-
immune cells, and thereby influence cell migration and a range of other 
processes including development, angiogenesis, and oncogenesis (Rossi & 
Zlotnik 2000). Chemokine receptor activation on leukocytes may have 
several possible effects on the cell, the most typical of which (in the case of 
chemokines acting on immune cells) is induction of cell migration, which is 
also the focus of this thesis section (Rot & Andrian 2004). The typical 
chemokine receptors signal through trimeric Gαi-type G-proteins (Sokol & 
Luster 2015; Kuang et al. 1996), whilst receptors associated with Gαq and 
Gαs G-proteins do not appear to induce migration (Arai et al. 1997). GPCR 
activation is followed by dissociation of the trimeric G-protein into α and βγ 
subunits in a GTP-dependent manner, and typically the production of second 
messengers (Dohlman 2015). Whilst chemokine induced chemotaxis is 
dependent on the Gβγ rather than the Gαi subunit of Gi-proteins, there is 
also evidence for Gβγ/Gαi-independent chemotaxis-inducing signals 
triggered by activation of the Gi-protein (Neptune et al. 1999; Arai et al. 
1997). The Gβγ subunit activates phosphatidylinositol 3-kinase (PI3K), that 
plays a critical role in cell polarisation and chemotaxis (Funamoto et al. 
2002). There are several known PI3K isoforms that are expressed in 
leukocytes, and the specific isotype that mediates chemotaxis depends on 
the cell type. For instance, PI3Kγ and PI3Kδ isoforms are essential in 
macrophage and neutrophil migration respectively (Hirsch et al. 2000; Sadhu 
et al. 2003). PI3K plays a role in chemotaxis mainly (but not exclusively) 
through the generation of the second messenger phosphatidylinositol 3,4,5-
triphophate (PIP3), that induces leukocyte polarisation, F-actin accumulation 
and cell migration (Niggli 2000; So & Fruman 2012). Both PI3K and PIP3 co-
localise in the leukocyte pseudopod together with Rac, where PIP3 and Rac 
induce actin polymerisation through direct and indirect mechanisms (Rot & 
Andrian 2004). Additional pathways exist downstream from PI3K following 
chemokine-receptor activation, including 1) protein kinase B (Thelen 2001) 
and 2) activation of mitogen-activated protein kinases (MAPK), the latter of 
which appears to be dependent on PIPKγ (Bondeva 1998).  
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1.1.3 Intracellular signalling events; non-PI3K pathways 
The Gβγ subunit activates further pathways beyond PI3K upon chemokine 
receptor activation. Specifically, the Gβγ subunit plays a role in the 
activation of phospholipase C isoforms, leading to a raise in inositol-1,4,5-
triphosphate (InsP3), intracellular Ca2+ and subsequent protein kinase C 
(PKC) activation, all of which play a role in cell migration and other 
leukocyte functions (Thelen 2001). Yet further complexity is added as 
activated GPCRs do not solely act through G-proteins (e.g. interact with β-
arrestins) and as GPCR oligomerisation modulates the biological activity of 
the chemokine receptors (Dohlman 2015). Together, and as reviewed in 
detail elsewhere (Thelen 2001), chemokine-receptor binding leads to 
signalling mediated by G-protein dependent and independent mechanisms, 
leading to the activation of complex intracellular signalling cascades, 
thereby affecting migration and a broad range of other cellular processes.  
 
1.1.4 Chemokine haptotactic gradient formation 
The sequence of events leading to leukocytes entering tissues from the 
blood, involves a series of complex interactions between the leukocyte, the 
vessel wall and tissues, as reviewed elsewhere (Ley et al. 2007). The steps 
include rolling (which involves selectins), leukocyte adhesion (involves 
chemokines) and cell arrest (involves integrins and chemokines), which is 
then followed by paracellular or transcellular migration into tissue (Ley et al. 
2007). Such migratory cells generally interact not with free soluble 
chemokines, but instead with chemokines that are bound to e.g. long 
sulphated polysaccharides known as glycosaminoglycans (GAGs) (Johnson et 
al. 2005; Rot & Andrian 2004). Chemokines that regulate cell migration may 
originate from within the vessel lumen, or directly from within tissues, and 
appear on the luminal side of endothelial cells through active 
internalisation/transport, or through diffusion through intercellular 
junctions(Rot & Andrian 2004). Interactions between GAGs and the bound 
chemokine can influence the function of the chemokine, thus playing a role 
in controlling leukocyte migration and inflammation (Johnson et al. 2005). 
GAG binding can also protect the chemokine against proteolytic cleavage 
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(Ley et al. 2007), or may functionally neutralise (by sequestration) 
chemokines released by e.g. degranulating T-cells (Wagner et al. 1998).  
Chemokine solubility allows chemokine diffusion from their site of origin, 
whilst GAG binding limits the spread (Rot & Andrian 2004). However, 
chemokine-GAG binding is not random; certain chemokines bind only certain 
GAGs, which in turn constitutes a sophisticated manner in which the bound 
chemokine gradients can be spatially organised (Witt & Lander 1994). 
Chemokine-GAG binding is influenced by factors such as pH and also the 
degree to which the GAG is sulphated, which has implications for how 
migration studies are interpreted if not performed in (near)-physiological 
conditions (Singh et al. 2015).  
Chemokine binding to GAGs has been exploited therapeutically in 
experiments where non-heparan sulphate binding CXCL12 failed to promote 
migration, but instead reduced leukocyte CXCR4 expression through 
desensitisation, and thereby limited chemotaxis (O'Boyle et al. 2009). Bound 
chemokines are sensed by leukocytes (in a manner that has been likened to 
‘fingers reading braille’), and are thus believed to migrate through 
‘haptotaxis’ (Rot & Andrian 2004; Rot 1993). These gradients can be 
replicated in vitro, through e.g. high-resolution printing of immobilised 
chemotactic gradients, that are then sensed and followed by leukocytes in 
vitro (Rink et al. 2015). Importantly, the strength of leukocyte-tissue 
adhesion in situations of e.g. high shear forces is not directly due to 
chemokine-chemokine receptor ‘anchoring’. Instead, adhesion is mainly 
achieved through chemokine-induced integrin activation, that allows 
leukocyte adhesion to tissues (Laudanna et al. 2002). 
 
1.1.5 Homeostatic chemokines in skin 
Chemokines are expressed in the skin, both in inflammation and under 
homeostatic conditions. Chemokines can be produced by stromal cells, 
infiltrating leukocytes and tissue-resident immune cells. Some chemokines 
are homeostatic and are expressed in healthy skin, and play a role in 
leukocyte positioning and trafficking in health. Similarly, chemokine 
receptors, expressed in non-inflammatory contexts, govern homeostatic 
leukocyte trafficking. CCL19/21 for instance bind to CCR7 and control DC/T-
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cell trafficking to tissue draining lymphoid tissue (Braun et al. 2011). In 
addition, CXCL14 is prominently expressed by non-inflamed skin vessels in 
the superficial dermal plexus and in basal keratinocytes (KC), and has a role 
in the recruitment of DC precursors that mature into APCs(Nibbs et al. 
2007). Similarly, CCL1 is constitutively expressed in the skin 
microvasculature, and plays a role in the localisation of CCR8+ T-cells, that 
when activated can produce both IFNγ and TNFα (Nibbs et al. 2007). 
Interestingly, CCR8 (which binds CCL1) can be induced by skin-specific 
soluble factors, expressed by keratinocytes. This represents an additional 
mechanism by which T-cell positioning within the skin is regulated (McCully 
et al. 2012). Although the induction of CCR10 on T-cells has been associated 
with recruitment to the skin, this does not appear to be the case in mice 
where skin T-cells lack CCR10 expression (Homey et al. 2002). Thus, both 
CCR10 and CCR8 co-ordinate the homeostatic recruitment and tissue 
localisation of T-cells.CXCL12 meanwhile is produced by dermal DC in 
healthy skin, and may play a role in recruiting naive non-activated T-cells 
that are CXCR4+ (Pablos et al. 1999). CCL27 is expressed within the healthy 
epidermal KCs, and is thought to mediate homeostatic T-cell trafficking 
(notably CLA+ memory T-cells), and thus promote immune surveillance 
(Morales et al. 1999). 
 
1.1.6 Chemokines in inflamed skin and psoriasis  
Whilst several chemokines/chemokine receptors are expressed in healthy 
skin, the chemokine/chemokine receptors expression profile of stromal and 
infiltrating cells can differ markedly in the context of inflammation. 
Regulation of chemokine production/removal and chemokine receptor 
expression represent a sophisticated system by which leukocyte migration 
and tissue positioning is controlled (Rot & Andrian 2004).  Only very small 
amounts of inflammatory chemokines are produced under homeostatic 
conditions. However, and as reviewed elsewhere, KCs have the capacity to 
express high levels of an array of chemokines, depending on the context, 
including e.g. CCL2/5/17/20/22/27 and CXCL1/8/9/10/11/16 (Singh et al. 
2013; Flier et al. 2001; Harper et al. 2009). Cytokines can activate the 
expression of many chemokines by KC, for instance IFNγ leads to a marked 
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upregulation of CXCL9/10/11 in KCs (which attracts CXCR3 expressing cells 
such as Th1 T cells).  In comparison IL-17 leads to an upregulation of several 
chemokines that are not significantly upregulated by IFNγ, such as 
CXCL1/3/5/6/8 (attracts neutrophils) and CCL20, (attracts CCR6 expressing 
Th17 T-cells, and some DCs) (Graham & McKimmie 2006). Other cells can 
produce T-cell attracting chemokines (Sokol & Luster 2015), including DCs 
and neutrophils, thus enabling orchestration amongst several classes of 
stromal cells and leukocytes.  
In psoriasis, IL-17A, TNFα and IL-22 lead to the upregulation of CCL20 when 
injected into skin in vivo. CCL20 in turn, is a chemoattractant for CCR6 
expressing Th17 cells, which provides one mechanism whereby Th17 cells 
can amplify accumulation of further T-cells through the induction of 
chemokine production by KC (Graham & Locati 2013)(Harper et al. 2009). 
Psoriatic KCs also produce CCL5, which is believed to account for the 
accumulation of activated T-cells and memory T-cells, that eventually 
migrate from the dermis into the epidermis in psoriasis (Raychaudhuri et al. 
1999). The localisation of T-cells in the epidermis, as opposed to the dermis, 
is in turn essential to see a full psoriasiform phenotype (Conrad et al. 2007). 
Thus, the chemokine/receptor expression profile of stromal cells (e.g. KC) 
and infiltrating cells (e.g. T-cells) is dynamic, and depends on the context. It 
should however also be noted, that whilst chemokines are considered the 
principal regulators of leukocyte migration, other classes of molecules can 
act as chemoattractants, including bacterial fragments and lipids (Sokol & 
Luster 2015). 
 
 
1.2 Immune cells and chemokines 
  
1.2.1 Dendritic Cells: chemokines and DC entry into and 
localisation in skin 
DCs play a central role in skin immunity and immune surveillance, and are 
found in healthy as well as inflamed skin. Numerous DC subsets have been 
described, and they play a critical role in the initiation and establishment of 
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psoriatic plaques (as illustrated in Figure 1.1). DCs in skin express a broad 
range of chemokine receptors, and are therefore able to respond to a wide 
range of chemotactic stimuli in the event of inflammation (Sokol & Luster 
2015). For instance, studies have shown that CCR2 and CCR6 are both 
involved in DC migration into inflamed dermal and epidermal skin (Bogunovic 
et al. 2006; Merad et al. 2002). Resident DCs in healthy skin may originate 
principally from two sources; 1) DC precursor migrating into the skin, where 
they mature into DCs (Griffith, Sokol & Luster 2014) and 2) DCs proliferating 
in situ (Bogunovic et al. 2006) (McKimmie et al. 2013). Immature APCs are 
localised in both the epidermis (where they are also referred to as 
Langerhans cells (LC) and express Langerin (Valladeau et al. 2000) and in the 
dermis (Bogunovic et al. 2006). Homeostatic turnover of the epidermal LCs is 
very slow compared to DCs localised elsewhere (Miller et al. 1976). However, 
the chemokines that govern this homeostatic turnover in non-inflamed skin 
are poorly understood (Sokol & Luster 2015).  
 
1.2.2 Dendritic Cells: chemokines and trafficking to draining 
lymph nodes (LN); a CCR7-dependent process 
Chemokines regulate not only DC entry into the skin, but also their egress 
from the skin. DCs are efficient antigen-presenting cells, that can take up 
antigen in peripheral tissues, but require migration to secondary lymphoid 
tissue in order to optimally elicit an immune response (Randolph et al. 
2008). It therefore follows that to function adequately; they need to possess 
the capacity to migrate both to and from peripheral tissues. DC maturation 
can be triggered by pro-inflammatory factors e.g., TNFα and LPS, both in 
vivo and in vitro. This leads to a down-regulation of skin homing molecules 
in KCs such as E-cadherin, and a change in chemokine responsiveness in 
CD103+ DCs; whilst immature DCs are responsive to e.g. CCL3, CCL5 and 
CCL20, mature DCs down-regulate e.g. CCR6 whilst upregulating CCR7 
(Forster et al. 1999).  
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Figure 1.1 Key pathways in psoriatic plaque initiation and maintenance 
Adapted from (Lowes et al. 2014). Psoriasis pathogenesis has an early 
initiation phase, where triggers such as trauma, lead to dendritic cell (DC) 
activation. DCs, as well as T-cells and neutrophils play a key role in the 
chronic phase, that is then characterised by keratinocyte hyperproliferation, 
and the development of characteristic psoriatic plaques. Note: Leukocyte 
images from Adobe Stock Photos. 
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CCR7 is indispensable for DC migration to LN; whereas contact sensitisation 
of skin using FITC causes DC maturation and migration to lymphoid organs in 
wild type mice, DCs in FITC skin-treated CCR7-/- mice fail to migrate to 
lymph nodes (Nibbs & Graham 2013). Mature DCs respond to CCL21 gradients 
and migrate to lymphatic vessels in the tissue. CCL21 in dermis is bound to 
sulphated sugars through its C-terminus, which allows chemokine 
immobilisation and retention and it has been suggested that this enables DCs 
to follow gradient through ‘haptotaxis’ (Weber et al. 2013). Subsequent to 
lymphatic entry, DCs follow gradients of both CCL21/CCL19 to migrate into 
the lymph nodes (LN) (Sokol & Luster 2015). Chemokines produced by the T-
cell zones of both the spleen and LN are critical for both appropriate DC 
localisation within secondary lymphoid organs, and in order to mount an 
adequate immune response to e.g. infection (Sokol & Luster 2015; Marsland 
et al. 2005). Once in the LN, DCs pass through the subcapsular sinus, from 
where they migrate into the LN parenchyma and then into the T-cell zone, in 
a CCR7 dependent manner (Braun et al. 2011)(Sokol & Luster 2015). 
 
1.2.3 T-cell migration: the role of chemokines 
T-cell trafficking is a highly regulated and complex process. Naïve T-cells 
utilise CCR7 to re-circulate between the blood and lymphoid tissue, where 
they interact with DCs (Braun et al. 2011). Naïve T-cells express CCR7 and 
CXCR4, that interact with CCL21/CCL19 and CXCL12 respectively, both of 
which are presented on the luminal endothelium of the lymph node high 
endothelial venules (Griffith, Sokol & Luster 2014). Once in the LN, T-cells 
co-localise with DC in the T-cell area of the LN (Masopust & Schenkel 2013). 
T-cells can follow bound (haptotactic) chemokine gradients in the LN, rather 
than soluble gradients (Woolf et al. 2007). T-cells exit the LN through 
cortical lymphatic sinuses as effector cells if antigen presentation has taken 
place by APCs, and T-cell differentiation has taken place (Benechet et al. 
2014). Whilst CCR7 is required for homing to lymphoid tissues, T-cells 
typically downregulate CCR7 once activated and upregulate inflammatory 
chemokine receptors, allowing them to egress from the lymphoid tissue and 
migrate to inflamed peripheral tissues. In addition to CCR7, different T-cell 
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subtypes express different chemokine receptor repertoires. For instance, 
Th1 cells express CCR5, CXCR3 and CXCR6, Th17 cells express CCR4 and 
CCR6, Th2 cells CCR2, CCR8, CX3CR1 and Th22 CCR4, CCR6 and CCR10 
(Griffith, Sokol & Luster 2014). These differences highlight the dynamic 
nature of chemokine receptor expression that depends on the context and 
function of the cell (Schulz et al. 2016). For instance, CCR5 (which binds 
CCL5, that in turn is produced by a range of tissues) is expressed on Th1 
cells, and plays a role in Th1 migration into peripheral tissues (Suffee et al. 
2011). CXCL9/10/11, which bind CXCR3, are particularly important 
chemokines in regulating T-cell migration in peripheral inflamed tissues, and 
are expressed in a broad range of diseases (including rheumatoid arthritis, 
inflammatory skin disorders, cardiovascular disease), with chemokine levels 
correlating with the number of infiltrating CXCR3+ T-cells in the tissue 
(Storelli et al. 2007). In addition to regulating migration, 
chemokines/chemokine receptors aid differentiation of T-cells. For instance, 
CXCR3 is implicated in Th1 differentiation, whilst CCL3/4 are required for 
formation of pre-memory CD8+ T-cells (Schulz et al. 2016).  
Advances in in vivo imaging techniques have enabled considerable insights to 
be gained in T-cell migration (Benechet et al. 2014). Concurrently, advances 
in techniques in printing haptotactic/chemotactic gradients have enabled 
the study of cell migration in vitro in a reductionist and targeted manner 
(Rink et al. 2015). T-cells move rapidly (5-10µm/min) in an amoeboid 
pattern following extravasation and entry into the interstitial space 
(Germain et al. 2012).  
The pattern of T-cell movement in the interstitial space can be apparently 
random (Brownian motion) or random, but with intermittent rapid 
directional motion (Lévy walk). The latter pattern is proposed to cover a 
larger surface area more quickly, and possibly enables finding the specific T-
cell target more efficiently, and is believed to be supported by CXCL10 
(Weninger et al. 2014). This serves to illustrate how chemokines not only 
govern direction of leukocyte migration, but also the finer nuances of the 
type and pattern of migration, adding yet further sophistication to an 
already complex system.  
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T-cell TCR binding to the target, generally leads to cessation of migration 
(Weninger et al. 2014). It is noteworthy, that in the context of Leishmania 
major infection, T-cells that are interacting with the antigen-presenting 
cell, are capable of generating an IFNγ gradient, that extends 80µm beyond 
the site of T-cell-Antigen interaction, believed to aid amplifying anti-
parasitic responses (Müller et al. 2012; Weninger et al. 2014). The retention 
signals leading to the arrest of CD3+ cells in the epidermis are thus unknown. 
Indeed, relatively little detail is known about the chemotactic signals that 
govern interstitial T-cell migration, compared to e.g. neutrophils (Weninger 
et al. 2014). 
 
 
1.3 The atypical chemokine receptors 
 
1.3.1 Atypical Chemokine Receptor family: nomenclature and 
overview 
In addition to the signalling GPCR chemokine receptors described above, 
there exists a family of 7-transmemebrane spanning (7TM) chemokine 
receptors that do not signal in a classical G-protein dependent manner upon 
chemokine binding. Common to this family is, instead, an ability to 
internalise chemokines (Nibbs & Graham 2013) and a role in regulating 
chemokine function (Graham et al. 2012). These are thus termed Atypical 
Chemokine Receptors (ACKR) of which there are four, and which have 
recently been re-named according to a new nomenclature; ACKR1 (formerly 
DARC), ACKR2 (formerly D6 or CCBP2), ACKR3 (formerly CXCR7) and ACKR4 
(formerly CCRL1) (Nibbs & Graham 2013). Additionally, two possible ACKRs 
are still undergoing functional characterisation but have reserved names, 
with one of these (ACKR6) apparently lacking a 7TM structure (Bachelerie et 
al. 2015).  
Unlike the classical chemokine receptors that signal through G-proteins upon 
ligand binding, ACKRs are unable to elicit and sustain such signalling 
pathways, despite sharing many structural similarities with conventional 
chemokine receptors (Graham et al. 2012). Although the reason for this 
apparent inability to signal is not completely understood, structural 
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differences between classical and atypical receptors (notably in the DRYLAIV 
amino-acid motif) may account for their inability to signal through G-
proteins. Conventional chemokine receptors possess a conserved DRYLAIV 
amino-acid motif between the second intracellular loop and the third 
receptor transmembrane domain (Nibbs & Graham 2013). Specific mutations 
(substitution of ARG-126 with Asn) in the DRYLAIV motif in a classical 
chemokine receptor was shown to prevent interactions with G-proteins (and 
thus impede signalling) but enhanced interactions with β-arrestin (and thus 
internalisation) (Lagane et al. 2005). The DRYLAIV motif is entirely absent in 
ACKR1 and modified in ACKR2-4, which is in keeping with the atypical 
properties of the ACKRs being at least in part due to an absence (or 
modification) of this motif (Nibbs & Graham 2013). Although these data 
highlight a role for an intact DRYLAIV motif for adequate chemokine receptor 
signalling function, other experiments where a signalling DRYLAIV motif has 
been reinstated in ACKR2, have yielded conflicting results (Graham et al. 
2012). Indeed, notwithstanding similarities between ACKR2 and classical 
chemokine receptors, there are also significant structural differences 
outside the DRYLAIV motif in the ACKRs, that could account for differences 
in signalling upon ligand binding (Nibbs & Graham 2013).   
Importantly, whilst classic chemokine receptors are predominantly expressed 
by leukocytes and mediate cell-autonomous leukocyte migration; ACKRs are 
predominantly expressed by stromal cells, and regulate leukocyte positioning 
by scavenging chemokines from the distinct tissue microenvironments in 
which they are expressed. Indeed, although ACKRs are not directly involved 
in leukocyte migration, they all have the capacity to internalise chemokines 
in a G-protein independent manner, and are believed to ‘fine-tune’ 
chemokine gradient formation (Bachelerie et al. 2000). Through this 
internalisation, ACKRs collectively play important roles in development, 
homeostasis and inflammation (Lee et al. 2014; Townson & Nibbs 2002; Lee 
et al. 2011; Nibbs & Graham 2013).  Whilst this capability to internalise 
chemokines has led to these ACKRs sometimes simplistically being termed 
‘chemokine decoys’ the precise mechanism/context of chemokine 
internalisation, as well as the fate of the chemokine internalised, is highly 
variable and subject to complex regulatory processes (discussed below). 
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Furthermore, although the ACKRs do not appear to signal through G-proteins, 
most do have some capacity to interact with some cytoplasmic proteins e.g. 
β-arrestin, which in turn plays a role in receptor internalisation and 
scavenging (Galliera, Jala, et al. 2004). Ligand binding characteristics of the 
atypical chemokine receptors is summarised in Table 1.2. 
 
1.3.2 ACKR2: molecular mechanism of chemokine scavenging 
ACKR2  (formerly D6) is highly promiscuous and binds almost all pro-
inflammatory (but not homeostatic (Graham & Locati 2013)) CC-chemokines 
(Bonecchi et al. 2004). The first demonstration that ACKR2 binds 
inflammatory chemokines in humans (Nibbs, Wylie, Yang, et al. 1997), and in 
mice (Nibbs, Wylie, Pragnell, et al. 1997), was carried out at the University 
of Glasgow, in the Graham laboratory. However, considerable insight into  
the ability of ACKR2 to function as a putative decoy receptor, was first 
suggested by an Italian group based in Milan (Fra et al. 2003). This paper is 
the first to report chemokine scavenging by ACKR2, and thereby suggested a 
key concept in atypical-chemokine receptor biology. The mechanism that 
regulate the expression and function of ACKR2, remained undescribed for 
several years. More recent work has begun to identify inflammatory factors 
that mediate its upregulation in both stromal (Singh et al. 2012) and 
leukocyte subsets (McKimmie et al. 2008). Whilst binding occurs with high-
affinity (like other atypical chemokine receptors) ACKR2 does not signal in a 
conventional manner upon ligand binding (Nibbs, Wylie, Yang, et al. 1997; 
Borroni et al. 2013). Instead, ACKR2 functions as a scavenger of pro-
inflammatory CC-chemokines, through binding, internalising and aiding in 
the degradation of chemokines (Weber et al 2004) (summarised in Figure 
1.2). ACKR2 is localised on recycling endosomes, and is thus constitutively 
cycled between the cell surface and intracellular compartment (Weber et al 
2004). It has been shown that over 80% of ACKR2 is localised in intracellular 
vesicles at rest (Blackburn et al. 2004), whilst maintaining constant 
expression of ACKR2 on the cell surface (Galliera, Galliera, et al. 2004). 
Indeed, ligand binding of ACKR2 enhances ACKR2 mediated scavenging in a 
Rab11 dependent manner, thus providing one mechanism by which its 
activity is regulated at the post-transcriptional level (Bonecchi et al. 2008).  
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Figure 1.2 Summary of ACKR2 function. 
a) ACKR2 binds most inflammatory CC-chemokines, after which b) the 
receptor-ligand is internalised, and c) the chemokine degraded. ACKR2 then 
continues to cycle back to the cell surface, and the process repeated. 
Adapted from (Graham & McKimmie 2006)  
cytoplasm 
CC chemokines 
inflammation 
nucleus 
ACKR2 
a 
c d 
b 
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RECEPTOR LIGANDS REFERENCES 
 
ACKR1 CCL2, CCL5, 
CCL7, CCL11, 
CCL13, CCL14, 
CCL17, CXCL1, 
CXCL2, CXCL3, 
CXCL5, CXCL8, 
CXCL11 
(Gardner et al. 2004; Szabo et al. 
1995; Chaudhuri et al. 1994; Mei et 
al. 2010; Neote et al. 1994) 
ACKR2 CCL2, CCL3, 
CCL3L1, CCL4, 
CCL5, CCL7*, 
CCL8*, CCL11, 
CCL12, CCL13, 
CCL14**, CCL17, 
CCL22 
(Nibbs, Wylie, Yang, et al. 1997; 
Hansell, Schiering, et al. 2011; 
Nibbs, Wylie, Pragnell, et al. 1997; 
Bonini & Steiner 1997; Bonecchi et 
al. 2004; Savino et al. 2009; Nibbs 
et al. 1999; Fra et al. 2003) 
ACKR3 CXCL11, CXCL12 (Burns et al. 2006) 
ACKR4 CCL19, CCL21, 
CCL25, CXCL13***                                                                                                                           
(Townson & Nibbs 2002; Gosling et 
al. 2000; Watts et al. 2013)
 
Table 1.2 Chemokine binding profiles of atypical chemokine receptors. 
Chemokine binding profiles of atypical chemokine receptors (ACKRs), adapted from (Nibbs & 
Graham 2013). This table lists all the chemokines that bind mouse and/or human ACKR2, for 
which affinity measurements are known, e.g. binding affinity (Ki) or dissociation constant 
(Kd) (defined as being less than 100nM). Some of the chemokines listed are expressed in 
humans but not in mice, including CCL3L1 (has high affinity for both human and mouse 
ACKR2), CCL13, CCL14, CCL16, CCL18, CXCL6 and CXCL8 (Zlotnik & Yoshie 2012). It should 
also be noted that CCL12 is fund in mice, but not humans (Zlotnik & Yoshie 2012). In 
addition to binding profiles listed, human ACKR1 also weakly binds to the following ligands, 
CCL1, CCL8, CCL16, CCL18, CXCL4, CXCL9, CXCL10 and CXCL13 (Ki between 100nm and 1µM) 
(Gardner et al. 2004; Szabo et al. 1995; Chaudhuri et al. 1994). Unpublished observations by 
Prof Robert Nibbs (referred to in Nature Review Immunology article), indicate human ACKR2 
also weakly interacts with CCL24 and CCL26, but their affinities are not known (Nibbs & 
Graham 2013). Although ACKR2 binding affinities to all known chemokines have been 
investigated, interactions between ACKR2 and the following chemokines appear to not have 
been studied; CCL3L1, CCL24, CCL28, CXCL7, CXCL14, CXCL16 (Nibbs & Graham 2013). 
*  Human ACKR2 binds to human CCL7 and CCL8, but mouse ACKR2 does not bind to mouse 
CCL7 and CCL8 (Nibbs, Wylie, Yang, et al. 1997; Hansell, Schiering, et al. 2011). 
** CCL14 is a homeostatic chemokine present at high concentrations in the serum, which in 
inflammatory conditions is cleaved at the N-terminal to a biologically active truncated 
version that also is a high affinity ligand for ACKR2 (Savino et al. 2009). 
*** Binding of CXCL13 by ACKR4 has been reported in humans, but not in mice (Townson & 
Nibbs 2002; Gosling et al. 2000).  
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The mechanisms underpinning ACKR2 cycling have proven controversial. In 
some studies, ACKR2 cycling has been shown to be dependent on the 
receptor’s C-terminus interacting with β-arrestin (Galliera, Galliera, et al. 
2004), which is a receptor associated protein that has a role in regulating 
internalisation of a range of receptors (Ferguson et al. 1996). In contrast, 
others have suggested that internalisation is not dependent on β-arrestins 
(McCulloch et al. 2008).  
Through the use of sophisticated immunohistochemistry to label both cell-
surface ACKR2 in live cells, and labelling of endosomal compartments post-
fixation, the localisation of ACKR2 within the cell, and its ability to 
continuously recycle from the cell surface to the cytoplasm and back again, 
was characterised (Weber et al Nibbs 2004). Ligand binding is followed by 
rapid internalisation of the ACKR2-ligand complex. Subsequently, the 
chemokine dissociates from ACKR2 following vesicle acidification and is 
degraded, whilst the ACKR2 remains intact and continues to cycle to the cell 
surface where it can bind and internalise more chemokine.  Thus, ACKR2 can 
act in a semi-catalytic manner to remove inflammatory CC chemokine from 
the extracellular environment (Weber et al 2004). ACKR2 cycling requires 
both Rab4 (fast cycling) and Rab11 (slow cycling) activity, whilst constant 
levels of cell surface ACKR2 are maintained (in proportion to chemokine 
binding) through a Rab11-dependent mechanism (Bonecchi et al. 2008). 
ACKR2 function is not dependent on N-terminal glycosylation nor its state of 
phosphorylation (Galliera, Galliera, et al. 2004), nor does ligand binding 
alter the state of phosphorylation of ACKR2 (Blackburn et al. 2004). 
However, ACKR2 function (including ligand binding, internalisation, 
scavenging) is highly dependent on a conserved tyrosine motif within its N-
terminus (Hewit et al. 2014). Additionally, the ACKR2 C-terminus has been 
shown to be critical for chemokine scavenging, as removing a portion of the 
C-terminus, whilst allowing internalisation of CC-chemokines, prevents 
continued cycling and scavenging (McCulloch et al. 2008). 
 
1.3.3 ACKR2: expression patterns and disease associations  
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ACKR2 is predominantly expressed in barrier tissues, with high expression by 
lymphatic endothelial cells (LEC), both in peripheral tissue (such as gut, skin 
and lungs) secondary lymphatic tissues (Nibbs et al. 2001), healthy 
keratinocytes (Singh et al. 2012), placental tissue (where some of the 
highest expression levels of ACKR2 are found) (Nibbs, Wylie, Yang, et al. 
1997; Bonini et al. 1997) hepatocytes (Berres et al. 2009; Wiederholt et al. 
2008), but also some leukocytes such as DCs (McKimmie & Graham 2006) and 
innate B-cells (Graham & Locati 2013). Inflammatory cytokines have been 
shown to be able to upregulate the expression of ACKR2. In particular, IL-6 
and TGFβ can upregulate expression of ACKR2 in cultured primary human 
lymphatic endothelial cells (McKimmie et al. 2013), whilst IFNγ can potently 
upregulate ACKR2 expression in primary cultures of keratinocytes (Singh et al. 
2012).  
ACKR2 binds at least 12 pro-inflammatory chemokines (Nibbs & Graham 
2013), with slightly fewer ligands in mice (Graham & Locati 2013). 
Unchallenged ACKR2-/- mice are relatively indistinguishable from WT mice, 
apart from some differences in B-cell and monocyte numbers/function 
(Graham & Locati 2013). But, differences rapidly become apparent in 
response to injury and infection. ACKR2 is differentially expressed in a range 
of pathological processes, with increased expression in clinically unaffected 
skin of patients with psoriasis (Singh et al. 2012), in pulmonary macrophages 
of patients with chronic obstructive pulmonary disease (COPD) (Bazzan et al. 
2013) and in peripheral leukocytes of patients with systemic sclerosis 
(Codullo et al. 2011). Studies have also implicated ACKR2 as playing a role in 
limiting overwhelming sepsis, as in ACKR2-/- mice, pulmonary inoculation of 
Mycobacterium tuberculosis led to overwhelming systemic inflammation and 
death, in contrast to WT mice where the disease followed a considerably 
milder and more localised course (Di Liberto et al. 2008).  
ACKR2 has been shown to have a role in the development of both 
gastrointestinal and cutaneous tumour (Nibbs et al. 2007). In ACKR2 null 
mice, exaggerated pro-tumorigenic inflammation and the associated 
inflammatory cell infiltration drives the generation of papillomas in response 
to application of a carcinogen (Nibbs et al. 2007). Thus ACKR2 plays an 
important, if indirect, role as a tumour suppressor by preventing cutaneous 
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inflammation from promoting tumorigenesis (Nibbs et al. 2007). 
Furthermore, studies have shown that certain single nucleotide 
polymorphisms in the ACKR2 are associated with a more severe inflammatory 
phenotype, in hepatitis C virus associated liver inflammation (Wiederholt et 
al. 2008). ACKR2 also has a key role in in the control of lymphatic branching 
morphogenesis during embryogenesis. In this case, ACKR2 regulates 
macrophage positioning relative to developing lymphatic vessels in the 
embryo and so controls the amount of pro-angiogenic factors delivered to 
lymphatic vessels as they develop (Lee et al. 2014). ACKR2 expression 
patterns are summarised in Table 1.3. 
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Tissue / cells Reference Comments 
Keratinocyte  (Singh et al. 2012) Expressed both in non-inflamed 
skin, and in psoriatic skin. 
ACKR2 expression upregulated 
by IFNγ.   
Lymphatic endothelial cells 
(primary cultures and in situ 
staining) 
(McKimmie et al. 2013) 
(Nibbs et al. 2001) 
ACKR2 expresson upregulated 
by IL-6, IFN-γ, IFN-β, VEGF-D 
and TGF-β in vitro. In the Nibbs 
et al study, vascular tumours 
also stained positive for 
ACKR2.  
Placental tissue, trophoblasts (Madigan et al. 2010; Bonini et al. 
1997) 
ACKR2 expression is very high 
and constitutive. ACKR2 on 
primary human trophoblasts 
plays role in development and 
also during inflammation-
induced abortion (Teoh et al. 
2014). 
Haematopoietic stem cells (Nibbs, Wylie, Pragnell, et al. 
1997) 
These cells , alongside 
placental tissue, were the site 
from which ACKR2 was 
originally cloned 
Hepatocyte (Berres et al. 2009) Role in context of hepatitis C 
associated liver inflammation. 
(Wiederholt et al. 2008) 
Innate B-cells (peritoneal, 
mouse) 
(Hansell, Schiering, et al. 2011) Innate B cells are the only 
leukocyte subset in which 
ACKR2 demonstrates functional 
uptake of CCL2.  
Mouse bone marrow-derived 
dendritic cells, mast cells and 
human circulating DCs 
(McKimmie et al. 2008) Expression determined by 
qPCR, flow cytometry and IHC. 
This paper also identifies 
putative TGF-β responsive 
Smad3-binding sites in the 
mouse ACKR2 promoter.  
Secondary lymphatic tissue (Bonini et al. 1997)  
Lung (alveolar macrophages) (Bazzan et al. 2013) Expression correlates with 
degree of inflammation 
Human peripheral blood 
mononuclear cells (from 
patients with systemic 
sclerosis) 
(Codullo et al. 2011)  
THP-1 monocytic cell line  (McKimmie et al. 2008) ACKR2 downregulated by 
lipopolysaccharide and 
upregulated by TGFβ. 
Gastrointestinal tract 
(lymphatic endothelial cells 
and leukocytes) 
(Vetrano et al. 2010; Nibbs et al. 
2001) 
ACKR2 expressed in resting 
tissue and during 
inflammation. Data suggest 
reduced ACKR2 expression in 
context of colonic 
adenocarcinoma, with low 
levels correlating with 
enhanced invasiveness 
(Langenes et al. 2013). 
 
Table 1.3 Overview of ACKR2 expression. 
Overview of cells and tissues where ACKR2 expression has been 
demonstrated, including in health, in the context of inflammation and 
cancer, and in which contexts ACKR2 expression can be induced. 
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1.3.4 ACKR2: in vivo function: lymphatic endothelial cells 
ACKR2 is highly expressed in lymphatic endothelial cells (LECs) in dermal and 
mucosal tissues (Nibbs et al. 2001). Its prominent expression on LECs and its 
chemokine scavenging capacity would support a role in clearing pro-
inflammatory chemokines from inflamed tissues by scavenging chemokines 
throughout the lymphatic network (Graham & McKimmie 2006). However 
ACKR2 is not found on all lymphatic vessels, suggestive of thus far 
unidentified mechanism whereby ACKR2 expression in lymphatics is 
regulated under homeostatic conditions (Graham & Locati 2013). In ACKR2-/- 
mice, pro-inflammatory chemokines accumulate in lymphatics and are bound 
onto LECs, thereby impairing APC (and subsequently fluid) flow from 
inflamed tissues and into lymphatics. Thus, it is possible that ACKR2 enables 
the LEC surface to be kept free from bound chemokines, thus enabling 
efficient interactions between CCR7+ APCs and the CCR7 ligands expressed 
on LECs, and free flow of both cells and fluid from inflamed sites (Lee et al. 
2011). In this context, ACKR2 functions as a facilitator of leukocyte 
movement into lymphatics and the draining lymph nodes. In addition, ACKR2 
chemokine scavenging in lymphatic vessels prevents inappropriate clustering 
of cutaneous CCR2+ inflammatory myeloid cells at lymphatic vessels during 
inflammation, thus limiting egress of leukocytes from tissues into lymphatic 
vessels. Furthermore, using cell culture systems it has been shown that 
ACKR2 may control immature DC position within tissues by enabling LECs to 
discriminate between immature DCs (iDC) and mature DCs (mDC) (McKimmie 
et al. 2013). Together these data suggest that ACKR2 helps 
compartmentalise chemokine function during inflammation, enabling 
interactions between lymphatics and CCR7+ DC, whilst simultaneously 
preventing interactions with leukocytes that express inflammatory 
chemokine receptors such as CCR2.  
 
1.3.5 ACKR2: in vivo function: skin and keratinocytes 
An early study of ACKR2 in vivo function demonstrated that repeated skin 
application of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) 
to ACKR2-/- mice, led to more skin inflammation as compared to wild type 
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mice. In particular, a TNF-dependent increase of CCL3 and CXCL2 (a mouse 
homolog of CXCL8) was demonstrated, as well as an inflammatory infiltrate 
of mast cells, macrophages and T-lymphocytes that was more marked in 
ACKR2-/- mice following TPA induced skin inflammation (Jamieson et al. 
2005). Since the initial experiments, it has also been suggested that ACKR2 
may play a role in human skin disease, specifically systemic sclerosis and 
psoriasis. One study of patients with systemic sclerosis demonstrated an 
association between ACKR2 expression and skin/systemic inflammation, 
where peripheral blood leukocyte ACKR2 expression (transcript and protein) 
was found to be high, whilst circulating chemokines such as CCL2/3/4 and 
CXCL8 were also elevated (Codullo et al. 2011). Expression of ACKR2 in 
sclerotic skin is however undetermined.   
As histopathological changes observed in the above outlined TPA 
experiments bore some resemblance to those seen in human psoriasis, it was 
hypothesised that ACKR2 may be involved in the pathogenesis of psoriasis. 
Interestingly, a subsequent study showed that ACKR2 transcript expression is 
higher in unaffected skin of patients with psoriasis, compared to the 
psoriatic plaque. ACKR2 expression is however unaffected in eczema, which 
suggests that high ACKR2 expression seen in psoriasis is not a generalizable 
feature seen in all forms of inflammation. ACKR2 in psoriasis is expressed 
throughout the epidermal keratinocytes in unaffected skin where it is closely 
associated with ACKR2 ligands such as CCL2 and CCL5, but is predominantly 
expressed in the basal keratinocytes in healthy control skin. Furthermore, 
mild trauma to unaffected skin of patients with psoriasis, (in the form of 
tape stripping, that induces a degree of epidermal damage and tensile 
stretch of skin), led to a rapid down-regulation of ACKR2 transcript (Singh et 
al. 2012). In keeping with a potential role in the pathogenesis of psoriasis, it 
has been shown that ACKR2 plays a key role in the regulation of type 1 IFN-
mediated inflammatory processes (Baldwin et al. 2013), that are recognised 
as important events in early psoriasis. Furthermore, a key role for ACKR2 in 
suppressing excessive inflammation was demonstrated by studies in which 
ACKR2 was transgenically expressed in keratinocytes of mice. This led to less 
inflammation (and reduced tumorigenesis) upon TPA stimulation of skin in 
vivo (Nibbs et al. 2007). 
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1.3.6 ACKR2: in vivo function: leukocytes 
ACKR2 is expressed on a range of leukocytes, in addition to being found on 
PBLs of patients with systemic sclerosis as discussed above (Codullo et al. 
2011). ACKR2 is expressed at variable levels by monocytes, DCs, mast cells, 
myeloid progenitor cells, on megakaryocytes (McKimmie et al. 2008), as well 
as being found in platelets in systemic inflammatory disease (Codullo et al. 
2011). ACKR2 is expressed by murine plasmacytoid DCs, where it internalises 
e.g. CCL2 (Ford et al. 2014) and also by innate-like B-cells in mice, where it 
has been shown that ACKR2 can interact with, and inhibit, CXCR5 function. 
ACKR2 expression can further be utilised to distinguish between innate-like 
B-cells and other B-cell subtypes (Hansell, Schiering, et al. 2011). However, 
whilst being expressed on leukocytes the function of ACKR2 in this context is 
not understood. It has however been suggested that ACKR2-mediated 
scavenging by leukocytes in inflamed tissue, may play a role in the resolution 
phase of inflammation (McKimmie et al. 2008). Additionally, neutrophil 
expression of ACKR2 may modulate neutrophil migration in a cell 
autonomous manner (Rot et al. 2013). 
The anti-inflammatory role of ACKR2 is also apparent in solid organs, 
including the liver, where ACKR2 is expressed by hepatocytes. ACKR2-/- 
mice were more susceptible to carbon tetrachloride in an in vivo model of 
acute liver injury, with liver damage being associated with elevated 
expression of the ACKR2 ligands CCL2 and CCL5 (Berres et al. 2009). In 
contrast, in experimental colitis, lack of ACKR2 was not associated with 
measurable differences in levels of CC chemokines, but was associated an 
unexplained increase in IL-17 production by γδ T-cells (Bordon et al. 2009). 
 
1.3.7 ACKR2: regulators of expression 
Relatively little is thus far known about the molecular mechanisms that 
underpin the differential regulation of ACKR2 expression and function. 
ACKR2 expression by LECs is strongly induced by both IL-6 and IFNγ 
(McKimmie et al. 2013) and is also upregulated, albeit to a lesser degree, by 
IL-1α and IFNβ (Singh et al. 2012). Simple skin trauma in the form of tape 
stripping of clinically clear skin of patients with psoriasis (where ACKR2 
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expression is relatively high), has been shown to rapidly down-regulate 
ACKR2, though the mechanism for this is thus far unknown (Singh et al. 
2012). In myeloid cells, it has been shown that ACKR2 expression is 
downregulated by some pro-inflammatory molecules such as 
lipopolysaccharide (LPS), but upregulated by the anti-inflammatory cytokine 
TGFβ (McKimmie et al. 2008). Overall however, our understanding of how 
ACKR2 expression is regulated in vivo and in vitro remains limited. 
 
1.3.8 The Atypical Chemokine Receptor 1 
Though the Duffy blood group antigen had been known for some times and 
was known to be important for Plasmodium vivax entry into red blood cells 
(Miller et al. 1976), it is only in the past two decades that it has been 
identified as a 7-transmemberane receptor that binds both CC- and CXC 
chemokines (Neote et al. 1994; Horuk et al. 1993). Thus, it subsequently 
became known as Duffy antigen/Chemokine Receptor (DARC) and more 
recently it was again renamed ACKR1 (Nibbs & Graham 2013). ACKR1 binds 
numerous, albeit not all, pro-inflammatory CC and CXC chemokines (Hansell, 
Hurson, et al. 2011), and has a particularly high affinity for CXCL2 (e.g. 
compared to CXCL11 (Nibbs & Graham 2013). Indeed, ACKR1 binds a variety 
of CC-chemokines (CCL2, 5, 7, 11, 13, 14 and 17) and CXC-chemokines 
(CXCL1, 2, 3, 5, 6, 8, 11), as reviewed elsewhere (Nibbs & Graham 2013). As 
such, ACKR1 is unique among the atypical chemokine receptors, in being 
able to effectively bind both CC and CXC chemokines. The capacity of RBC-
expressed ACKR1 for binding chemokines released from tissues is 
considerable, and is believed to play a role in buffering and regulating 
bioavailability of circulating chemokines. In this manner, it is believed that 
ACKR1 buffering acts to ensure that leukocyte interactions with chemokines 
are at vessel endothelial cells, rather than freely in the circulation (Nibbs & 
Graham 2013).  
 
1.3.9 The Atypical Chemokine Receptor 3 
ACKR3 (formerly CXCR7) was identified as a new non-Ca2+ mobilising 
receptor that binds (with high affinity) both CXCL12 and CXCL11 and is 
expressed on a range of cell types, including endothelial cells, hepatic cells 
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(Burns et al. 2006) and heart valves (Naumann et al. 2010). From its 
discovery, it has been implicated in oncogenesis, where antagonism of 
ACKR3 was found to inhibit tumour growth in several model systems (Burns 
et al. 2006). ACKR3 acts as a scavenger for both CXCL11 and CXCL12 
(Naumann et al. 2010). Constitutive β-arrestin-dependent cycling of ACKR3 
from the surface to the intracellular compartment has been demonstrated in 
breast cancer cells, where ACKR3 was shown to facilitate the degradation 
and extracellular depletion of CXCL12 (Luker et al. 2010). ACKR3 cycling can 
however also take place without ligand binding (Naumann et al. 2010). 
Chemokine scavenging by ACKR3 has shown to be, dependent on receptor C-
terminus (Hoffmann et al. 2012), with ubiquitination being important for 
correct receptor cycling (Canals et al. 2012). Further complexity into the 
regulation of ACKR3 function is added by receptor dimerisation. 
ACKR3/CXCR4 dimerisation result in activation of β-arrestin linked signalling 
in preference over CXCR4-linked G—protein pathways (Decaillot et al. 2011). 
Although ACKR3 does not signal through classical G-protein pathways, there 
is evidence for MAP kinase pathways in a β-arrestin dependent manner 
(Rajagopal et al. 2010). 
 
1.3.10   The Atypical Chemokine Receptor 4 
ACKR4 (formerly CCX-CKR, CCR11 or CCRL1) binds to the homeostatic CC-
chemokines CCL19/21 (CCR7 ligands), and CCL25 (CCR9 ligand) (Townson & 
Nibbs 2002) and to a lesser degree to CXCL13(Gosling et al. 2000). ACKR4 is 
believed to play a role in adaptive immune processes and inflammation 
(Comerford et al. 2006; Nibbs & Graham 2013). ACKR4 is expressed in certain 
LECs in secondary lymphoid tissues (Astarita et al. 2012), and it has been 
shown that it is involved in regulating homeostatic trafficking of skin DCs to 
skin draining LNs (Heinzel et al. 2007). In the EAE model of multiple 
sclerosis, using ACKR4-/- mice it has additionally been shown that absence of 
ACKR4 is associated with a Th17 skewing (from Th1) in T-cell responses, and 
increased expression of IL-23 (Comerford et al. 2010). In keeping with a key 
role in adaptive immunity, ACKR4-/- mice also display aberrant self-
tolerance, develop a Sjögren’s-like pathology and display abnormalities in 
thymic leukocyte development (Bunting et al. 2013). There is a role for 
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ACKR4 in the formation of functional CCL21 gradients in lymph nodes, that 
facilitate DC migration (Ulvmar et al. 2014). Recent studies have also 
demonstrated ACKR4 in the the thymus, but any functional significance in 
terms of thymic development and function remains unclear (Lucas et al. 
2015). 
 
1.3.11 Chemokines as therapeutic targets 
Due to their prominent role in the regulation of leukocyte migration, it is 
perhaps surprising that there are so few approved therapies that specifically 
target chemokines/chemokine receptors. The two best examples of 
chemokine-based therapies are CCR5 blockade (Maraviroc™) for the 
treatment of HIV infection (Tan et al. 2013), and CXCR4 blockade 
(Plerixafor™) for bone marrow mobilisation (Devi et al. 2013). There have 
been no drugs licenced for use that target inflammatory chemokine 
pathways to date. This is due to a number of reasons and ultimately reflects 
our relative lack of understanding of the chemokine system in health and 
disease. Despite the two successes above, progress in therapeutic targeting 
of chemokines has been slow. Significant receptor-ligand binding promiscuity 
has led to suggestions that the chemokine system is redundant, where 
blocking one chemokine/receptor will merely be compensated by another 
chemokine/receptor. There is however evidence that true redundancy 
appears relatively uncommon; for instance CCL5 binds CCR1/3/5 but induces 
different receptor recycling in each case. Furthermore, knockout studies of 
different CCRs (with apparently ‘redundant roles’) yield specific phenotypes 
(Schall & Proudfoot 2011), and indeed, clinical trials have also shown 
efficacy when using CXCR2 blockade in COPD (Durham et al. 2016).  Thus, 
rather than being merely a function of redundancy, it has been argued the 
lack of progress in translation of advances made in chemokine biology to 
novel therapies lies in 1) inappropriate target selection in past trials (e.g. 
CCR2 as a target in rheumatoid arthritis, where it has a questionable role) 
and 2) inappropriate dosing (existing pharmacological approaches tend to 
overestimate in vivo lead compound potencies) (Schall & Proudfoot 2011). 
There exist several further potential chemokine drug targets, some of which 
show considerable promise. In the case of psoriasis, due to the high 
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expression of CCL20, targeting CCL20/CCR6 has been proposed as a 
therapeutic strategy (Mabuchi et al. 2012). Whilst there are chemokine 
targeting drugs in current development, no skin-targeting chemokine-based 
therapies have yet been licenced. It has been suggested that previous 
shortcoming in this area of drug development can be overcome in several 
different ways, including through improved target selection (by means of 
more judicious and critical use of animal models of disease), and through 
improved methodology for performing potency assays/improved dosing in 
trials (Schall & Proudfoot 2011). 
 
 
1.4 Clinical aspects of psoriasis 
 
1.4.1 Overview  
Psoriasis is a common, systemic inflammatory disorder that profoundly 
impacts those affected (Eberle et al. 2016; Di Meglio et al. 2014). It is 
typically characterised by red plaques with adherent white scale on the skin 
(Figure 1.3-4), but increasingly it is recognised as a systemic disorder 
associated with significant co-morbidities. Management of psoriasis remains 
complex and challenging. However, significant advances having been made 
in recent years in our understanding of its pathogenesis, with an increasing 
availability of therapeutic options (Di Meglio et al. 2011). 
 
1.4.2 Structure and function of skin in health and psoriasis 
There are three main compartments of skin; the outermost stratum 
corneum, the intermediary epidermis and the dermis (Figure 1.5). 
Keratinocytes (KC) are the principal cell type in the epidermis, which 
proliferate at the basal layer (superior to the basement membrane that 
separates the epidermis from the dermis). KC gene and protein expression 
changes progressively upon maturation, and as they mature different 
protein/lipid expression patterns lead to the characteristic appearance of 
the spinous and subsequently granular layer of the epidermis. KCs normally 
lose their nuclei as they continue to mature, eventually forming the 
outermost stratum corneum (composed of lipids and proteins) that protects 
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against infection, dehydration and additionally provides tensile strength. The 
stratum corneum is continually shed in health, and is replaced by 
proliferating KCs from beneath; this orderly maturation process takes some 
28 days in health. Additional cells in the epidermis include melanocytes (that 
produce melanin and account for pigmentation) as well as a range of 
immune cells (both transient and resident populations) (Clark 2015). 
Normally, there is a degree of undulation forming shallow broad based 
‘waves’ parallel to the skin surface at the dermo-epidermal junction (known 
as rete ridges), thought to confer additional structural integrity. The dermis 
that lies beneath the epidermis in turn, is predominantly composed of 
extracellular-matrix-producing fibroblasts, and is the compartment in which 
the majority of skin appendages are found, including sweat glands, 
sebaceous glands, hair follicles, loops of blood vessels and lymphatic vessels.  
Whilst KC proliferation/maturation is a relatively ordered process in health, 
in psoriasis, KC proliferation is much more rapid. The maturation is 
accelerated many-fold to approximately 4 days (compared to 28 healthy 
skin) (Lowes et al. 2014). Through this accelerated turnover (summarised in 
Figure 1.5), the epidermis is thickened (acanthosis; accounts for the 
thickening of skin and thus plaque formation), nuclei are retained high in the 
epidermis (parakeratosis), the stratum corneum is thickened with the 
haphazard cross linking of keratin (hyperkeratosis, which accounts for the 
scaling that characterised psoriasis, and a reduced barrier function), the 
rete ridges are elongated/deeper, and blood vessels dilated and more 
numerous (accounting for the redness of plaques) (Nestle, Kaplan, et al. 
2009). Additionally, Munro’s microabscesses (neutrophil filled cavities in the 
stratum corneum) and Kogoj Pustules (neutrophil filled cavities in the 
epidermis) are seen, as is a lymphocyte infiltrate, notably in the epidermis 
(Lowes et al. 2014).  
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Figure 1.3 Typical psoriatic plaques 
Typical psoriatic lesions at elbows, demonstrating raised, well-demarcated 
erythematous plaques, with characteristic silver scale. Photograph from 
Adobe Stock Photos. 
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Figure 1.4 Anatomical sites typically involved with psoriasis. 
Image indicated sites frequently involved in psoriasis, which tend to be more 
common in skin flexures (e.g. natal cleft), and at sites of repeated tensile 
trauma (e.g. elbows and knees). Human figure from Adobe Stock Photos. 
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Figure 1.5 Schematic representation of psoriatic plaque development. 
a) normal skin, displaying keratinocyte maturation into distinct epidermal 
layers, with an ordered basket weave stratum corneum b) psoriatic skin, 
with epidermal thickening, retention of nuclei is stratum corneum 
(parakeratosis), and elongation of rete ridges c) comparison of whole skin 
including dermis, in normal and psoriatic skin.  
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1.4.3 Diagnosing psoriasis 
The clinical history and clinical appearance of psoriasis is usually sufficiently 
typical, that a clinical diagnosis can be made in most patients (Lebwohl 
2003). A diagnostic skin biopsy is required only in exceptional cases, where 
the appearance is atypical and significant doubt persists over the underlying 
diagnosis. The first accurate clinical description of psoriasis is attributed to 
Robert Willan in 1808 (Griffiths & Barker 2007), although it took another 
three decades before a firm distinction was made between psoriasis and 
leprosy (Nestle, Kaplan, et al. 2009). Despite refinements in our 
understanding of psoriasis in modern times, the physical manifestations of 
psoriasis remain a source of misconceptions among the public, which can 
cause a profound degree of social stigmatisation and suffering for patients 
with psoriasis (Halioua et al. 2015).  
Despite the clinical appearance of psoriasis being well characterised for over 
two centuries, it is only in recent years that significant advances have been 
made in our understanding of the molecular and cellular basis of psoriasis 
pathogenesis, and how genetic and environmental factors interact in the 
establishment of psoriatic lesions (Di Meglio et al. 2014). Several clinical 
subtypes of psoriasis have been described, the most common of which 
include psoriasis vulgaris (80% of cases), guttate psoriasis (10% of cases), 
pustular psoriasis, erythrodermic psoriasis (each under 3% of cases) and 
palmo-plantar pustulosis (Biondi Oriente et al. 1989). Sub-classification can 
be clinically meaningful, as prognosis and treatment responses do vary 
between many of these subtypes (Di Meglio et al. 2014). The current 
classification system is based on physical appearance, though molecular 
insights gained in recent years suggest there are important differences in 
pathogenesis subtypes (Di Meglio et al. 2014). With an increasing 
understanding of the molecular mechanisms that underpin psoriasis, it is 
likely that the way we classify psoriatic sub-types, and choose treatments, 
may change in the future. Transcriptomic analysis of psoriatic subtypes 
already suggest there are distinct gene expression patterns for different 
subtypes, although the clinical and therapeutic significance of these 
differences remain to be fully elucidated (Ainali et al. 2012). For example, a 
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specific mutation in IL36RN, a member of the IL-1 family, has been recently 
identified as being causative in certain familial forms of generalised pustular 
psoriasis, which has highlighted IL-1 blockade as a potential therapeutic 
strategy in that patient cohort (Onoufriadis et al. 2011).  
Whilst psoriasis is typically diagnosed on clinical grounds, several co-
morbidities (e.g. metabolic syndrome, hypertension, arthritis) are associated 
with psoriasis and must also be considered. Therefore, guidelines suggest 
screening for diabetes, arthritis and determining the body-mass index in all 
patients diagnosed with psoriasis, with further screening being warranted 
depending on the individual’s risk factors and other co-morbidities (Paul et 
al. 2010). 
 
1.4.4 Features of clinical variants of psoriasis 
The most common variant of psoriasis is psoriasis vulgaris (some 80-90% of 
cases), that is characterised by scaly, erythematous, sharply demarcated 
plaques, that have a particular predilection for extensor surfaces (e.g. 
elbows, knees), the scalp, buttocks, genital skin and umbilicus (Griffiths & 
Barker 2007) (Figure 1.4). Plaques are typically symmetrically distributed 
and affect certain body sites more frequently, though they can affect any 
site (Di Meglio et al. 2014) (Figure 1.4). Though the clinical manifestations of 
psoriasis are generally dynamic over time, individual established plaques 
tend to remain static, and are often persistent unless treated (Ayala 2007). 
Guttate psoriasis is a relatively common psoriasis variant (10% of cases 
(Biondi Oriente et al. 1989) that typically occurs in children, adolescents and 
young adults. It is characterised by small (typically around 5mm in diameter) 
drop-like psoriatic plaques (Latin; gutta = droplet), which often appear 
acutely and occurring some 2-4 weeks following a Strepcotococcal infection 
(Griffiths & Barker 2007). T-cell clones have been identified in both the 
tonsils and skin in this variant that are homologous, in keeping with cross 
reactivity (Diluvio et al. 2006). Guttate psoriasis is often self-limiting, and 
responds particularly well to e.g. UV therapy and/or topical treatments, 
though it can on rare occasions progress to a chronic form of psoriasis 
(Lebwohl 2003; Di Meglio et al. 2014). 
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Erythrodermic psoriasis is characterised by widespread erythema (typically 
affecting >75% of the body surface area), can lead to haemodynamic collapse 
and death (Lebwohl 2003). Generalised pustular psoriasis (GPP) too is a 
potentially fatal variant (also known as von Zumbush psoriasis in older 
literature), that is characterised by sterile, neutrophil predominant pustules 
and severe systemic features (e.g. fever) (Di Meglio et al. 2014). It is 
relatively rare, accounting for less than 3% of psoriasis cases (Biondi Oriente 
et al. 1989). Both erythrodermic psoriasis and GPP are most commonly 
triggered by withdrawal of systemic corticosteroids, which are therefore 
generally avoided in psoriasis management (Lebwohl 2003), but flares can 
also occur in response to triggers such as pregnancy, drugs and infection 
(Ayala 2007). There is mounting evidence for GPP being significantly 
different from other types of psoriasis. Mutations have been identified in the 
IL36RN gene in a minority of affected families (Onoufriadis et al. 2011; 
Marrakchi et al. 2011), though there is  likely also significant contribution by 
other, hitherto undetermined genes (Di Meglio et al. 2014). Such genetic 
differences may explain, at least in part, long-standing clinical observations 
that GPP patients respond poorly to anti-psoriatic therapies such as TNF-
blocking monoclonal antibodies (Di Meglio et al. 2014). 
There are also other subtypes that are frequently described, which include; 
palmo-plantar pustulosis, nail psoriasis, seborrhoeic psoriasis and flexural 
psoriasis (Ayala 2007). Some have features suggestive of them being distinct 
disease entities (e.g. palmo-plantar pustulosis), whilst others likely 
represent a specific focal manifestation of a psoriatic variant (e.g. nail 
psoriasis). 
 
1.4.5 Quantification of disease severity 
Psoriasis is a complex multi-factorial disease, thus making quantification of 
its severity challenging. Presently, the Psoriasis Area Severity Index (PASI) is 
the most common and well-established means of quantification used in the 
clinic and gives a score between 0=no disease to 72=severe disease 
(Fredriksson & Pettersson 1978). This is a widely used and well validated 
scoring system, that quantifies the severity of the physical manifestation of 
psoriasis, and takes into account 1) the percentage of body covered, 2) the 
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degree of erythema (redness), 3) skin thickening and 4) scaling. However, as 
the impact of psoriasis on the psycho-social well-being of the patient can be 
profound, the PASI score on its own would give an incomplete picture of the 
severity of disease. Hence, it is also common to quantify the psycho-social 
impact of psoriasis using quality-of-life questionnaires, in particular the 
well-established Dermatology Life Quality Index (DLQI), that is frequently 
performed alongside the PASI (Paul et al. 2010). These quantitative scores 
are frequently used both in a research and clinical setting, to determine 
whether patients are eligible for certain categories of treatment, and to 
quantify/assess treatment response over time. Indeed, national treatment 
guidelines (such as the British Association of Dermatologists guidelines for 
the treatment of psoriasis) have set criteria for both PASI and DLQI scores, 
before biological agents should be considered (Smith et al. 2009). In the 
research setting, the gold-standard marker of improvement in clinical trials 
is the PASI75 that is defined as the percentage of trial participants that 
display a 75% improvement in their PASI score (Papp et al. 2005). With 
increasing efficacy of modern therapies however, some advocate that higher 
response categories, such as the PASI90 would be more appropriate 
(percentage of participants that display a 90% improvement in their PASI 
score) (Puig 2015). 
 
 
1.5 Treatment of psoriasis 
 
1.5.1 Principles of treating psoriasis 
There are no curative therapies for psoriasis. Treatments aim to 1) lessen 
the appearance of skin manifestations 2) improve psycho-social well-being 
and more recently 3) prevent/manage co-morbidities. Psoriasis pathogenesis 
is complex, and it follows that its management is similarly multi-faceted. 
The precise choice of treatment needs to be personalised to the individual 
circumstances of the patient, the type of psoriasis and the severity of 
disease. As a T-cell driven (notably Th17/Th1) disorder, as expected, the 
most efficacious treatments alter T-cell associated immune processes. Milder 
disease is frequently controlled with topical treatment, whilst phototherapy 
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and systemic agents are required for more severe/refractory disease (Di 
Meglio et al. 2014) (treatment options summarised in Table 1.4). 
Frequently, it becomes necessary to combine different treatment modalities 
for optimal effect, e.g. using topical coal tar plus UVB (the Goeckerman 
regimen) (Lebwohl 2003; Bailey et al. 2012; Gustafson et al. 2012), and 
retinoids combined with UV (Almutawa et al. 2013). Furthermore, the 
precise choice of therapy will also depend on co-existing co-morbidities. For 
instance some systemic anti-TNFα directed biologicals and PDE4 antagonists 
would also treat any co-existing psoriatic arthritis, whilst e.g. topical 
treatments/phototherapy do not have any effect on co-morbidities. For 
limited or localised disease, it is common for topical treatments to be the 
first line choice (Leonardi et al. 2015; Lebwohl 2003). In contrast, more 
severe and/or widespread disease (especially where topical agents have 
failed) warrant the use of phototherapy and/or systemic agents to achieve 
disease control (Di Meglio et al. 2014). The individual patients’ needs are 
also dynamic over time, and the treatment choice must reflect these 
changes (e.g. spontaneous regression with old age), and the life events 
applicable to the patients (e.g. avoidance of teratogenic retinoids in women 
of childbearing age). 
 
1.5.2 Biological agents 
Numerous biological agents are used in psoriasis (Table 1.4), with a meta-
analysis showing some of the most efficacious ones for induction of remission 
as being infliximab, adalimumab and ustekinumab (Menter et al. 2008; Papp 
et al. 2005; Baerveldt et al. 2013; Schmitt et al. 2014). Infliximab is a 
chimeric human-mouse IgG1 monoclonal antibody that binds and neutralises 
both soluble and membrane bound TNFα (A. B. Gottlieb et al. 2003), and 
was initially licenced for inflammatory bowel disease. Early case-reports 
indicated patients who received infliximab for inflammatory bowel disease, 
unexpectedly noted a rapid improvement in their concurrent psoriasis (Oh et 
al. 2000). Subsequent studies in patients with psoriasis demonstrated a rapid 
normalisation in skin histology, with normalisation of skin thickness and a 
significant reduction in epidermal CD3+ T-cells, 2 weeks after administration 
of infliximab (A. B. Gottlieb et al. 2003).  
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Table 1.4 Common anti-psoriasis therapies currently used. 
Information collated from (Eberle et al. 2016; Di Meglio et al. 2014). The 
most common treatment modalities for the treatment of psoriasis 
summarised 
  
Category Agent Comments/target 
 
Topical therapies Corticosteroids 
 
Intracellular receptors; multiple anti-
inflammatory effects 
Calcipotriol 
 
Keratinocyte proliferation 
Tazarotene 
 
Intranuclear retinoid receptor, 
keratinocyte proliferation 
Tacrolimus 
 
Calcineurin inhibitor/immune 
modulation 
Tar 
 
mode of action unclear 
Dithranol 
 
mode of action unclear  
 
Systemic 
therapies 
Acitretin 
 
Intranuclear retinoid receptor, 
keratinocyte proliferation 
Methotrexate 
 
Folic acid reductase 
Ciclosporin 
 
Calcineurin inhibitor/immune 
modulation 
Fumaric acid 
esters 
Dimethylfumarate: mode of action 
unclear 
 
Light based 
therapies 
UVB (narrow 
band, 311nm) 
LC depletion 
PUVA (UVA plus 
methoxypsoralen) 
LC depletion (deeper skin 
penetration vs UVB) 
 
Systemic small 
molecules 
Apremilast 
 
PDE4 inhibitos; cAMP/PKC 
signalling in DCs/macrophages 
Tofaticinib 
 
JAK1/JAK3 
 
Anti-
cytokine/receptor 
monoclonal 
antibodies and 
fusion proteins 
 
 
 
 
Infliximab 
 
TNF (murine-human chimaeric 
IgG1) 
Etanercept 
 
TNF (human IgG1) 
Adalimumab 
 
TNF (Human IgG1) 
Ustekinumab 
 
IL12/23 shared p40 subunit (human 
IgG1) 
Secukinumab 
 
IL-17A (Human IgG1) 
Ixekizumab 
 
IL-17A (Human IgG4) 
Brodalumab 
 
IL-17RA (human IgG2) 	
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A mean 50% improvement in PASI score was noted at both 5mg/kg and 
10mg/kg doses of infliximab. Treatment with the TNF-targeting etanercept 
(an IgG1 Fc portion/TNF-receptor (CD120b) fusion protein (Scallon et al. 
2002), similarly, shows a significant reduction in epidermal thickening and T-
cells, and a reduction in the expression of IFNγ, IL12/23 and the chemokines 
CXCL8, CCL20 and CXCL10 (A. B. Gottlieb et al. 2005). Adalimumab is a fully 
human IgG1 antibody that also targets TNFα (Menter et al. 2008). Despite 
targeting the same cytokine-receptor pair, differences in binding 
characteristics leads to difference in therapeutic activity between the 
different TNF-blocking drugs (Scallon et al. 2002). More recently, biologicals 
have become available that target cytokines other than TNFα. One of these 
is ustekinumab, which targets the p40 subunit that is shared by both IL-12 
and IL-23 (Sivamani et al. 2012). Ustekinumab has the added advantage of 
needing to be injected only every 3 months, thereby aiding patient 
compliance.  
The efficacy of the above first generation anti-TNF biologicals highlights Th1 
T-cell pathways as being important in the pathogenesis of psoriasis. 
However, our understanding of psoriasis has since become more refined, and 
psoriasis is believed to be mediated by both Th1 and Th17 cells (Zaba et al. 
2008). Etanercept for instance, is known to have an early effect on Th17 
inducing DCs, Th17 products, but in the later stages of resolution also Th1 
products including IFNγ (Zaba et al. 2007).  
More recently, biological agents have become available that specifically 
target Th17 T-cell cytokines. The IL-17A directed monoclonal antibody 
secukinumab has been approved for use in psoriasis and has been shown to 
act, at least in part, through normalising keratinocyte-neutrophil 
interactions (Reich et al. 2015). Meanwhile, another IL17A targeting 
antibody ixekizumab has shown favourable efficacy in trials (Griffiths et al. 
2015), and now has marketing approval (Markham 2016). Furthermore, given 
the central role of T-cells and IFNγ in the pathogenesis of psoriasis, it is 
perhaps surprising that recombinant IFNγ injections have been used 
successfully to treat psoriasis with the improvement appearing to be dose-
dependent (Morhenn 1987). The results is not as striking as TNFα inhibitors 
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at the doses used in studies, but it is noteworthy that the degree of 
improvement appeared to be dose-dependent (Morhenn 1987). This, coupled 
with the potential adverse effects of IFNγ suggests that greater 
improvements may have been achievable (at least in theory) had higher 
doses been tolerated/safe. 
The use of biologicals, though often efficacious, is not without challenges. 
Whilst the above biologicals remain in use today (e.g. etanercept, 
adalimumab, ustekunumab), two other early biologicals, alefacept and 
efalizumab, have been withdrawn, due to unspecified reasons and due to 
cases of progressive multifocal leukoencephalopathy on treatment, 
respectively (Tan & Koralnik 2010). All biologicals are associated with a risk 
of serious infections and re-activation of latent infection with e.g. 
Mycobacterium tuberculosis, with the use of biological treatments (Sivamani 
et al. 2012; Cantini et al. 2015). Favourable long-term safety data for 
biologicals is progressively becoming available (Leonardi et al. 2011), and 
results suggest that serious adverse events are generally rare, with a 
discontinuation rate due to serious infection of 0.7% for ustekinumab over a 
5-year period (Papp et al. 2013).  
However, as reviewed elsewhere (Di Meglio et al. 2014), 1/3 of patients will 
not respond to biologicals, or progressively respond less well over time (e.g. 
due to formation of anti-drug antibodies), and additionally they remain very 
costly. Critically also, many patients on biologicals will still require 
topical/other treatments to achieve adequate disease control, which 
underlines the continued need for further therapies to be developed in the 
future (Warren et al. 2015).  
 
1.5.3 Small molecule antagonists 
Advances have also been made in small molecule drugs in the treatment of 
psoriasis, which unlike current biologicals, can be delivered topically, and 
are less costly to manufacture. The Janus kinase (JAK) inhibitor tofacitinib 
has shown efficacy in trials, both as an oral and topical preparation (Papp, 
Menter, et al. 2012), and acts through suppression of Th1/Th17 cell 
differentiation (Ghoreschi et al. 2011). Another is a small molecule drug that 
inhibits PDE4 (Schafer et al. 2009), and has shown promise in clinical trials, 
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albeit to a lesser degree than e.g. TNFα blockade (PASI75 achieved in 41% on 
highest dose in a small trial) (Papp, Cather, et al. 2012). Apremilast inhibits 
production of TNFα and IL-12/23 (Schafer et al. 2009), and is now in clinical 
use both for psoriasis and psoriatic arthritis (Schafer et al. 2009). Despite 
initial studies suggesting the clinical benefit is not comparable to biological 
agents, favourable adverse event profile and reports of their use in 
combination regimes for psoriasis (Rothstein et al. 2016), underlines an 
important niche for these small molecule drugs. 
 
 
1.6 Genetics of psoriasis 
 
Psoriasis pathogenesis is complex, with numerous overlapping pathways and 
disease mechanisms at play. Further complexity is introduced due to 
increasing recognition of heterogeneity between psoriasis sub-types that 
were previously, possibly simplistically, placed under the same umbrella 
term of ‘psoriasis’ on grounds of appearance. Unless otherwise specified, 
this chapter refers to chronic plaque psoriasis/psoriasis vulgaris. 	
 
1.6.1 Heritability of psoriasis 
Familiar clustering of psoriasis is well described. However, a clear Mendelian 
patter of inheritance is not apparent, even though many of those affected 
have a positive family history of psoriasis (Di Lernia et al. 2014).  Twin 
studies have demonstrated higher concordance rate in monozygotic as 
compared to dizygotic twins (33 versus 17%), and that genetic factors 
account for 60-75% of psoriasis risk (Lønnberg et al. 2013). Additionally, in 
concordant twins the clinical course of psoriasis (e.g. age of onset) tends to 
be similar in both individuals (Oka et al. 2012). It has been suggested that 
some of the global variation in prevalence of psoriasis (e.g. higher in 
Caucasians than patients of African heritage (Gelfand et al. 2005)) may 
relate to heritability, rather than merely ambient UV levels (Enamandram & 
Kimball 2013). Further evidence for this notion is provided by high rates of 
psoriasis in Australia, despite relatively high UV levels, which is likely 
accounted for by the predominantly European genetic heritage of the 
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Australian population (Parisi et al. 2012). Significant advances have been 
made in our understanding of individual gene variants that confer psoriasis 
susceptibility, but all the identified disease associated loci alone do not 
explain psoriasis risk entirely (Tsoi et al. 2012; Zuo et al. 2015). Together, 
this underpins the complex heritability of psoriasis, and the importance of 
genetic as well as environmental factors in determining the absolute 
psoriasis risk (and disease characteristics) of individuals.  
 
1.6.2 Genetic determinants of psoriasis: PSORS1 and HLA-C 
A correlation between psoriasis and the MHC class I molecule HLA-C (and 
specifically HLA-Cw6) has been known for several decades, with a high 
carrier rate among patients with psoriasis (Tiilikainen et al. 1980). Advances 
in genomic technologies e.g. genome-wide association studies (GWAS), have 
since enabled the genetic basis of psoriasis to be studied in increasing detail 
(Baurecht et al. 2015). Studies have shown that nearly half of the 
susceptibility in genetic variables in psoriasis is likely conferred by the 250kb 
PSORS1 locus, which spans the MHC complex on chromosome 6p21.3 (Di 
Meglio et al. 2014). GWAS studies have enabled this risk-conferring region to 
be further refined, and it is now believed that the human leukocyte antigen-
A (HLA-C) is the most likely gene candidate in the PSORS1 locus. Specifically, 
the gene with the overall highest association with psoriasis is HLA-Cw*0602 
that encodes HLA-Cw6, which is in keeping with serologic typing studies from 
the 1970s and 1980s (Tiilikainen et al. 1980). Whilst abnormal HLA-Cw6 
protein function/expression has not been demonstrated in psoriasis (Nair et 
al. 2006; Duffin et al. 2009; Clop et al. 2013), HLA-Cw*0602 carriers tend to 
develop psoriasis at an earlier age, have skin disease that is more extensive 
and are more likely to have guttate psoriasis compared to controls 
(Gudjonsson et al. 2006). The important role that HLA-C plays in both 
adaptive and innate immune processes, further underlines the plausibility of 
its association with psoriasis, although the mechanism(s) by which HLA-
Cw*0602 affects phenotype remain elusive. One study aimed to characterise 
the functional implications of psoriasis associated SNPs, and demonstrated 
that 144 variants of PSORS1 are associated with HLA-Cw*0602, and that some 
of these SNPs may constitute new binding sites for transcription factors that 
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are involved in immune regulation (Clop et al. 2013). Other studies have 
however failed to show HLA-C responsiveness to psoriasis associated 
interferons and TNF (Hundhausen et al. 2011). There is also evidence for 
epistasis between HLA-C and endoplasmic reticulum aminopeptidase 1 
(ERAP1), which plays a role in class I processing/antigen presentation 
(Strange et al. 2010), as well as between HLAC-C and the late cornified 
envelope genes LCE3B and LCE3C (which play a role in barrier function) 
(Riveira-Munoz et al. 2010), thus demonstrating the complexity of psoriasis 
genetics. 
 
1.6.3 Genetic determinants beyond HLA-C 
In recent years, genome-wide association studies (GWAS) have collectively 
enabled the identification of over 40 susceptibility loci for psoriasis (Tang et 
al. 2013). Although HLA-C SNPs are associated with the greatest increase in 
psoriasis risk (odd ratio 3.07) (Chen et al. 2011), GWAS studies have 
highlighted numerous other genes and pathways involved in diverse 
biological processes, including antigen-presentation, skin-barrier function, 
Th1/Th17 function and NFκB signalling (Hébert et al. 2015; Duffin et al. 
2009; Strange et al. 2010). Many of the identified genetic variants are in fact 
shared between psoriasis and other conditions that have an immune basis, 
such as rheumatoid arthritis, multiple sclerosis and Crohn’s disease, thus 
meaning that one SNP can confer risk to psoriasis, but also a range of other 
conditions with an immune basis (Cotsapas et al. 2011).  
 
 
1.7 Environmental triggers of psoriasis 
 
Numerous exogenous factors can trigger psoriasis/psoriasis-like lesions, 
including trauma (so called koebnerisation), medicines (such as beta-
blockers, imiquimod and lithium), stress and infections (O'Brien & Koo 2006; 
Hampton et al. 2012; Di Meglio et al. 2014; Lowes et al. 2014), illustrating 
the heterogeneity of possible causative agents. Current estimates from twin 
studies suggest approximately one third of psoriasis risk is due to 
environmental triggers (Lønnberg et al. 2013), though these triggers are 
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often technically difficult to study and remain poorly characterised. It is also 
noteworthy, that there is evidence for interaction between risk conferring 
single-nucleotide polymorphisms (SNPs) and body mass index (BMI) (Li et al. 
2013). The relative contribution of genetic factors and environmental 
factors, and how such factors interact in the pathogenesis of psoriasis are 
currently unknown. 
Several drugs have been implicated as acting as triggers of psoriasis, 
including beta-blockers (S. Wu et al. 2014), lithium (O'Brien & Koo 2006), 
and even paradoxical flares induced by anti-TNFα blockers (Osório et al. 
2012). The mechanism underlying these are largely unknown, but there is 
evidence for e.g. lithium possessing pro-inflammatory properties (Hampton 
et al. 2012; Petersein et al. 2014). 
 
 
1.8 Immunopathogenesis of psoriasis 
 
Psoriasis pathogenesis is complex, incompletely understood and involves 
innate and adaptive immune pathways. A particular importance has been 
assigned to Th1/Th17 pathways (Nograles et al. 2008; Ortega et al. 2009; 
Lowes et al. 2014) (Figure 1.1 and 1.6). In its briefest form, psoriasis 
pathogenesis has been described as a cascade of events starting with 
activation of DCs that release IL-12/23, subsequently leading to activation of 
Th17/Th1 and Th22 T cells, that express high levels of IL-17, IFNγ, TNF and 
IL-22. These cytokines drive keratinocyte hyperproliferation and further 
immune activation (Lowes et al. 2014). The development of a psoriatic 
plaque is not simply a linear chain of events. Instead, there is an increasing 
recognition that the immunopathogenesis of psoriasis is driven by a 
combination of stromal cells, immune cells and mediators acting together in 
complex, often concurrent pathways that are in turn 
activated/driven/perpetuated by both genetic and environmental factors 
(Lowes et al. 2013; Swindell et al. 2014). There is much debate in the 
literature surrounding attempts to organise various cell types in a hierarchy 
according to ‘importance’.  
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Figure 1.6 Summary of interactions between somatic cells and leukocytes 
in psoriasis. 
Adapted from (Di Meglio et al. 2014). Key interactive pathways between the 
principal cells in psoriasis pathogenesis summarised. 
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The comparable clinical efficacy of biologicals despite them targeting 
different cytokines/receptors (e.g. TNF, IL-17, IL-12/23), highlights difficulty 
in ranking components of a complex interconnected system in order of 
relevance. This caveat notwithstanding, psoriasis is broadly considered to be 
a predominantly T-cell driven disorder, notably driven by Th1 and Th17 T-
cell pathways (Lowes et al. 2014). 
Psoriasis was, in the past, considered a condition caused principally by 
abnormal keratinocyte proliferation and differentiation. Though this model 
is now believed to be too simplistic (Lebwohl 2003; Di Meglio et al. 2014), 
undoubtedly keratinocytes (the main cell type in the epidermis) play a 
critical role in psoriasis pathogenesis. Over the past two decades, there has 
been an increasing emphasis on the role of immune cells, notably in light of 
the success of drugs that specifically target immune mediators/pathways 
(Papp et al. 2008; Ohtsuki et al. 2014; Swindell et al. 2014). The importance 
of leukocytes is illustrated by experiments in which psoriatic leukocytes 
induce psoriasis-like lesions upon injection into dermal skin (Wrone-Smith & 
Nickoloff 1996). Furthermore, bone marrow transplantation from patients 
with psoriasis to non-affected donors, has been known to lead to the 
development of psoriasis in the recipient (Snowden & Heaton 1997). It is 
notable that psoriasis risk is associated with HLA-genes, and that 
autoreactive T-cells have been identified in psoriatic skin (Eberle et al. 
2016), again underlining the importance of the immune system. For 
instance, CD8+ cells have been identified that display reactivity to 
ADAMTSL5 expressing skin cells, suggesting that this is a putative antigen in 
psoriasis (Arakawa et al. 2015).  
Importantly, even grossly normal skin contains a large number of immune 
cells, leading to the skin compartment often being considered an immune 
organ (Di Meglio et al. 2011), with the immune component being termed 
skin-associated lymphoid tissue (SALT) (Lowes et al. 2014). 
Xenotransplantation models, whereby unaffected skin from patients with 
psoriasis are transplanted onto mice, demonstrate that the psoriatic skin has 
inherent factors that can drive lesion development (Boyman et al. 2004), and 
it is likely that resident leukocytes also play a critical role.  
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1.8.1 T-cells in psoriasis: overview  
T-cells play a central role in adaptive immune responses, of which there are 
several subtypes, the majority of which express the αβ T-cell receptor 
heterodimer, most of which are either CD4+ T-cells (that binds MHCII, and 
include T helper Th1 cells, Th2 cells, T regulatory (Treg) cells, Th17 cells), 
and CD8+ T-cells (that bind MHCI) (Singh et al. 2013). In general, T-cells are 
classified according to the cytokines which they produce (Lowes et al. 2014). 
It has been known for decades that there are large number of T-cells in 
psoriatic lesions (Bos et al. 1983), but psoriasis was nonetheless initially 
considered to be driven by abnormal keratinocyte (KC) proliferation. This 
notion was supported by the dramatic, rapid turnover of epidermal KCs, and 
the apparent efficacy of retinoids that are known to inhibit KC 
hyperproliferation (Marcelo & Tomich 1983; Di Meglio et al. 2014). From the 
late 1980s, with the emergence of lymphocyte targeting drugs such as 
ciclosporin (first mainly used to prevent rejection of organ transplants), it 
became apparent that leukocytes appeared to play a key role in psoriasis 
pathogenesis (Ellis et al. 1991; Elder et al. 1993). The emergence of 
denileukin-diftitox, that induces apoptosis of IL-2 receptor expressing active 
T-cells, confirmed further that specific targeting of T-cells could indeed aid 
resolution of psoriatic lesions (S. L. Gottlieb et al. 1995) Additionally, there 
was a direct correlation between epidermal thickening in psoriatic plaques, 
and the number of infiltrating T-cells (S. L. Gottlieb et al. 1995). In more 
recent times, the therapeutic approach to T-cells has been refined yet 
further. The clinical efficacy in psoriasis of biological agents specifically 
targeting T-cell pathways, have further underlined how such T-cells play a 
central role in psoriasis pathogenesis. Psoriasis was initially considered a Th1 
mediated disease, based on the presence of Th1 cytokines, such as IFNγ and 
TNFα, and a relative deficiency of Th2 cytokines (e.g. IL-4/5/10) (Schlaak et 
al. 1994; Di Cesare et al. 2009). Whilst Th1 cytokines are still believed to be 
important, there is an increasing appreciation for a central role of Th17 
cytokines; in particular for IL17 and for γδT-cells in psoriasis pathogenesis. 
Th1 and Th17 mechanisms are not mutually exclusive, and some have 
suggested that that immune activation in psoriasis has two interconnected 
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phases; initiation of the lesion being predominantly Th17 driven, and 
perpetuation being Th1 driven (Christophers et al. 2014). Though other cell 
types, beyond Th1/Th17 have also been implicated in psoriasis (e.g. Th22 
cells and Treg), comparatively little is known about their role in psoriasis 
pathogenesis (Van Belle et al. 2012; Lowes et al. 2014).  
It is also noteworthy that whilst psoriasis is not generally considered an 
autoimmune disorder per se, CD8+ cells have recently been identified that 
display reactivity to ADAMTSL5 expressing skin cells, suggesting this is a 
putative antigen in psoriasis (Arakawa et al. 2015).  
 
1.8.2 T-cells subsets in healthy skin  
Most epidermal CD3+ T-cells in normal healthy human skin are CD8+ memory 
cells, which bear αβ T-cell receptors (TCR), which is in contrast to murine 
skin where the majority of epidermal T cells bear γδ TCRs. The ratio of 
CD8+/CD4+ cells in human healthy epidermis has however been shown to be 
very variable in health, depending on the body site investigated. Human 
epidermal T-cells tend to be localised in the basal layer, whilst dermal T-
cells tend to be preferentially localised just below the dermo-epidermal 
junction (Foster et al. 1990). Effector-memory T-cells that are imprinted to 
localise into the skin, express the skin-homing chemokine receptors (CCR) 
CCR4 and CCR10, as well as ligands for E- and P-selectin. This skin targeting 
of T-cells occurs in skin draining lymph node where skin-derived DC present 
antigen to T cells, and appears to be dynamic; the tissue tropism of CD8+ T-
cells is reversible, and their migratory potential can be altered (Mora 2005). 
In addition to CD8+ T-cells, several types of CD4+ T-cells can also be found in 
inflamed skin, and express cytokine profiles that identify them as either 
Th1, Th17, or Th2 cells (Nestle, Di Meglio, et al. 2009). 
 
1.8.3 Cytotoxic CD8+ T-cells in psoriasis; early arrivals in the 
epidermis 
Xenotransplantation models (using AGR129 mice) have shown that 
development of psoriasiform inflammation is dependent on the migration of 
CD8+ T-cells from the dermis to the epidermis. Blockade of this migration 
through targeting α1β1 integrin effectively prevents psoriasiform lesion 
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development in an experimental model (Conrad et al. 2007). Animal studies 
have shown a central role for such cytotoxic CD8+ cells in 1) CD4+ activation, 
2) neutrophil recruitment/microabscess formation, 3) recruitment of γδT- 
and Th17-cells. Furthermore, skin inflammation induced in this model 
(through H-RASV12G expression in suprabasal KCs in AGR129 mice) was not 
reduced by depletion of CD4+ T-cells, emphasising the particular importance 
of CD8+ T-cells in this context (Gunderson et al. 2012). CD8+ cells are 
increased in the psoriatic epidermis, and are a source of key psoriasis-
associated cytokines, including IL-17A, TNF, IL-22 and IFNγ (Di Meglio & 
Duarte 2013; Di Meglio et al. 2014). 
 
1.8.4 Th17 cells in psoriasis; the IL-23/Th17 axis  
Whilst animal models suggest that resident skin T-cells may be sufficient for 
initiating psoriasiform inflammation, it is also clear that several subtypes of 
circulating T-cells infiltrate human plaques, and that they play a role in both 
plaque initiation and maintenance. As introduced above, there is an 
increasing recognition that Th17 cells play a pivotal role in psoriasis 
pathogenesis, a discovery that was largely made through studies into IL-23. 
High levels of IL-23 are detected in psoriatic skin (Lee et al. 2004), the main 
sources of which are myeloid inflammatory DCs, Langerhans cells as well as 
macrophages (Di Meglio et al. 2014; Piskin et al. 2006). IL-23 is a 
heterodimeric cytokine that is composed of a p19 and p40 subunit (p40 
subunit shared with IL-12), and can bind both IL-23R and IL-12Rβ1 (Suzuki et 
al. 2014; Oppmann et al. 2000). IL-23 is known to be central in the 
pathogenesis of psoriasis due to a number of findings; firstly, the p40 subunit 
(common to both IL-12 and IL-23) is targeted by ustekinumab, which has 
been shown to be one of the most efficacious biologicals available in the 
treatment of psoriasis. Secondly, it is now known that variation in the IL-23R 
genes modulate psoriasis risk (Capon et al. 2007). Upon its discovery, IL-23 
was found to induce proliferation of both murine and human memory T-cells 
(Oppmann et al. 2000) and was subsequently shown to particularly induce IL-
17 production by a new IL-17 producing T-cell subtype (Aggarwal et al. 
2003). It is now known that IL-23 induces IL-17 production by CD4+ T-cells 
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(i.e. Th17) but also by cytotoxic CD8+ T-cells (Tc17), which frequently co-
produce IFNγ and TNFα concurrently with IL-17 (Ortega et al. 2009).  
Beyond its role regulating Th17 cells/IL-17 production, IL-23 also plays a role 
in inducing IFNγ production by tissue-resident memory T-cells (TRM) cells 
(Piskin et al. 2006). Although KC produce very low levels of IL-23, KC derived 
IL-23 has been shown to be sufficient to induce IFNγ production by TRM cells, 
even in the absence of APC derived IL-23 (Piskin et al. 2006). Nonetheless, 
the principal role of IL-23 in psoriasis pathogenesis, appears to be the 
maintenance of the IL-23/Th17 axis (Suzuki et al. 2014). Indeed, 
polymorphisms in IL-23A, IL-23R, STAT2, RUNX3 and TYK2 have been 
implicated in psoriasis, all of which are associated with Th17 pathways 
(Eberle et al. 2016). It should however be noted, that several cell types 
(apart from Th17 cells) are now recognised as producers of IL-17, including 
γδT-cells, pDCs, innate lymphoid cells, mast cells and neutrophils (Lowes et 
al. 2014; Eberle et al. 2016). Th17 T cells in turn are also capable of 
producing cytokines other than IL-17A, including IL-9, IL-10, IL-17F, IL-21 and 
IL-22 (Eberle et al. 2016). Interestingly, TNFα blockade limits IL-17 
production by T-cells (Ortega et al. 2009), which further illustrates that key 
psoriasis–associated immune pathways are intimately interconnected, and do 
not operate in isolation from each other. 
 
1.8.5 γδT-cells in psoriasis: innate-like pro-inflammatory cells  
Not all IL-17 producing T-cells express the αβ T-cell receptor. The  γδT-cell 
receptor expressing T-cell subtype has also been shown to express this 
cytokine in psoriasis. These γδT-cells are skin homing, require no priming in 
lymphoid tissues, can therefore respond quickly and thus are sometimes 
referred to as ‘innate-like’ cells (Nestle, Di Meglio, et al. 2009). In humans 
γδT-cells only make up <10% of total T-cell numbers in dermis/epidermis, 
but the murine γδT-cell equivalent (Vγ5+ Dendritic Epidermal T-cells; DETC) 
constitutes the majority of epidermal T-cells in mice (Nestle, Di Meglio, et al. 
2009). In humans, γδT-cells become more abundant in traumatised skin 
(induced by e.g. suction blisters) and are also found in large numbers in 
psoriatic plaques. In psoriasis, high numbers of γδT-cells are also localised in 
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unaffected skin of patients with psoriasis, and may play a role in the 
‘priming’ of clinically normal skin that allows for rapid plaque development, 
if appropriate triggers are encountered (Laggner et al. 2011). γδT-cells 
produce (constitutively) high amounts of CCL5, but also CCL3/4 and CXCL8 
upon activation and can activate KCs through the production of pro-
inflammatory cytokines such as TNFα and IFNγ (Laggner et al. 2011), and 
thereby can perpetuate leukocyte infiltration and inflammation.  
 
1.8.6 Regulatory T-cells 
Regulatory T-cells (Treg) are a heterogeneous group of CD4+ cells that play 
important roles in regulating immune processes, notably in preventing 
autoimmunity. Their effect is exerted through the modulation of IL-2 
production (Oberle et al. 2007), induction of apoptosis and production of 
other cytokines that regulate immune cells (Shevach 2009; Goodman et al. 
2012). In this manner, Tregs target a broad range of immune cells, including 
CD4+/CD8+ T-cells, DCs, B-cells, macrophages, mast cells, NK and NKT cells 
(Shevach 2009). FoxP3 is a marker for murine Tregs, but other CD4+ cells can 
also express FoxP3 (Fontenot et al. 2003). Treg function has been shown to be 
abnormal in psoriasis, with a suppressed regulatory function, thus possibly 
contributing to unrestricted inflammation that characterises psoriasis 
(Sugiyama et al. 2005). 
 
1.8.7 Resident memory T-cells; initiators of psoriasiform 
inflammation  
A large number (an estimated 20 billion) of T-cells are present in skin and 
outnumber circulating T-cells (Clark 2015).  Recent data suggest that there 
are two distinct populations of resident memory T cells; and two populations 
of recirculating memory T-cells, all of which are functionally distinct 
(Watanabe et al. 2015). Tissue resident cell populations, most of which are 
CD103+, provide a pool of rapid responders to injury. Tissue resident 
memory T-cells (TRM) likely have a key role in the early phases of plaque 
induction, but our understanding of their role in disease is only beginning to 
emerge (Di Meglio et al. 2014). For instance, TRM in psoriasis express higher 
levels of both IL-17A and IL-22 compared to cells in healthy controls (Eberle 
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et al. 2016). Most cutaneous T-cells express the cutaneous lymphocyte-
associated antigen (CLA) (Clark 2009), and it has been shown that the 
chemotactic chemokine CCL27 produced by KC plays a role in recruiting 
CLA+ TRM to skin (Morales et al. 1999). Skin homing circulating T-cells 
(CCR4/6/10) positive) play a role in skin immune surveillance, are found in 
the circulation and periodically enter tissues in response to e.g. danger 
signals (Boyman et al. 2007). However, it has been shown that significantly 
more T-cells reside in the skin than exist in the circulation (ratio 2:1), with 
most of the skin resident T-cells being Th1 effector memory cells (Clark 
2015). Most CLA+ effector memory T-cells are localised in skin, and display a 
very diverse T-cell repertoire. T-cell responses in the skin can be initiated 
very rapidly, even before additional T-cells are recruited from the 
circulation (Clark et al. 2006). The capability of resident immune cells to 
promote psoriasiform inflammation in the absence of circulating B/T-cells or 
NK cells, is confirmed by studies where psoriasiform inflammation is rapidly 
established in unaffected human skin that is transplanted onto AGR129 mice. 
In this particular model, TRM already in the human graft, migrate from the 
dermis into the epidermis, and cause psoriasiform inflammation without the 
need for circulating T-cells (Boyman et al. 2004). Resident T-cell populations 
may also account for why certain body sites in the same patient may develop 
plaques recurrently; studies have shown that both CD8+ and CD4+ T-cells can 
remain in skin even after apparent clinical normalisation of the skin upon 
treatment, and retain their ability to produce psoriasis-inducing cytokines 
(Cheuk et al. 2014). 
 
1.8.8 Keratinocytes in health and disease: overview  
Keratinocytes (KC) make up >90% of the epidermal layer (Nestle, Di Meglio, 
et al. 2009), and provide a crucial barrier function, as well as playing a role 
in innate and adaptive immune processes (Perera et al. 2012). In health, 
generally only basal KCs proliferate, whilst differentiation is the 
predominant process in the higher epidermal layers (Perera et al. 2012). 
Both KC proliferation and differentiation are grossly abnormal in psoriasis (Di 
Meglio et al. 2014). The clinical efficacy of retinoids that primarily target KC 
differentiation and proliferation, suggested the notion that KCs were the 
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main culprits in psoriasis in early studies. Though KCs are now not considered 
the sole drivers of psoriasis immunopathogenesis, there is again an 
increasing appreciation for their central role in this disease. Indeed, KCs play 
a role in all stages of plaque initiation, development, maintenance, and even 
in response to therapies (Barker et al. 1991; Lowes et al. 2013). KCs are e.g. 
capable of regulating recruitment and function of T-cells in the skin (Lowes 
et al. 2014), and there are extensive interactions between keratinocytes and 
immune cells, mediated by a range of cytokines and chemokines, many of 
which are in fact produced by KCs themselves  (Figure 1.6).  
 
1.8.9 Keratinocytes in psoriasis; environmental and immune 
sensors 
Inflamed/damaged KCs display a different phenotype compared to normal 
cells. There is an upregulation of keratins 6, 16 and 17, cytoskeletal 
components and cell surface receptors (Perera et al. 2012), and cytokines 
including IL-1, IL-6, TNFα and chemokines (Vinter et al. 2014). Traumatised 
KCs are also a key source of anti-microbial peptides or AMPs (including LL37) 
and self-nucleic acids (RNA and DNA) that play a role in breaching self-
tolerance through activating TLR-receptors (Lande et al. 2015). Specifically, 
LL37-DNA complexes act on TLR9, thereby activating pDCs leading to 
production of IFNα (Lande et al. 2007). In addition, LL37-RNA complexes 
activate mDCs by acting on TLR8, leading to production of TNFα and IL-6 
(Ganguly et al. 2009) (Figure 1.1). The TNFα produced in this process 
enhances KC proliferation and is a key driver of psoriasiform inflammation as 
evidenced by the efficacy of TNFα targeting therapies (Sweeney et al. 2011). 
Meanwhile, IL-6 expression is thought to aid the differentiation of Th17 cells 
(Sweeney et al. 2011).  
In addition to DCs, KCs play a role in immune surveillance, by expressing a 
range of TLRs (1-6 and 9) (Sweeney et al. 2011). In addition to KC expressed 
TLRs, there is a recently characterised family of proteins capable of sensing 
danger-associated molecular patters (DAMPs) which can lead to activation of 
pro-inflammatory cascades (Nestle, Di Meglio, et al. 2009). 
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1.8.10  Keratinocytes in psoriasis; amplifiers of immune signals 
and recruiters of leukocytes 
Inflamed KCs produce a variety of chemokines, including CXCL8, CXCL20 
(Sweeney et al. 2011), CCL20, CXCL9, CXCL10 and CXCL11 (Nestle, Di Meglio, 
et al. 2009), that together can recruit a range of inflammatory leukocytes. 
Some of these chemokines can be induced in KC by T-cell sourced cytokines. 
In this manner, KCs act as amplifiers of T-cell signals; Th1 cells produce 
IFNγ, which induces the expression of CXCL9/10/11 (CXCR3 ligands) by KC, 
and thereby promote the further recruitment of CXCR3-expressing Th1 cells. 
In addition, Th17 T-cells release IL-17, leading to KC expression of 
CXCL1/2/8 and CCL20, which promotes recruitment of neutrophils and more 
CCR6-expressing Th17 T-cells (Nograles et al. 2008; Lowes et al. 2014). Th22 
derived IL-22 in turn leads to enhanced KC proliferation, disordered KC 
maturation, and thereby contributes to the characteristic histological 
appearance of psoriatic plaques (Eyerich et al. 2009).Additionally, KC 
derived AMPs LL37 and β-defensin, together, act as chemoattractants for a 
range of psoriasis-associated leukocytes including T-cells, monocytes, 
neutrophils, DCs and mast cells (Oppenheim & Yang 2005). Inflamed 
keratinocytes furthermore produce pro-angiogenic factors, including VEGF, 
which lead to the formation of the tortuous abnormal vasculature that 
characterises psoriasis. These vessels are ‘leaky’ and permissive to enhanced 
leukocyte transmigration, thus further facilitating leukocyte recruitment 
(Costa et al. 2007). Psoriasis-associated IFNγ increases expression of 
intercellular adhesion molcecule-1 (ICAM-1) and thereby enhances T-cell 
adhesion to the vasculature (Dustin et al. 1988).  
KCs are the main IL-17R expressing cells in psoriasis, and respond to IL-17 
and other key psoriasis-associated cytokines (including TNF, IFNγ, IFNα and 
IL-22), leading to keratinocyte hyperproliferation, production of further pro-
inflammatory cytokines and chemokines and further leukocyte recruitment, 
thereby are at the core of a self-amplifying pro-inflammatory loop (Lowes et 
al. 2014). It has been argued that the profound clinical effect observed with 
the blockage of IL-17 is rather unexpected (by virtue of IL-17 being a 
cytokine relatively far down the inflammatory cascade, and regulates a 
relatively low number of genes in KC). It has been suggested however, as 
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reviewed elsewhere, that this may in part be to IL-17 stabilising chemokine 
mRNA and synergising with TNF (Lowes et al. 2014). 
 
1.8.11  Dendritic cells in psoriasis; bridging adaptive and 
innate immune systems 
Dendritic cells (DCs) are a heterogeneous group of cells, that bridge the 
innate and adaptive immune systems, recognise external signals through 
Toll-like receptors and migrate to lymph nodes where they present antigens 
and activate T-cells (Ganguly et al. 2013). They are believed to play a 
critical role in psoriasis pathogenesis, and their numbers are reduced by 
several anti-psoriatic therapies, including ultraviolet B (UVB) and anti-TNF 
antibodies (Lowes et al. 2014). Though DC numbers are increased in 
inflammatory skin disorders, their source, origin and function remains an 
area of controversy (Haniffa et al. 2015). DCs are abundantly present in 
psoriasis where they tend to be localised in the dermis (Nestle et al. 1994; 
Lowes et al. 2005), and are capable of producing several key psoriasis-
associated cytokines. pDCs and mDCs dominate in psoriatic lesional skin, 
whilst Langerhans cell numbers are less variable in lesional as compared to 
unaffected skin. Early studies showed that DCs are present in psoriatic 
lesions, and mediate T-cell production of Th1 cytokines such as IFNγ and IL-2 
upon stimulation (Nestle et al. 1994). It has furthermore been demonstrated 
that psoriatic plaques express high levels of chemerin, and it has been 
proposed that the so called chemerin/ChemR23 axis is important for pDC 
recruitment to skin in the initiation stages of psoriasis (Albanesi et al. 2009). 
Indeed pDC numbers are increased in psoriatic plaques, but comparatively 
rare in unaffected skin of patients (Glitzner et al. 2014). Psoriatic pDCs have 
been shown to produce IFNα, and play a key role in the initiation of T-cell 
driven psoriatic lesion development (Nestle et al. 2005). Recently, it has 
been suggested that pDC (rather than Th17 T-cells) may be the principal 
producers of IL-17. 
 
1.8.12   DC activation in psoriasis by antimicrobial peptides  
Keratinocyte-DC interactions appear to be central to psoriasis pathogenesis 
(Figure 1.6). A range of antimicrobial peptides (AMP) are produced by KCs 
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(and some other skin cells) in response to damage and injury. These AMPs 
exert an antibacterial effect principally by e.g. disrupting microbial 
membranes, and thereby play a role in innate skin defences (Borkowski & 
Gallo 2011; Nakatsuji & Gallo 2011; Wimley 2010). The AMP LL37 is a 
mediator in the initiation stages of psoriasis, is highly expressed in psoriatic 
lesions and is released principally by keratinocytes. It has been shown that 
LL37 forms aggregates with self-DNA that have been shown to act on Toll-
like receptors (TLR) 9 and 10, that are expressed by plasmacytoid dendritic 
cells (pDCs) (Lande et al. 2007). LL37 also forms complexes with self-RNA 
and thereafter activates pDCs by acting on TLR7 and 8 (Ganguly et al. 2009). 
LL37 been shown to act as an autoantigen in psoriasis, that induces 
proliferation of skin-homing LL37-reactive T-cells, that produce e.g. IFNγ, IL-
17 and IL-22 (Lande et al. 2014). KCs in psoriasis thus help produce the AMP 
LL37 that complexes with self-nucleic acids, and thereby enables the 
immune system to overcome self-tolerance, in the context of trauma. This 
leads to the production of psoriasis-associated cytokines and inflammation. 
TLR9, in addition to being expressed on pDCs, is also expressed by KC (that 
are themselves also producers of LL37). Stimulation of KC with first LL37 and 
then subsequently genomic DNA has been shown to lead to enhanced KC 
production of type I IFN, in a non-LL37-DNA complex dependent manner 
(Morizane & Gallo 2012).  
The ability to activate pDCs via TLR9 is not a feature unique to LL37. A 
recent study has shown that other AMPs that are overexpressed in psoriasis 
can exert similar effects as LL37. Specifically, human beta-defensin (hBD) 
hBD2 and hBD3 are also capable of forming pDC activating aggregates 
together with self-DNA (Lande et al. 2015). Studies have shown a significant 
(albeit weak) association between the risk of psoriasis and the copy number 
of beta-defensin genes (odd ratio OR=1.1-1.3) which would be in keeping 
with it playing a role in psoriasis pathogenesis (Stuart et al. 2012).  
 
1.8.13 Neutrophils in psoriasis 
Neutrophils are abundantly present from a very early stage in psoriatic 
lesions where they accumulate in particularly large numbers to form the so 
called Munro’s microabscesses (Sweeney et al. 2011). Expression of 
SHAMS 2016 
	74 
neutrophil chemoattractants is enriched in psoriasis, with the degree of 
enrichment correlating with the number of infiltrating neutrophils (Choy et 
al. 2012), with neutrophils tending to accumulate particularly in the 
epidermis (Lowes et al. 2014). Though neutrophils are present in psoriasis, 
and it is known that they are capable of producing a range of psoriasis-
associated mediators (including IL-6, IL-17 and TNFα) (Sweeney et al. 2011), 
it is only relatively recently that the mechanistic role of neutrophils in 
psoriasis pathogenesis has become apparent. Recent trials of the IL-17 
neutralising monoclonal antibody secukinumab demonstrated that neutrophil 
clearance, and a reduction in IL-17 inducible neutrophil attracting CXCL1/8, 
were some of the earliest events in lesion clearance following treatment. 
This would be in keeping with the efficacy of secukinumab in clearing 
psoriatic plaques being, in part, due to an effect on neutrophils (Reich et al. 
2015). Additionally, neutrophils are producers of IL-17 (Lin et al. 2011). 
Despite recent advances, the precise role and function of neutrophils in 
psoriasis pathogenesis remain to be determined. 
It has been suggested that ‘unevenness’, in terms of the degree of 
inflammation within a psoriatic lesion, coincides with localised clustering of 
neutrophils, and that such neutrophils can induce localised acute 
inflammatory flares within already inflamed tissues. The resulting damage in 
turn leads to the release of pro-inflammatory and neutrophil attracting 
complement (C3a and C5a) and CXCL8 (formerly IL-8) (Terui et al. 2000). It 
is hence possible, that whilst psoriasis is predominantly T-cell driven, 
neutrophils play a role in perpetuating and potentiating T-cell mediated 
inflammation. 
 
 
1.8.14  Macrophages in psoriasis 
Previous experiments have identified the monocyte attracting chemokine 
CCL2 in psoriasis (Deleuran et al. 1996), though its role was originally 
undefined. Further studies demonstrated that IFNγ stimulation of 
keratinocytes led to an increased expression of CCL2, and furthermore that 
CCR2 (the receptor for CCL2) was expressed on the majority (though not all) 
of peripheral monocytes in patients with psoriasis (Vestergaard et al. 2004). 
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Subsequently, studies have shown that specific CD163+ macrophage 
populations are activated in psoriasis, and that they produce pro-
inflammatory mediators, thereby perpetuating Th1/Th17 responses 
(Fuentes-Duculan et al. 2010). However, the precise role of 
monocytes/macrophages in psoriasis remains relatively unexplored. 
 
 
1.9 Laboratory models of psoriasis 
 
1.9.1 Animal models of psoriasiform inflammation 
The complexity of psoriasis pathogenesis, coupled with psoriasis being found 
almost exclusively in humans (with the exception of rare isolated reports of 
psoriasiform inflammation in primates) (Jayo et al. 1988; Lowe et al. 1981), 
makes modelling and studying psoriasis in vivo challenging. For this reason, 
the term ‘model of psoriasiform skin inflammation’ is a more accurate 
description than ‘model of psoriasis’ when referring to non-human disease 
models of psoriasis as such models though helpful, never perfectly mimic 
human disease (Swindell et al. 2014). The lack of adequate animal models 
had for some time hampered research into psoriasis pathogenesis 
(Gudjonsson et al 2007). Research into psoriasiform inflammation in primates 
is generally not undertaken for practical and ethical reasons. There have 
also been some attempts to induce psoriasis-like inflammation in animals 
such as guinea pigs, but with relatively poor results (Wolf et al. 1994). Over 
recent years however, a large number of mouse models of psoriasiform skin 
inflammation has become available. There are proposed criteria for what is 
required of a good model of psoriasis; 1) typical epidermal changes; e.g. 
thickening (acanthosis), retained nuclei in the stratum corneum 
(parakeratosis) 2) elongation of rete ridges (papillomatosis) 3) presence of 
cells including T-cells, monocytes/ macrophages, DCs and neutrophils 4) T-
cells playing a role in the pathogenesis 5) altered vascularity/tortuous 
capillaries and 6) response to typical anti-psoriatic drugs (e.g. retinoids, 
ciclosporin, anti-TNFα antibodies) (Nestle & Nickoloff 2006). Existing mouse 
models fulfil these criteria to a greater or lesser extend. Although a perfect 
model of psoriasis does not exist and each of the available mouse models has 
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specific inherent limitations, the murine models have, collectively, provided 
important insights into not only psoriasis, but also psoriasis-associated 
conditions (Weitz & Ritchlin 2013). Such mechanistic insights into psoriasis 
immunopathogenesis have already been translated into many novel therapies 
as reviewed elsewhere (Nickoloff & Nestle 2004). 
 
1.9.2 Imiquimod mouse model: the conception of the IMQ 
model 
Imiquimod 5% cream (Aldara™, IMQ) is mainly used for the treatment of 
anogenital warts (Grillo-Ardila et al. 1996), actinic keratoses (Szeimies et al. 
2004), superficial basal cell carcinomas (Geisse et al. 2004), likely mediated 
by pDC recruitment. Imiquimod (IMQ) acts on toll-like receptor (TLR) 7 and 
8, and when applied to skin, induces a strong immune response (Schön & 
Schön 2007), that is characterised by activation of pDCs, Langerhans cells, 
neutrophils, T-cells, γδT-cells and RORγt+ innate lymphocytes. It should be 
noted that whilst IMQ acts as an agonist of TLR7 and TLR8 in humans, it acts 
on TLR7 in mice (Flutter & Nestle 2013; Walter et al. 2013; Urosevic et al. 
2005; Pantelyushin et al. 2012).  
Cytokines including IL-17, IL-22, and IL-23, as well as pro-inflammatory 
chemokines are found in skin of Aldara treated mice and humans (Walter et 
al. 2013; Ueyama et al. 2014) with IL-17A, IL-17F and IL-22 being essential 
for the formation of plaques in mice (Pantelyushin et al. 2012). Additionally, 
it has been demonstrated that Aldara cream induces inflammation through 
TLR-independent mechanisms, and that the vehicle alone (and specifically 
the excipient isostearic acid used to aid solubility (Chollet et al. 1999), is 
capable of inducing inflammasome activation in the absence of the active 
agent imiquimod (Walter et al. 2013). For consistence and convenience, IMQ 
in this thesis refers to Aldara cream rather than pure imiquimod (in line with 
published literature), unless otherwise stated. There have been reports of 
topical IMQ application causing enlargement of pre-existing psoriatic plaques 
(Gilliet et al. 2004), inducing widespread psoriatic lesions where the patient 
has a history of (previously) stable psoriasis (Fanti et al. 2006; J. K. Wu et al. 
2004), and triggering development of de novo psoriasis (absence of a 
personal, or family history) (Patel et al. 2011). The widespread nature of 
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new psoriatic lesions induced by localised topical IMQ in such reports, 
suggests that lesions did not occur simply due to e.g. koebnerisation and 
focal irritation (Rajan & Langtry 2006).  
 
1.9.3 Imiquimod mouse model: characteristics  
Skin changes in the IMQ model closely resemble human psoriasis 
macroscopically (erythema, scaling, thickening), microscopically (acanthosis, 
parakeratosis, angiogenesis), in terms of infiltrating immune cells (that 
include CD4+/CD8+ T-cells, macrophages, DCs and γδT-cells) and broadly 
also in terms of cytokine pathways involved (van der Fits et al. 2009). Given 
the key similarities with human psoriasis, it is likely that understanding the 
precise mechanisms, by which IMQ induces psoriasiform skin changes in 
mice, will help provide insights into psoriasis pathogenesis in humans. For 
instance, there is an increasing appreciation for IMQ activating several 
concurrent pathways, both TLR-dependent and independent, which leads to 
inflammation (Walter et al. 2013).  
pDCs express TLR-7 receptors (Kadowaki et al. 2001), and it has been shown 
that IMQ is an inducer of pDC type-1 IFN production through TLRs, and also 
enhances pDC viability in vitro (Gibson et al. 2002). In vivo skin studies have 
confirmed that IMQ acts on pDC TLR7, leading to pDC production of e.g. IL-
23, IL-6 and TNFα (Ueyama et al. 2014). Data from a melanoma model in 
mice have demonstrated that IMQ leads to an upregulation of CCL2 by mast 
cells (and thereby recruitment of pDCs to the skin), and that the CCL2 
upregulation was dependent on IFNα/β-receptor 1. This suggests that IMQ 
not only stimulates pDC cytokine production and pDC viability, but 
potentially may play a role in regulating pDC numbers in skin (Drobits et al. 
2012). 
IMQ-induced increases in expression of IL-23p19 by pDCs occur after 48h in 
the IMQ model, and is subsequently followed by an increased expression of 
IL-17A, IL-17F and IL-22 after 72h (van der Fits et al. 2009). Application of 
IMQ to IL-17RA-/- mice, and IL-23p19-/- mice, shows that psoriasiform 
inflammation is significantly suppressed, thereby suggesting that 
psoriasiform inflammation in the IMQ mouse model is not only associated 
with, but is dependent on the human psoriasis-associated IL-17/IL-23 
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pathway (van der Fits et al. 2009). The main producers of IL-17 in the IMQ 
model are IL-23 responsive γδT-cells (Cai et al. 2011). γδT-cells have been 
found to be the key producer of IL-17 in response to IL-23 stimulation, in an 
IL-1β dependent manner (Cai et al. 2011). Dermal γδT-cells, whilst appearing 
skewed towards IL-17 production, also produce TNFα and IL-22 whereas γδT-
cells in the lymph nodes also produce IFNγ in response to IL-23 (in addition to 
IL-17/IL-22/TNFα). Furthermore, IL-23 was found to drive γδT-cell expansion 
in vitro, and likely plays a role in γδT-cell homeostasis and maintenance. 
Thus, there appears to be a central role for IL-17 production by γδT-cells in 
the IMQ model (Cai et al. 2011), and indeed also in humans there is an 
increasing recognition that IL-17 is produced by a range of immune cells, and 
not only Th17 cells. 
Beyond IL-17, the phenotype of the IMQ model is also dependent on IL-22, as 
studies have shown that IL-22 knockout mice (and mice treated with 
neutralising IL-22 antibodies), are relatively protected against IMQ induced 
psoriasiform inflammation (Van Belle et al. 2012). The principal producers of 
IL-22 were again γδT-cells, although one-third of IL-22+ cells in one study 
were αβTCR+ T-cells. However, as IL-22 production was preserved in Rag2-/- 
mice treated with IMQ, this suggests that αβT-cells are not essential for IL-
22 production, and that in addition to the adaptive system, innate cells play 
a role in IL-22 production (and therefore psoriasiform skin changes) (Van 
Belle et al. 2012). Importantly, although it has been suggested that innate 
immune processes alone are sufficient for promoting the key features of 
psoriasiform skin inflammation (Pantelyushin et al. 2012), the overall T-cell 
dependence of the IMQ model, underlined by CD3+ depletion greatly 
attenuating IMQ induced psoriasiform skin inflammation, suggests that T-
cells do play a key role in the IMQ mouse model, as they do in human 
psoriasis (van der Fits et al. 2009). It is also noteworthy, that data from 
other model systems (e.g. EAE) suggest that IL-23/IL-1β activated γδT-cells 
can act on CD4+ Th17 cells to stimulate IL-17 production, thus serving as an 
amplification loop (Sutton et al. 2009). However, it remains unclear to what 
extent this mechanism may apply in psoriasiform inflammation. 
 
1.9.4 Spontaneous mouse models  
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Numerous spontaneously occurring mouse models have been described, some 
of which display some key features of human psoriasis (Sundberg & King 
1996). Specifically, this includes homozygous mouse models for flaky skin 
(fsn), asebia and chronic proliferative dermatitis (cpd) (Boehncke & Schön 
2007). The ‘flaky skin’ (Ttcfsn/Ttcfsn) mouse model displays hyperkeratotic 
plaques and some histological similarities with human psoriasis, and is 
possibly the best characterised of the spontaneous models. Interestingly the 
Ttcfsn/Ttcfsn mouse model also demonstrates koebnerisation in response to 
tape stripping, which few other models have been reported to do (Sundberg 
et al. 1990). The flaky skin mice also have some severe haematological 
abnormalities (Sundberg & King 1996). Despite histological similarities, in 
general, these spontaneous models are rarely used due to important 
differences compared to human disease, including differing skin vascular 
changes (Mizutani et al. 2003), and a relative absence of T-cells, which as 
discussed above are central in human psoriasis (Gudjonsson et al 2007).  
 
1.9.5 Xenotransplantation mouse model 
Xenotransplantation models are technically challenging compared to many 
other mouse models of psoriasis, require unaffected human donor skin from 
patients with psoriasis and are also very costly (Gudjonsson et al 2007). 
Some of the earliest studies of xenotransplantation models of psoriasis (XMP) 
suggested that unaffected psoriatic skin grafted onto nude mice develop 
certain features of psoriasis: these early findings were initially interpreted 
as meaning that (undefined) features inherent to the skin were the sole 
drivers of psoriasis, independently of other (non-skin) host factors such as 
immune cells (Fraki et al. 1982). This is now considered too simplistic. The 
generation of modern XMP involve either one of 1) psoriatic plaque skin from 
human patients, that will contain high numbers of leukocytes, to be grafted 
onto the back of immunodeficient mice (Villadsen et al. 2003; Kvist et al. 
2009), or 2) unaffected (clear) skin from human patients with psoriasis 
treated with superantigen, grafted onto the back of immunodeficient mice, 
plus the addition of psoriatic donor leukocytes, pre-treated with bacterial 
superantigen, injected systemically (Boehncke et al. 1996) or alternatively 
directly into the lesion (Wrone-Smith & Nickoloff 1996), 3) unaffected skin 
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from patients with psoriasis grafted onto AGR129 mice, that are deficient in 
B-/T-cells and type I and II IFN receptors (Boyman et al. 2004), or 4) 
bioengineered skin equivalents grafted onto immunodeficient mice 
(Guerrero-Aspizua et al. 2010). Histologically, the psoriasiform skin that 
results following successful grafting, bears a close resemblance to human 
plaque psoriasis, with e.g. increased epidermal thickening and elongated 
rete ridges being apparent (Villadsen et al. 2003). In models using 
unaffected psoriatic skin plus injected epidermotropic T-cell injections, 
CD3+ T-cells were found to localise in the epidermis, and most of these were 
found to be CD8+ rather than CD4+ (Wrone-Smith & Nickoloff 1996). The XMP 
is often used to assess potential responses to novel therapies, and to assess 
the effect of therapies in vivo and in the development of biomarkers (Kvist 
et al. 2009). Indeed, and as expected, the use of anti-psoriatic therapies 
such as ciclosporin and etanercept effectively reverse the psoriasiform 
changes seen in the plaque transplant XMP (Villadsen et al. 2003). The 
current methods of generating XMP are in broadly in keeping with current 
thinking of psoriasis pathogenesis, where both skin cells (e.g. keratinocytes) 
and immune cells (e.g. T-cells) play critical roles in pathogenesis, though the 
XMP model often depends on T-cells already resident in the skin, rather than 
those present in the circulation. Critically however, both the skin cells and 
T-cells are derived from the donor in current XMP, as the host mouse (SCID, 
RAG-/-, AGR129 mice) generally lacks both T- and B-cells (and have deficient 
NK cells), which is necessary for successful engraftment of the human donor 
skin (Boyman et al. 2004). The absence of host B-/T-cells/other cell 
mediators in XMP is in some respects a weakness of this model, in that the 
systemic host immune responses to the cutaneous inflammation are 
inherently limited. The lack of host immunity can however also be 
experimentally very useful; for instance, the development of psoriasiform 
lesions in unaffected psoriatic transplanted skin using the AGR129 mouse 
(Boyman et al. 2004), 1) demonstrates the importance of T-cells resident in 
the skin in pathogenesis and 2) suggests that systemic factors in the human 
donor may prevent plaque formation whilst in the human; once this 
‘systemic suppression’ is removed through grafting, skin inflammation 
develops rapidly. Furthermore, early work in this AGR129 XMP has also 
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implicated TNFα as an essential driver of resident T-cell mediated 
psoriasiform plaque development (Boyman et al. 2004). 
 
1.9.6 Transgenic mouse models 
Several mouse transgenic mouse models have been developed, that e.g. 
target the Stat3 pathways, TGFβ, the AP-1 transcription factor family, cell 
adhesion molecules, growth factors and the NFKB pathways, as reviewed in 
detail elsewhere (Gudjonsson et al 2007). Most of these models bear 
significant similarities to human psoriasis, as assessed by genome-wide 
expression profiling (Swindell et al. 2011). In one model Tie2 (an 
angiopoietin receptor) is overexpressed in keratinocytes and endothelial 
cells (KC-Tie2), leading to infiltration of epidermal CD8+ cells, dermal CD4+ 
cells, and the expression of psoriasis-associated cytokines, including IFNγ, IL-
6, IL-17 and TNFα (Wolfram et al. 2009). Comparisons between these models 
are difficult to make due to the sheer number of transgenic models 
available, but also due to inconsistencies in terms of e.g. the strain in which 
the model is generated, which in turn can affect the resulting phenotype 
(Gudjonsson 2007). Furthermore, inflammation cannot be easily induced at 
specific sites in most of these models, as in e.g. the IMQ- and 
xenotransplantion models. There are however some examples of transgenic 
psoriasis models where lesions may be partially inducible; transgenic skin 
overexpression of vascular endothelial growth factor VEGF (K14-VEGF) leads 
to spontaneously occurring psoriasiform lesions, but that can also be induced 
in response to cutaneous trauma (so called koebnerisation) (Xia & Zhang 
2014).  
 
1.9.7 Exogenous IL-23 induced mouse model 
A role for IL-23 in psoriasis pathogenesis is suggested by its overexpression in 
plaques (Lee et al. 2004), and further underlined by one of the most 
clinically efficacious drugs on the market (ustekinumab) that targets the 
common p40 subunit of IL-12 and IL-23 (Papp et al. 2008). It has been shown 
that intradermal injections of IL-23 recapitulate many aspects of psoriasis 
pathogenesis. The psoriasiform inflammation in this model is dependent on 
TNFα and IL-20R2, but apparently independent of IL-17A (Chan et al. 2006). 
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This model has since been used to demonstrate a possible role for CXCR4 to 
counteract some of the pro-inflammatory effects of Th17 cytokines 
(Takekoshi et al. 2013), and has further highlighted a role for the CCL20 
receptor CCR6 (that is expressed on IL-17A producing T-cells) (Hedrick et al. 
2009). Whilst the IL-23 injection model has been useful in some regards, it 
has some deficiencies, such as an absence of typical structural changes (e.g. 
elongated rete ridges). Perhaps more critically, it is also not associated with 
recruitment of psoriasis-associated (CD8+) T-cells into the epidermis (Chan 
et al. 2006). 
 
 
1.10 Overview of thesis 
Psoriasis is a common, systemic inflammatory disorder that affects 
approximately 2% of the adult and 0.5-1% of the paediatric population. It 
profoundly impacts on those who are affected both in terms of morbidity and 
mortality, notably in severe disease (Eberle et al. 2016; Di Meglio et al. 
2014). Several clinical subtypes of psoriasis exist, the most common of which 
(and that is the focus of this thesis) is psoriasis vulgaris. Psoriasis vulgaris is 
characterised by thick, erythematous (red) plaques on the skin, with silver-
white scaling (Figure 1.2). Such plaques have a particular predilection for 
extensor surfaces, such as the elbows and knees, as well as skin folds 
(Lebwohl 2003) (Figure 1.3). The cause for psoriasis is multifactorial and 
complex, with interactions between genetic and environmental factors. 
Recent genome-wide association studies (GWAS) studies have identified 
multiple gene susceptibility loci, and several environmental triggers are 
known, including skin trauma (Lowes et al. 2014). Though significant 
advances have been made, important gaps remain in our understanding of 
psoriasis.  
Histopathologically, the psoriatic plaques are characterised by epidermal 
hyperproliferation and thickening, elongation of the rete ridges, 
hyperkeratosis, and an infiltration of inflammatory cells. Psoriasis is 
considered predominantly a Th17 and Th1 driven condition, though numerous 
other cells have been implicated including Th22 cells, CD8+ cytotoxic cells, 
neutrophils, mast cells and dendritic cells (myeloid dendritic cells (mDCs) 
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plasmacytoid dendritic cells (pDC), Langerhans cells). Additionally, 
keratinocytes play a central role in disease pathogenesis (Lowes et al. 2014; 
Di Meglio et al. 2011; Diani et al. 2015). Numerous inflammatory mediators 
play a role in psoriasis, particularly Interleukin-17 (IL-17), IL-23, IL-22, 
Tumour Necrosis Factor (TNF), Interferon α (IFNα) and IFNγ being central to 
pathogenesis (Di Meglio et al. 2014). T-cell entry into the epidermis itself 
does appear to be critical for the development of psoriatic plaques (Conrad 
et al. 2007). A great deal of insight into psoriasis pathogenesis has been 
gained through studying the effect of an ever-increasing armamentarium of 
effective anti-psoriatic therapies. These include newer biological agents 
(monoclonal antibodies) targeting TNF, IL-12/23, IL-17, small molecule 
inhibitors targeting PDE4 and the JAK/STAT pathways, as well as older 
therapeutic strategies, such as UV-based therapies, ciclosporin, fumaric acid 
esters, methotrexate and retinoids. The mode of action of the majority of 
these drugs confirm that T-cells are key players in psoriasis (Di Meglio et al. 
2014). 
Critically, psoriasis is no longer considered merely a disease confined to the 
skin, but one that is systemic. This is perhaps best illustrated by psoriasis 
being associated with several comorbidities (e.g. cardiovascular, 
musculoskeletal and metabolic diseases) as well as increased mortality (Di 
Meglio et al. 2014). However, despite such recent insights, little has been 
known about how focal skin inflammation interacts, on a molecular level, 
with remote skin and other tissues. Furthermore, though epidermal T-cell 
entry appears to be critical for the pathogenesis of psoriasis, little is known 
about how T-cell positioning within skin is controlled, and how such 
regulation may influence the disease course.  
Chemokines are the principal regulators of leukocyte migration, and play a 
key role in the pathogenesis of psoriasis (Lowes et al. 2014). The atypical 
chemokine receptor ACKR2 is a scavenger for pro-inflammatory CC-
chemokines, and is believed to play a role in regulating chemotactic 
chemokine gradients in vivo. Recently, it has been shown that ACKR2 is 
differentially expressed in human psoriatic skin, where there is an 
upregulation in unaffected skin, and a relative downregulation in 
inflammatory plaques. ACKR2 is mainly expressed in basal epidermal 
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keratinocytes, and also in lymphatic endothelial cells, in human psoriatic 
skin (Singh et al. 2012). However, the functional relevance of this 
observation is not understood, nor do we understand the molecular basis for 
differential regulation of ACKR2 expression. Here, it is hypothesised that 
differential regulation of ACKR2 in skin is critical for the development of 
psoriatic plaques, and that modulation of ACKR2 expression can regulate the 
disease through its ability to remove inflammatory chemokines and so 
control leukocyte positioning within the skin. Specifically, it is hypothesised 
that high expression of ACKR2 protects against psoriatic plaques (by 
chemokine scavenging and regulation of T-cell migration), whilst focally 
reduced ACKR2 levels leads to dysfunctional chemokine gradient formation 
(as a result of inadequate scavenging by ACKR2), and thereby uncontrolled 
inflammation.  
 
This thesis is organised across 4 main results chapters, that explore; 
1) the role of ACKR2 in psoriasiform inflammation and its effect on T-cell 
migration and tissue positioning 
2) regulation of ACKR2 in skin remote from the lesion, and the effect of 
ACKR2 modulation on disease pathogenesis 
3) the role of microRNAs as epigenetic regulators of ACKR2 in human cells 
4) the role of tensile trauma in regulating ACKR2 expression  
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CHAPTER 2 2
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2 Methods and materials 
 
2.1 Animal work 
 
2.1.1 General principles of experiments involving mice 
All animal work was conducted following approval from the University of 
Glasgow Ethical Review Committee, and carried out under the authority of a 
UK Home Office Licence, in accordance with all applicable regulations. All 
mice were housed in environmentally enriched boxes in maximum groups of 
6, had access to food and water ad libitum, and received additional calorie 
supplementation with fruit puree during treatment. All mice were given a 7-
day acclimatisation period following any transfers prior to the 
commencement of experimental work. Mice were weighed daily, with weight 
loss >20% of the baseline being the cut-off for a cull as per the applicable 
Home Office regulations; no mice reached this threshold in any of the 
experiments in this thesis. The sole exclusion criterion for mice from data 
analysis was if the individual mouse was in a hair re-growth cycle, as this 
would preclude clinical assessment of skin inflammation.  
 
2.1.2 Imiquimod mouse model  
The imiquimod mouse model was based on previously published work (van 
der Fits et al. 2009), and modified as indicated in the results section. 6-8 
week female C57BL/6J wild-type (WT) mice (Charles River, UK) and ACKR2 
deficient mice (Jamieson et al. 2005), on a pure C57BL/6J background 
(backcrossed >12 generations) were used in the studies. 62.5mg of Aldara™ 
IMQ cream (Aldara™ cream, Meda, UK) or 10% Vaseline Lanette cream as 
negative control (Fagron, Netherlands), was applied to shaved mouse flank 
or to ear skin on a daily basis. Details of the treatment area are given in 
Chapter 3, whilst specific treatment application schedules are indicated in 
the results and relevant figures. Hair bearing skin was shaved using electric 
clippers (WAHL, USA) 24 hours prior to the first application of cream. In vivo 
experiments included a minimum of 6 mice per treatment group. 
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2.1.3 Cytokine treatment of mice 
IFNγ treated mice were treated with 10,000U or 20,000U recombinant 
murine IFNγ (R&D systems) either intraperitoneally (i.p.) or subcutaneously 
(s.c.) twice daily (as indicated in figure legends). IFNγ was reconstituted in 
0.01% sterile BSA in PBS (Sigma, UK), whilst 0.01% sterile BSA in PBS acted as 
negative vehicle control. Boluses of IFNγ/vehicle control for injection were 
standardised to 100ul across experiments, and were allowed to reach room 
temperature prior to injection. All injectable treatments were prepared 
aseptically, using sterile equipment in a tissue culture hood.  
 
2.1.4 Assessment of skin inflammation in vivo 
Mice were fully assessed individually at least once daily throughout all 
experiments, and severity of any psoriasiform skin inflammation quantified 
daily using a newly developed severity score (detailed in Chapter 3), taking 
into account the degree of skin thickening, erythema (redness) and skin 
scaling. Ear thickness was assessed using calipers (accurate to 0.01mm). Ear 
thickness was measured post-cull across three different sites on the mouse 
ear, and mean values used for analysis. Additionally, mice were weighed and 
the weight charted on a daily basis. 
 
2.1.5 Infection of mouse skin with Bunyamwera virus 
Mouse skin was injected with 4×104 plaque-forming units of Bunyamwera 
virus (BUNV) intradermally, kindly donated by Dr Clive McKimmie, University 
of Leeds. Injected skin and internal organs were harvested following cull 24h 
post injection, as detailed below.  
 
2.1.6 Processing of tissues post cull  
Mice were culled by means of a rising concentration of carbon dioxide (CO2), 
following which the thoracic cavity was immediately opened and the 
ventricles cut along the coronal plane, and blood removed by means of a 5ml 
syringe (BD, Germany). Treated and control skin (as indicated in figures), the 
heart, liver, spleen, and lymph nodes draining flank skin were dissected out. 
Tissues were immediately placed in RNAlater (Sigma, UK), and stored 
overnight at 4°C prior to further processing as detailed below. Where long-
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term term storage was necessary, RNAlater treated samples were stored at -
80°C prior to RNA extraction. Where samples were also to be used for 
microscopy in addition to RNA extraction, half the tissue was placed in 10% 
neutral buffered formaldehyde (Sigma, UK). All tissue processing took place 
in a tissue culture hood. 
 
2.2 Protein quantification in murine skin 
Secreted cytokines/chemokines in murine skin were quantified through the 
removal of skin upon cull. 20×2mm diameter circles (dermis and epidermis) 
of skin were obtained per treated site, by means of a 2mm diameter punch 
biopsy (Stiefel, UK). Skin was maintained at 4°C during all processing, to 
reduce the risk of protein degradation. Skin samples were placed in 0.1ml 
PBS (Sigma, UK) in the presence of Pierce protease inhibitor (Thermo Fisher, 
UK), and gently agitated (4 rotations per minute) at 4°C for 4 hours. Skin 
sections were subsequently removed, and any residual cell debris removed 
by means of centrifugation at 1000×g for 10 minutes at 4°C. The PBS 
containing the secreted protein was immediately frozen at -80°C until 
needed. Secreted protein was quantified by means of ELISA; CCL5 (R&D 
Systems), CCL20 (R&D Systems), IFNγ (BD Bioscience and IL-17 (BD 
Bioscience), as per manufacturer’s instructions. 
 
2.2.1 Dermal-epidermal skin splitting 
The dermis and epidermis were separated where it was necessary to 
determine differences in gene expression between the dermis and 
epidermis. Full thickness murine skin was fully submerged in 0.025mM EDTA 
(LifeTechnologies, UK) and incubated at 4°C for 12 hours. This enabled the 
epidermal layer to be easily curetted off the dermal layer using a number 15 
surgical blade (Swann-Morton, UK). Both the epidermal and dermal 
components were immediately lysed in Qiazol (Qiagen, UK) and processed as 
detailed below. The level of split was further confirmed by QPCR for the 
epidermal/keratinocyte marker involucrin (not expressed in the dermis), 
thereby enabling confirmation that the dermal compartment was relatively 
KC free (details of QPCR below). 
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2.3 Immunohistochemistry 
 
2.3.1 Immunohistochemistry of tissues  
Tissue sections intended for histological sections were maintained in 10% 
neutral buffered formaldehyde (Sigma, UK) for 24 hours prior to further 
processing. Tissue sections were processed overnight in an automated tissue 
processing workstation (Thermo Fisher, UK). Briefly, individual tissue 
samples were placed in a cassette and submerged sequentially as follows; 
1. 70% ethanol; 1h 
2. 90% ethanol; 1h 
3. 95% ethanol; 1h 
4. 100% ethanol; 1h, 2h and 2.5h 
5. 100% Xylene; 1h, 1h and 1.5h 
6. 100% Xylene; 1h and 1.5h 
7. Heated paraffin; 4h and 5h 
Processed tissues were thereafter embedded in solid paraffin. 
Immunohistochemistry was performed by technical staff at the University of 
Glasgow Veterinary School. Briefly, for H&E, Ki67 and CD3+ staining, paraffin 
embedded fixed skin was cut to 2 micron thickness. Heat-induced antigen 
retrieval was performed in pH 6 sodium citrate buffer for 100 seconds at 
125°C under pressure. Polyclonal rabbit anti-human CD3 was used at 1:100 
dilution and Polyclonal rabbit anti-Ki67 used at 1:400 (both Dako, UK), or 
negative controls, and counterstained with haematoxylin. 
 
2.3.2 Fluorescent immunocytochemistry 
Cells for fluorescent immunocytochemistry were cultured in 4-well plastic 
chamber slides (ThermoFisher Nunc, or BD Falcon, UK). Cells were washed 
gently at room temperature in PBS without Ca2+ (Sigma, UK), fixed in 100% 
methanol for 20 min and allowed to air dry. Slides were washed (twice, with 
0.05% PBST, Sigma, UK), and subsequently blocked with 20% horse serum in 
0.05% PBST (Sigma, UK), and thereafter Avidin/Biotin block. Slides were 
subsequently washed, and blocked with 30% normal horse serum (Dako, UK) 
in 0.05% PBST for 40 min. Cells were washed as per above, and stained 
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(overnight at 4°C) for ACKR2 using anti-human ACKR2 IgG antibody (Sigma 
Prestige Antibody, UK) at 0.5µg/ml in 0.05% PBST with 2.5% of each of horse 
and human serum. DAKO Negative Control Rabbit Immunoglobulin Fraction 
was used (0.5µg/ml) was used as isotype control. Next, biotinylated anti-
rabbit IgG raised in goat was used as the secondary antibody, in 0.05% PBST 
with 5% human serum, and incubated for 30 min at room temperature. Slides 
were washed in 0.05% PBST, incubated with Avidin-D fluorochrome 
conjugated with FITC (Vector Laboratories, UK). Slides were incubated in a 
lightproof humidified box. Slides were fixed with DAPI-containing 
Vectamount®, and visualized through confocal microscopy (LSM510, Zeiss, 
Germany) 
 
 
2.4 Cell culture 
Cell culture was performed aseptically in laminar flow hoods at all times. All 
experimental work was conducted at Passage 3-4, at 70% confluence 
(averaged across the entire vessel). All cells were maintained at 37°C in a 
humidified tissue culture incubator with 5% CO2. Cells were grown in the 
presence of 1% Penicillin/Streptomycin (Sigma, UK) and 0.1% Gentamicin 
solution (50mg/ml, Sigma, UK). Experiments were generally repeated using 
cells from at least 2 separate cell donors. 
 
2.4.1 Primary cell cultures: keratinocytes (KC) 
Healthy primary human skin keratinocytes (KC) from adult truncal skin were 
purchased from (Promocell, Germany), and were in passage 2 (P2) upon 
thawing and culturing (see below). KC were grown in KCGM2 medium with 
added CaCl2 (as per manufacturer’s instructions).  
 
2.4.2 Primary cell cultures: lymphatic endothelial cells (LEC) 
Healthy primary skin lymphatic endothelial cells (LEC) from neonatal 
foreskin, were purchased from (Promocell, Germany), and were in passage 2 
(P2) upon thawing and culturing (see below). LEC were grown in ECMV2 
medium (as per manufacturer’s instructions). 
 
SHAMS 2016 
	91 
2.4.3 Cell line culture; HEK293 and HEK293 ACKR2 transfectants 
HEK293 cell lines were kindly donated by Dr Kay Hewit, and were grown in 
DMEM (Sigma, UK) to which was added 50ml Foetal Calf Serum and 5ml L-
glutamine per 500mls (Sigma, UK). HEK293 transfectants were grown in the 
presence of G418 (plasmid expresses a neomycin resistance gene), at 
0.8mg/ml (Promega, UK).  
 
2.4.4 Freezing of cells 
Where long-term storage was necessary, primary cells and cell lines were 
frozen in CryoSFM (a serum free, methylcellulose based cryopreservation 
medium PromoCell, Germany), as per the manufacturer’s instructions. In 
brief, detached cells were frozen at a concentration of 1.5 million cells/ml 
CryoSFM in cryovials. Cryovials were frozen down to -80°C at a rate of 1°C 
per minute, and subsequently stored in liquid nitrogen.  
 
2.4.5 Thawing of cells 
All cells were thawed in accordance with the instructions of the suppliers of 
KC/LEC (PromoCell, Germany). Purchased primary cells (PromoCell, 
Germany) arrived frozen, on dry ice. Medium and all vessels were pre-
warmed to 37°C. Frozen cells were stored in liquid nitrogen, and where 
necessary transported surrounded by dry ice. For thawing, vials were 
submerged in water at 37°C and gently agitated until thawed (approximately 
180 sec). The vial was subsequently rinsed in 70% ethanol and wiped. Cells 
were transferred to the heated medium and incubated at 37°C at 5% CO2 
until adherent (approximately 16 h), after which the medium was changed.  
 
2.4.6 Subculture protocols 
Once a confluence of 90% was reached, cell cultures were split and either 
frozen for later use or subcultured. PromoCell DetachKit was used for all 
subculture of KC and LEC as per manufacturer’s instructions (PromoCell, 
Germany). In brief, culture medium was removed, and the cells washed with 
100µl HEPES BSS per cm2 vessel surface for 15 seconds, and the HEPES BSS 
removed. 100µl Trypsin was added per cm2 vessel surface at room 
temperature, and the vessel gently agitated until cells detached. For LEC 
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this took <5 min and for KC <10 min. Trypsin was neutralised by adding the 
same volume of Trypsin Neutralization Solution, and the cell suspension spun 
for 3 min at 220×g.  
HEK293 cells were washed in 0.25ml fresh pre-warmed medium per cm2 
culture vessel surface. Cells were detached using a sterile cell scraper into 
0.33ml fresh pre-warmed medium per cm2 culture vessel surface, prior to 
the cell suspension being spun for 3 min at 220×g. 
The pellets obtained above were resuspended in CryoSFM (as detailed above, 
if cells were intended for freezing) or in fresh medium at 37°C if for 
subculture. Primary cells were subcultured at a ratio of 1:4, and HEK293 
cells at a ratio of 1:10. 
 
2.4.7 Cytokine treatment of cells 
In order to ensure even distribution of cytokine across the cultured cells, 
cytokines were dissolved in the appropriate cell culture medium at the 
concentrations indicated in figures/results. Old medium was subsequently 
removed and replaced with cytokine containing medium, whilst control 
treated cells had their medium changed to fresh cytokine free medium. 
Where medium had to be treated (e.g. antibody neutralisation of cytokines 
using anti-human IFNγ monoclonal antibody (R&D Systems, UK), or 
complexing of cytokine/receptor (IL-6/IL-6R), the reaction took place in the 
medium prior to addition to the cells. 
 
2.4.8 Generation of skin equivalents 
All skin equivalents were prepared by collaborators (Dr Ellen van den 
Bogaard and Prof Joost Schalkwijk) at Radboud University Nijmegen, the 
Netherlands, as previously described (van den Bogaard et al. 2013). Briefly, 
healthy human donor dermis was enzymatically decellularised, and 
populated with primary healthy human keratinocytes on its upper aspect. 
CD4+ T-cells were added to selected skin equivalents form underneath, and 
were purified from healthy donors through negative selection (Koenen et al. 
2008), and magnetically depleted for CD25high Treg (Miltenyi-Biotec, 
Germany). Isolated human T-cells were activated with anti-CD3/CD28 beads 
(LifeTechnologies, the Netherlands) at a cell:bead ratio of 5:1 for 5h prior to 
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being washed and added to the skin equivalents as described above. 
Treatment of skin equivalents with anti-psoriatic drugs took place 48h after 
T-cells had been added to the skin equivalents, as follows; ciclosporin A 
(400ng.ml, Novartis, Netherlands) and all-trans retinoic acid (10-6M, Sigma, 
the Netherlands) 
 
2.4.9 Tensile stress of cells 
Cells intended for tensile stress experiments were grown on BioFlex™ 6-well 
plate format silicon membranes (BioFlex™, Dunn, Germany). KC were grown 
on Collagen I pre-coated plates. For LEC, uncoated silicon plates were 
coated with Fibronectin as follows; each well was filled with 1.5ml of 
Fibronectin solution (at 10µg/ml in PBS, both Sigma, UK) at 4°C for 24 hours, 
after which the solution was removed prior to the plating of LEC. Cells were 
grown until approximately 70% confluent (confluence was generally higher at 
the centre of the well, and more sparse at the edges, partially due to the 
flexibility of the silicone membrane) 
Once sufficiently confluent, the membranes were stretched using the 
FlexCell™ FX5000 machine. This incorporates a computer controlled base 
unit, and a plate with a solid stage (detailed in Figure 6.1) on which 4 
separate 6 well plates can be placed. The solid stage is then placed in an 
incubator at 37°C for the duration of stretching (the principles of the 
FlexCell™ are summarised in Figure 6.1). Static control plates were also 
placed on the solid stage (to minimise sources of variation), but the vacuum 
underneath turned off. Stretching was set at 0.8Hz, 15% effective stretch, ½ 
Sine wave-form for 12 hours (Figure 6.2). Lubricant was applied to the solid 
stage against which the membrane would move for two reasons 1) to reduce 
friction and thus enable effective stretching and 2) to reduce heat 
generation due to friction. Due to the lubricant between the membrane and 
the stage being progressively pushed to the side, lubricant was re-applied 
every 30 minutes throughout the experiment. Cells were lysed directly on 
the silicone membrane using Qiazol, the homogenate vigorously pipetted up-
down and the lysate put through Qiashredders to optimise homogenisation 
(as per manufacturer’s instructions, Qiagen, UK) prior to RNA extraction, as 
detailed above. 
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2.4.10   Isolation and stimulation of human T-cells 
T-cells were isolated from buffy coats supplied by the Scottish Blood 
Transfusion service. These were depleted for CD14+ cells using magnetic 
columns (Miltenyi, UK). Cells were grown in RPMI (ThermoFisher, UK) with 5% 
added fat-depleted human AB serum, gentamicin (Sigma, UK), 20U/ml 
human recombinant IL-2 (Peprotech, UK) and Concanavalin A (5ng/ml, 
Sigma, UK). Cells were incubated for 8 days at 37°C with 5% CO2, after which 
the cell suspension was purified on Ficoll-Paque (GE Healthcare, Sweden), 
and grown as before, but in the presence of IL-2 alone for 4 days. Cells were 
subsequently activated using CD2/CD3/CD28 beads at a 1:2 bead:cell ratio 
(Miltenyi, UK, as per manufacturer’s instructions). A bead:cell ratio of 1:4 
was used where T-cells were to be used for migration assays. Cells were 
activated for 24 prior to removing the conditioned medium (tissue culture 
supernatant) and before T-cells were used for further downstream 
applications. Where T-cell supernatant was to be used to stimulate KC or 
LEC, T-cells were grown in serum free KC/LEC medium, as detailed above 
(Promocell, UK).  
 
 
2.5 Cell migration 
 
2.5.1 Preparation of migration chambers 
Migration chambers were constructed using sterilized materials. A sterile 
16×16mm glass cover slip was suspended 1mm above the surface of a glass 
microscopy slide, using a 1:5 mixture of paraffin and Vaseline, heated to 
80°C. Using the paraffin/Vaseline mix, 3 edges of the slide were sealed, 
forming a pocket on one side. Slides were sterilized using UV light prior to 
use. The construction of the slides is represented diagrammatically in Figure 
3.15-16). 
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2.5.2 Preparation of cell layers 
0.5×106 activated T-cells were suspended in 300µl semi-solid collagen 
matrix, and used to fill the chamber halfway up (Figure 3.16). This was 
allowed to set in a humidified incubator at 36°C with 5% added CO2. The 
collagen matrix was made as follows; 
166.6µl bovine collagen solution, 22.2µl MEM and 11.2µl NaHCO3 (all Sigma, 
UK) were carefully mixed. For the T-cell layer, 0.5×106 activated T-cells 
were suspended in 100µl serum free medium, and mixed with 300µl of the 
collagen mixture above. For KC and HEK layer, 1.05×106 or 3.6×106  HEK293 
were mixed into 16.7µl of serum free culture medium, and mixed with 
33.3µl of collagen solution (166.6µl bovine collagen solution, 22.2µl MEM and 
11.2 µl NaHCO3). Please note that these quantities were scaled up as 
appropriate to reduce error. 
A cellular (KC or HEK293) interface was subsequently layered on top of the 
T-cell layer, with the cells making up 10% of the total volume of the 
interface. That volume of cells was shown not to inhibit the formation of a 
chemotactic chemokine gradient as cells could migrate towards a 
chemotactic stimulus beyond the cell layer. Once the interface layer was 
set, the chemokine layer was made up in KC medium where the interface 
consisted of KC, and HEK medium where the interface consisted of HEK293 
cells, as detailed previously (but maintained serum free so as to not 
interfere with chemotaxis). This was layered on top of the other layers, and 
the chamber top sealed using paraffin/Vaseline. The slide was subsequently 
maintained flat on a heated stage (37°C) and photographs obtained every 30 
sec for 3 hours.  
 
2.5.3 Analysis of cell migration 
All cells visible in the recorded field of view were tracked using ImageJ with 
a cell tracker plugin (see Figure 3.17-18). Entirely non-motile cells were 
excluded form analysis as viability could not be determined. Vector data 
were assessed by the Rayleigh test for vector data in chemotaxis plugin in 
ImageJ (http://imagej.nih.gov/ij/). P<0.05 was deemed significant. 
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2.6 microRNAs 
 
2.6.1 microRNA in silico selection 
MicroRNAs that were predicted to bind to the 3’-untranslated region (UTR) of 
ACKR2 were identified using TargetScan version 6.2 (www.targetscan.org). 
MicroRNAs with the highest likelihood of binding (as indicated by the total 
context, CT score) the ACKR2 3’-UTR and that were concurrently identified as 
being upregulated in psoriatic plaques in humans were selected for further 
study. Further detail of the selection process is provided in Section 5.5.1, 
and Figures 5.1-3. 
 
2.6.2 microRNA transfection of cells 
Cells were transfected with Lipofectamine RNAiMax as per manufacturer’s 
instructions (ThermoFisher, UK). Cell culture medium was changed to 
antibiotic free equivalents 24h prior to transfection, and maintained 
antibiotic free throughout the transfection process.  Cells were transfected 
at 70% confluence. microRNAs, scrambled microRNA control and miR 
inhibitors (miRvana, ThermoFisher, UK) were aseptically reconstituted in 
nuclease free water so as to yield 10pmol of miR/µl. miR/control/inhibitors 
were transfected at the recommended 10nM, unless otherwise indicated in 
figures. Briefly, 6pmol of miR was dissolved in 50µl Opti-MEM (reduced serum 
medium, ThermoFisher, UK), and separately 1.5µl RNAiMax was mixed with 
50µl Opti-MEM. The two were mixed, and allowed to complex at room 
temperature for 20 minutes. 100µl of this mix was added to each 24-well 
tissue culture plate (this was scaled up/down according to well/plate size). 
Transfection was allowed to occur at 37° for 24 hours before the cells were 
lysed (or the medium was changed for prolonged incubation, as indicated in 
figures). At this concentration, the microRNAs had no detectable effect on 
cell viability. A minimum of 3 replicates (tissue culture wells or flasks) were 
used for each experiment. 
 
2.6.3 Luciferase microRNA assay 
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The 3’-untranslated region (UTR) of ACKR2 was amplified from genomic DNA 
using primers 8aNheI (tgacctagctcaaagtgctctctccagg) and 8bSalI 
(tgccccaacttcattatcaaagtcgactcga) and Platinum Pfx Polymerase (Invitrogen, 
ThermoFisher, UK). The ACKR2 UTR was subsequently cloned into the dual 
luciferase system containing the pmiRGLO vector (as per manufacturer’s 
instructions, Promega, UK). Subsequently, the PCR product and pmiRGLO 
Vectors were digested using NheI and SalI. Fragments were run along with a 
1kb ladder (Promega, UK). 10µl ladder was used with 1µl BlueJuice 
(ThermoFisher, UK) and run on a 0.7% agarose gel with added ethidium 
bromide. Fragments were cut out and extracted from the gel (ACKR2 3’-UTR 
1577bp, pmirGLO 7332bp) using the QiaQuick Gel extraction kit (Qiagen, 
UK). Fragments were ligated (T4 ligase, Invitrogen, ThermoFisher, UK) and 
transformed into chemo-competent Escherichia coli bacteria (OneShot® 
TOP10 Chemically Competent E coli, Invitrogen, ThermoFisher, UK). The 3’-
UTR region was sequenced to ensure putative microRNA binding sites were 
intact (Eurofins, UK, see Figure 5.11). The plasmid was transfected into 
HEK293 cells and stable transfectants generated through selection with 
0.8mg/ml G418 (Promega, UK). Non-ACKR2 containing pmiRGLO vector was 
transfected as a control. HEK293 cells were cultured as outlined above 
(Section 2.4.3). Several clones were identified for further testing, and two of 
these clones were transfected with the relevant microRNAs/controls (Section 
2.6.2), cells lysed and Firefly luciferase activity normalised to Renilla 
luciferase (as per manufacturer’s instructions, Promega, UK). pmiR 
containing HEKS (i.e. with no ACKR2 3’-UTR) and native HEK293 cells were 
used as controls in the assay, that was repeated using two separate HEK293 
clones.  
 
 
2.7 Western Blots 
 
2.7.1 Lysis of Cell cultures 
Cell cultures were lysed in lysis buffer, made up as follows; 1µl HALT 
Protease and Phosphatase Inhibitor (ThermoFisher, UK) in 100µl MACS Lysis 
Buffer (Miltenyi, Germany), and kept on ice at all times. Cell pellets were 
SHAMS 2016 
	98 
prepared form tissue cultures plates as described in detail above and lysed 
by the addition of the lysis buffer (1ml lysis buffer per 1×106 cells), followed 
by pipetting up-down multiple times to ensure even lysis, as per 
manufacturer’s instructions. Cell debris was removed through centrifugation 
for 10 min at 10,000×g at 4°C, and the supernatant removed, and aliquots 
frozen at -80°C were kept until needed. Where lysates were to be 
compared, the same cell numbers were lysed for each lane of the Western 
Blot.  
 
2.7.2 Preparation of Western Blot Gel 
15µg protein lysate (prepared as per above) was mixed with 5µl LDS buffer, 
after which 2µl NuPage Sample Reducing Agent (ThermoFisher, UK) was 
added to each sample. 20µl of each sample (or 20µl ladder, Invitrogen, 
ThermoFisher,UK) added of each lane of a pre-cast NuPAGE Bis-Tris SDS gel 
(ThermoFisher, UK). The gel was run at 150V, 125mA, 100 Watts for 60 
minutes (ThermoFisher; nuPage MES SDS running buffer 25ml into 500ml 
distilled water, kept at 4°C).  The gel was cut out, and electrophoretically 
transferred to a methylcellulose membrane using the iBlot system 
(ThermoFisher, UK). Even protein loading was confirmed through the 
addition of 10ml 0.1% Ponceau S in 5% acetic acid for 10 sec (Sigma, UK). 
Ponceau stain was removed by 4×5 min washes with 25ml 0.05% PBST (250µl 
Tween into 500ml Dulbecco’s PBS without Ca2+). The membrane was blocked 
overnight at 4°C under gentle agitation in 20ml 5% dried skimmed milk 
(Marvel, UK) in PBS.  
 
2.7.3 Antibody staining of Western Blot (for ACKR2) 
Following overnight block, the 10% milk solution was removed and replaced 
with 20µl anti-CCBP2 (ACKR2) antibody raised in rabbit (Sigma Prestige 
Antibody, UK) dissolved in 20ml 5% dried skimmed milk in PBS. Binding of the 
primary antibody took place at 4°C overnight under gentle agitation. The 
solution was washed off with 5×5min 20ml 0.05% PBST washes. 2µl anti-
rabbit IgG linked to HRP (Cell Signaling Technologies, USA) was used as a 
secondary antibody, dissolved in 20ml 5% dried skimmed milk, and allowed 
to react with the blot for 1h at room temperature. The membrane again 
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underwent 5×5min 20ml 0.05% PBST washes. Subsequently 750µl 
SuperSignal® West Femto Luminal Enhancer (ThermoFisher, UK) was mixed 
with the same volume of SuperSignal® West Femto Stable Peroxide Buffer 
ThermoFisher, UK), and added to the blot, and allowed to react for 2 
minutes. The blot was then placed in a transparent plastic pocket, excess 
liquid removed, and the edges sealed shut. The blot was kept in a dark 
developing box, until being developed onto photographic film (Kodak, UK). 
Where signal was too strong, multiple blank films were placed between the 
blot and the final film in order to optimize exposure.  
 
2.7.4 Antibody staining of Western Blot (for β-tubulin, 
housekeeping gene) 
Following development, the membrane was washed for 10 min in 0.05% 
PBST, then 25ml Strip Buffer at room temperature for 15 min, and a further 
3×15min washes with 0.05% PBST. The blot was then blocked with 20ml 5% 
BSA in PBST for 1h at room temperature, before adding 20µl anti-β-tubulin 
rabbit antibody 9F3 pre-conjugated with HRP (Cell Signaling Technologies, 
USA) in 20ml 5% BSA in PBS, and allowed to react for 1h at room 
temperature. The blot was washed 3×15min washes with 0.05% PBST, and 
was developed with SuperSignal® West Femto, as above. 
 
2.7.5 Western blot band densitometry  
Band density was quantified using ImageJ 
(http://rsb.info.nih.gov/ij/index.html), as detailed at; 
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/ 
In this manner, the density of bands (as indicated in Figure 5.23a) of ACKR2 
were quantified, and normalised to the house keeping β-tubulin band. 
 
 
2.8 RNA extraction 
 
2.8.1 RNA purification from cell cultures 
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Total RNA from adherent and non-adherent cell cultures was extracted by 
using the RNeasy Micro kit (Qiagen, UK), where samples were not intended 
for microRNA quantification. The kit is based on a silica gel column that 
relatively excludes rRNA and tRNA (www.qiagen.com), and extraction was 
carried out as per the manufacturer’s instructions. In brief, prior to lysis, 
tissue culture medium from confluent cell monolayers was removed, and the 
cell layer gently washed by once adding/removing the same volume of PBS 
at 37°C in order to remove any dead/non-viable cells. For non-adherent 
cells, cells were washed in PBS and a cell pellet obtained through 
centrifugation prior to lysis (300×g for 5 min). Cell lysis was subsequently 
achieved through the addition of RLT buffer (with 10µl β–
mercaptoethanol/ml RLT buffer, in order to denature any RNases released 
during the lysis process). The lysate was pipetted up-down vigorously to 
ensure homogenisation of the sample. Additionally, each sample was 
immediately vortexed for 10 seconds to ensure full homogenisation. RNA was 
bound to the column by means of centrifugation, and washed once with RW1 
buffer. The RW1 buffer was diluted with molecular grade isopropanol rather 
than ethanol (Fisher, UK) as per the manufacturer’s instructions, in order to 
enable retention of microRNAs. This was followed by an additional 15min on-
column DNAse digestion step (DNAse1, Qiagen, UK), prior to two further 
washes with RW1 buffer and one wash with each of RPE buffer and 80% 
ethanol, prior to drying of the column. The purified RNA was eluted in 20µl 
nuclease free water, and the eluted sample put through the column twice, 
to ensure maximal RNA yield. The concentration and purity of the eluted 
RNA was determined through the use of a Nanodrop that measures optical 
density (Thermo, UK), as per the manufacturer’s instructions. All plastics 
and reagents used were of molecular grade and were RNAse free. 
 
2.8.2 RNA purification from skin and solid organs 
Total RNA from skin and solid organs and cell culture (where microRNA 
quantification was intended) was extracted by using the miRNeasy Mini kit 
(Qiagen, UK). The kit is based on a silica gel column that relatively excludes 
rRNA and tRNA (www.qiagen.com), and extraction was carried out as per the 
manufacturer’s instructions. Quantities of samples that were processed in 
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this manner were as follows; 1) skin: approximately 5×5mm; 2) heart: 
quarter, cut along coronal and sagittal plane so as to include both ventricles 
3) liver: lateral 1/5 cut along sagittal plane 4) spleen: quarter 5) lymph 
nodes: whole node. Cell culture samples were lysed directly in 700µl Qiazol 
by means of rapid/vigorous pipetting of the cells, and the aspirate 
additionally vortexed for 10 sec. Solid tissue samples (previously fixed using 
RNA later) were placed in 700µl Qiazol in 2mm tubes (Eppendorff, UK) and 
were homogenized using two 5mm stainless steel beads per tube (Qiagen, 
UK) at 50Hz for 10 minutes at room temperature.  
The homogenate was removed, and 140µl chloroform added as per the 
manufacturer’s instructions and the sample shaken at 50Hz for 1 minute. 
Samples were centrifuged for 15 min at 12,000×g at 4°C, which separated 
the sample into three phases. The upper clear phase was removed, and 100% 
ethanol at 1.5 times the volume of the aspirate added, and the RNA bound 
to the silica column by means of centrifugation. The column was washed 
with buffer RWT, which was followed by an additional 15min on-column 
DNAse digestion step (DNAse1, Qiagen, UK) The column was washed twice 
with RPE buffer before drying of the column. The purified RNA was eluted in 
50ul nuclease free water, and the eluted sample put through the column 
twice, to ensure maximal RNA yield. The concentration and purity of the 
eluted RNA was determined through the use of a Nanodrop. All plastics and 
reagents used were of molecular grade and were RNAse free. 
 
2.8.3 Reverse transcription of RNA 
500-1000ng RNA (depending on the total yield/RNA source, which was 
generally lower for cell culture samples grown in a 24-well format, and 
higher for solid organs/whole skin) was reverse transcribed to cDNA using 
PrimerDesign RT or RT2 kits (the former discontinued and replaced with the 
latter during the thesis) as per the manufacturer’s instructions 
(PrimerDesign, UK). In brief, 500-1000ng RNA plus RT primer (a mixture of 
random primers and oligodT) in water to a volume of 14µl were heated to 
65°C for 5min for the annealing step, and the samples immediately placed 
on ice. For the extension step, Nanoscript™ Buffer, dNTP, DTT and RT 
enzyme were added as per the manufacturer’s instructions (up to a volume 
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of 20µl per tube), and the tubes heated as follows; 25°C for 5 min, 55°C for 
20 min and heat inactivation of the reaction by heating to 75°C for 15 min. 
Samples were diluted 1:5 in nuclease-free water prior to being used as a 
template for QPCR. 
For samples intended for microRNA QPCR, 440ng total RNA was reverse 
transcribed using miScript II RT kit as per manufacturer’s instructions 
(Qiagen, UK). Samples were diluted 1:5 in nuclease-free water prior to being 
used as a template for QPCR.  
All cDNA was stored at -20°C until use, and thawed on ice prior to use. 
 
 
2.9 Polymerase chain reaction  
 
2.9.1 Quantitative Polymerase Chain Reaction (PCR) primer 
design 
For QPCR two sets of primers were designed; 1) one ‘inner pair’ for 
amplification of a specific smaller DNA sequence within the gene of interest 
and 2) an ‘outer pair’ that amplified DNA sequence that incorporates the 
smaller DNA sequence amplified by the ‘inner’ primer pair. The outer primer 
pair is utilized for generation of a standard, enabling the generation of a 
standard curve, and hence quantification of gene expression. (see also 
section 2.9.5). Primers were designed using Primer3 (available on 
http://primer3.ut.ee) to the following basic specifications, in order to 
minimize risk of primer dimer formation; 
• 18-23 base pairs in length 
• 40-65% GC content (50% deemed optimal) 
• Tm of primer between 59.5-61°C 
• Max 3’-self complementarity: 1 
• Overall self complementarity: 2 
• Amplicon size <150bp 
• ≤2 G or C bases in last 5 bases at 3’ end 
• <4 G or C in a row in primer 
If no suitable primers were identified, these parameters were gradually 
relaxed until a suitable primer pair was found in the following order; 1) 
relaxation of self-complementarity up to 3 and 2) lowering the Tm of the 
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primer down to 59°C (however maintaining 3’ self-complementarity at 1). 
BLAST analysis was performed for all primers to ensure the primers were 
specific to the gene of interest (http://www.mcbi.nlm.gov/BLAST/). Primers 
were synthesized (IDT, Belgium), and were diluted down to a concentration 
of 1nmol/10µl in nuclease free water prior to use. 
Subsequently, primer specificity was confirmed by means of PCR (see below) 
for each primer pair, and the PCR product visualized on a 2% agarose gel 
through the use of ethidium bromide. Briefly, 2g agarose were dissolved in 
100ml tris-acetate EDTA buffer and heated until the agarose had dissolved, 
prior to the addition of ethidium bromide and pouring of the gel. The gel 
was run at 100V in tris-acetate EDTA buffer until a clear separation of the 
ladder was evident, and visualized using an Alpha Imager ultraviolet light 
visualization station. Only primer pairs that yielded one single distinct band 
of an expected size (as per Primer3 in silico predictions) were deemed 
specific (Invitrogen 0.1-2Kb ladder, ThermoFisher, UK). The gene product of 
the outer primer pair for the specific gene was thereafter cut out and 
purified (PureLink™ PCR Purification kit, ThermoFisher, as per 
manufacturer’s instructions; experienced users’ procedure), eluted in 
nuclease free water (Qiagen, UK) and subsequently used for the generation 
of a QPCR standard (see below) 
 
2.9.2 Polymerase Chain Reaction (PCR)  
For non-quantitative PCR, the following steps were undertaken; 1ul of each 
forward and reverse primer for the gene of interest was added to a master 
mix (Red PCR mastermix, Rovalab, UK), in a 100ul clear PCR tube with a 
domed cap, plus 2ul of the diluted cDNA template and 2ul of nuclease free 
water. The sample was vortexed, and spun down prior to undergoing; one 
cycle at 94°C for denaturation, and subsequently 35 cycles of; 1) 94°C for 15 
sec (denaturation/strand separation), 2) 60°C for 15 sec (annealing) and 
72°C for 30 sec (PCR product extension). This was followed by 7 min at 72°C 
after which the samples were kept on ice. 
 
2.9.3 Generation of standard curve for QPCR 
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A standard curve was necessary for quantification of gene expression. In 
general the absolute copy number was not calculated, as it was the relative 
change in gene expression that was of principal interest in the presented 
experiments. The absolute quantity of gene expression can however be 
calculated by determining the copy number of the gene of interest within 
the standard using a Nanodrop that measures optical density, thereby 
calculating the concentration of transcript (Thermo, UK).  
The purified PCR product generated using outer primer pair product for the 
gene of interest (detailed in section 2.9.1, and sequences given in section 
2.9.5), was denoted 100, and was diluted to 10-2 (in TE buffer, that enhances 
stability for freeze/thawing and additionally inhibits DNAse) for long-term 
storage. For the generation of a standard curve of QPCR, this was serially 
diluted in nuclease free water to yield a range of standards from 10-4 down 
to 10-10 (plus a negative Non-Transcript Control, NTC). This range would 
enable accurate quantification of genes that are expressed both at very high 
and very low levels. For ACKR2 in contrast, instead of generating a standard 
using a PCR fragment, a plasmid containing the cDNA of interest was used for 
the same purpose.  
 
2.9.4 Quantitative Polymerase Chain Reaction (PQCR) protocol 
All samples (including standards) were analysed as quadruplicate technical 
replicates on the QPCR machine (Applied Biosystems, HT7900, Thermo 
Fisher, UK), in a 384-well format for all experiments. For each 
well/reaction, the following reagents were used; 
• 5µl SYBR Green Mix (Quanta, UK) 
• 4µl nuclease free water (Qiagen, UK) 
• 0.15µl primer mix (at 1:1 ratio for forward and reverse primers, diluted as 
per above) 
• 1µl cDNA (sample or standard, or nuclease free water only for NTC) 
To increase accuracy, a master mix containing all the above (minus cDNA) 
was prepared, and contents for each 384-well prepared in a 96-well format 
using a multi-channel pipette. The contents were mixed and centrifuged in 
this format, and 9.1µl of the contents transferred to each well in a 384-well 
format. This approach minimized pipetting errors. Care was taken not to 
SHAMS 2016 
	105 
touch the 384-well plate, and the plate was light-protected as far as was 
practically possible. The plate was spun (3 min at 300×g) prior to analysis. As 
all product sizes were small (<150bp) a fast run was utilized on the QPCR 
machine, as follows; 
1. 3 min at 94°C (once only) 
2. 3 sec at 94°C and 30 sec at 60°C (repeated for 40 cycles) 
3. Melt curve generation (once only, see below) 
In addition to primer validation (outlined above) a melt curve was always 
performed to ensure the presence of one single PCR product in all samples. 
In this process the reaction temperature is progressively increased from 65-
94°C, yielding a concurrent measure of fluorescence. One single product size 
yields one clear peak in fluorescence, thus confirming that a product of one 
size only is present. NTC samples were analysed to ensure there was no 
background signal. 
For samples intended for microRNA quantification, QPCR was performed 
using the miScript SYBR Green PCR kit, with primers for miR-146a and 146b 
normalised to RNU6B expression (all Qiagen, and as per manufacturer’s 
instructions), and analyzed on a 384-well Applied Biosystems 7900HT (Life 
Technologies). Results for microRNA were analysed according to the ΔΔ-
method, rather than semi-absolute methods as used for mRNA. 
 
2.9.5 Primer sequences 
Gene/ 
species Reference QPCR1 QPCR2 Standard	1 Standard	2 
ACKR2 
mouse 
 NM_001276719.1 
TTCTCCCACT- 
GCTGCTTCAC 
TGCCATCTCA- 
ACATCACAGA 
Plasmids of cloned  
gene used 
 
ACKR2 
human 
 NM_001296.4 
AGGAAGGA- 
TGCAGTGGTGTC 
CGGAGCAAG- 
ACCATGAGAAG 
Plasmids of cloned 
gene used 
 
18S 
mouse/ 
human NR_003286 
gactcaacac- 
gggaaacctc 
taaccagaca- 
aatcgctccac 
cgtagttccga- 
ccataaacga 
catctaagggc- 
atcacagacc 
TBP 
human 
 M55654 
aggataagag- 
agccacgaacc 
gctggaaaac- 
ccaacttctg 
gggcacca- 
ctccactgtatc 
catcttctcac- 
aacaccacca 
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INVO- 
LUCRIN 
mouse NM_008412  
gcttcaagga- 
aacagcagct 
tacttctcctg- 
ctgtgtccg 
cagcagcaa- 
cagatagagcg 
tgtgggatgg- 
ttggagagtc 
 
2.9.6 QPCR data analysis 
The median value of the four technical replicate reactions that were 
conducted for each biological sample was utilized for analysis. All results 
were normalised to a housekeeping gene, that was 18S for murine samples 
and TATA-binding protein (TBP) for human samples, unless otherwise 
indicated in figures. These were selected as previous experience in the 
laboratory have found that they remain stably expressed irrespective of 
treatments. Results are expressed as copies of the gene of interest / copies 
of housekeeping gene.  
 
 
2.10 Statistical analyses 
 
Student’s t-test, One-way ANOVA, two-way ANOVA and correlation tests 
were performed in Prism Version 7.0 (GraphPad Software Inc.), with multiple 
comparison tests as appropriate. P<0.05 was deemed significant. All data are 
n≥3 and given as Mean ± SEM unless otherwise stated. 
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3 ACKR2 determines the severity of psoriasiform 
cutaneous inflammation in vivo and T-cell 
positioning in skin. 
 
 
3.1 Contents 
3.2  
Hypotheses 
3.3 Aims 
3.4 Introduction 
3.5 Results 
3.5.1 A murine model of cutaneous inflammation for studying the in vivo 
role of ACKR2.  
3.5.2 ACKR2 expression levels in the IMQ mouse model of psoriasiform 
inflammation. 
3.5.3 ACKR2 expression in remote internal organs in the IMQ mouse model 
of psoriasiform inflammation. 
3.5.4 Absence of ACKR2 was associated with more severe psoriasiform 
inflammation in the IMQ mouse model. 
3.5.5 Absence of ACKR2 was associated with enhanced epidermal 
thickening and basal keratinocyte hyperproliferation.  
3.5.6 ACKR2-/- mice demonstrated enhanced CD3+ T-cell entry into 
epidermal skin layers in response to topical IMQ. 
3.5.7 A novel in vitro model of T-cell migration towards a chemokine 
stimulus.  
3.5.8 A barrier layer of cells expressing ACKR2 regulated T-cell migration 
towards a chemokine stimulus. 
3.6 Summary Chapter 3 
 
3.2 Hypotheses 
• ACKR2 expression in IMQ treated mice will replicate the pattern seen in 
psoriatic patients (high in uninvolved skin; low in plaques) 
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• Lack of ACKR2 expression increases severity of psoriasiform inflammation 
in vivo. 
• ACKR2 expression regulates T-cell positioning in the epidermis 
• ACKR2 expression in human keratinocytes regulates T-cell migration 
towards the inflammatory chemokine CCL5 
 
3.3 Aims 
the aims of this chapter were to; 
• validate a murine model of cutaneous inflammation suitable for studying 
the role of ACKR2 in psoriasiform pathology in vivo 
• determine the role of ACKR2 in the development of psoriasiform 
pathology using the IMQ in vivo murine model of psoriasis 
• determine whether keratinocyte ACKR2 expression influences the 
positioning of inflammatory T cells within the skin 
 
3.4 Introduction 
Previous studies have shown significant differences in ACKR2 expression 
between affected psoriatic human skin, and apparently unaffected skin of 
patients. Specifically, ACKR2 expression is relatively deficient in 
inflammatory psoriatic plaques but significantly increased in the unaffected 
(normal looking) skin of the same patients (Singh et al. 2012). However, the 
role of differential expression of ACKR2 in psoriasis has not previously been 
explored. Here, it is hypothesised that reduced ACKR2 expression in skin 
leads to deficient chemokine scavenging, thereby allowing uncontrolled skin 
inflammation and thus psoriasiform plaque development. In contrast, it is 
hypothesised that where ACKR2 expression is high, enhanced scavenging of 
pro-inflammatory chemokines reduces inflammatory cell influx and 
inflammation. 
In order to optimally study psoriasiform inflammation in vivo, a model is 
required that has sufficiently high fidelity to human psoriasis, whilst also 
enabling the induction of psoriasiform inflammation at discrete skin sites, in 
an immunocompetent organism. In recent years, the imiquimod mouse 
model of psoriasis (IMQ model) has become a widely used and extensively 
validated research tool that bears significant similarities to human psoriasis 
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(van der Fits et al. n.d.; Walter et al. 2013; Ueyama et al. 2014). This model 
has the added benefit of being inducible in several different mouse strains 
thus being appropriate for our ACKR2-/- mice that are on a C57BL/6 
background. Furthermore, the psoriasiform plaques in the IMQ model can be 
induced at specific pre-determined sites (Van Belle et al. n.d.), thereby 
enabling detailed analysis of differences between affected and unaffected 
skin.  
Studies have shown that T-cell migration from the dermis (deeper skin 
layers) into the epidermis (outer skin layer) is critical for the development of 
psoriasiform inflammation in vivo (Conrad et al. 2007). Thus, development 
of psoriatic plaques appears to not only depend on the presence of T-cells in 
whole skin, but also on their precise positioning within skin. Chemokines play 
a critical role in regulating T-cell migration into skin in psoriasis, as reviewed 
elsewhere (Lowes et al. 2014). The capacity of ACKR2 for scavenging CC-
chemokines (Galliera, Galliera, et al. 2004), would therefore be in keeping 
with ACKR2 playing an important role in T-cell positioning in the epidermis. 
Therefore, it was hypothesised that ACKR2 plays a role in determining T-cell 
localisation in psoriasiform skin inflammation. 
ACKR2 in unaffected psoriatic skin is particularly highly expressed in the 
basal keratinocytes (KC) of the epidermis (Singh et al. 2012). Keratinocytes 
are the most abundant cells in the epidermis, and the basal KCs form a 
confluent layer at its base, thus forming an interface between the epidermis 
and dermis (Nestle, Di Meglio, et al. 2009). As discussed above, T-cell 
migration from the dermis into the epidermis is critical for plaque 
development (Conrad et al. 2007). It is also known that CC-chemokines that 
bind ACKR2, and which attract T-cells (CCL2 and CCL5), are expressed in the 
psoriatic plaque epidermis (Singh et al. 2012). Here it is hypothesised that 
ACKR2 expressed in a barrier layer of keratinocytes, acts as a scavenger of 
CC-chemokines originating in the epidermis. The absence of ACKR2 is 
predicted to result in enhanced chemokine gradient formation that extends 
its reach beyond the epidermal KC layer, enabling leukocytes to migrate 
towards a CC-chemokine gradient that originates in the epidermis. Thus, it is 
furthermore also hypothesised that ACKR2 expressed in KCs plays a direct 
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role in regulating T-cell migration, in addition to eventual positioning within 
tissue. 
 
 
3.5 Results 
 
3.5.1 A murine model of cutaneous inflammation for studying 
the in vivo role of ACKR2. 
The TLR agonist imiquimod (as Aldara™ cream) is conventionally used for the 
treatment of cutaneous warts and non-melanoma skin cancers in humans 
(Grillo-Ardila et al. 1996; Geisse et al. 2004). In recent years, imiquimod has 
been increasingly used for the induction of psoriasiform lesions in mice, 
where repeat application of topical imiquimod (IMQ) gives rise to skin 
changes that bear key histopathological and molecular similarities to human 
psoriasis (Walter et al. 2013; Ueyama et al. 2014). The IMQ model has 
several benefits for the purposes of the experiments below; 1) it shares 
important features with human disease, 2) lesions can be induced at 
specific, pre-determined skin sites, 3) it is well characterised in the 
literature, 4) it is typically generated in C57BL/6 mice (the same strain into 
which ACKR2-/- are back-crossed) and 5) it is a model that can be induced in 
immunocompetent mice, in contrast to many other murine psoriasis models 
that make use of immunodeficient mice (Boehncke & Boehncke 2005). 
In order to study the role of ACKR2 in psoriasiform inflammation in vivo, the 
IMQ model of psoriasiform inflammation (henceforth referred to as the IMQ 
model) was initially established in WT C57BL/6 mice. The methodologies 
used in these experiments were based on the original publication that first 
described this model, in which 62.5mg of 5% imiquimod cream (or a specific 
control cream) was applied to the central shaved back skin of C56BL/6 mice 
for up to 6 consecutive days (van der Fits et al. 2009). In the experiment 
below, the same treatment schedule was used as in (van der Fits et al. 
2009), but with the treatment area being changed to one flank (detailed in 
Figure 3.1), unless otherwise indicated. This was in order to enable accurate 
like-for-like comparisons between treated inflamed skin and control treated 
contralateral skin. 
SHAMS 2016 
	112 
Whilst previous studies typically rely on changes only on the day of cull in 
the mouse models of psoriasis (Cai et al. 2011), there was a need to more 
closely study the dynamics of cutaneous change also during the course of 
induction of skin inflammation in the experiments below. For this reason, a 
comprehensive clinical scoring system to quantify the severity of skin 
changes was developed. The scoring system developed was based, in 
principle, on the Psoriasis Area Severity Index (PASI), that is widely used 
both in the clinical and research settings in human psoriasis, to determine 
the severity of psoriasis and the response to treatment (Fredriksson & 
Pettersson 1978). The murine psoriasis severity score developed comprised 
points awarded over three domains; erythema, scaling and skin thickness 
(detailed in Figure 3.2), which is largely analogous to the human PASI score. 
Because inflammation in this model was induced at a discrete site, the 
murine score differed from the human PASI score by not including 
percentage of body part covered. The criteria for the murine PASI 
(henceforth referred to as the modified PASI or mPASI) were chosen such 
that they could be performed with relative ease in a moving, non-
anaesthetised animal. The mPASI yields a total score from 0 (normal skin) to 
12 (most severe inflammation). 
In keeping with the work by van der Fits et al., following application of IMQ 
to the skin, there was a rapid induction of erythema, scaling and skin 
thickening. Accordingly, the PASI scores in WT C57BL/6 mice treated with 
IMQ over a 6-day period increased, with the PASI score plateauing at day 6 
(Figure 3.3). Inflammation was apparent after only 1 application of IMQ, and 
reached statistical significance after 2 applications of IMQ (as assessed on 
day 3). In order to validate the mPASI against objective histopathological 
changes in skin, the mPASI scores were correlated with mean epidermal 
thickness and the degree of basal epidermal proliferation in the mice, as 
assessed by Ki67 staining (details on histopathological analysis below). There 
was a positive and significant correlation between the mPASI score at the 
time of cull with both epidermal thickness and hyperproliferation, which are 
both key features of human psoriasiform skin inflammation (Figure 3.4) (Di 
Meglio et al. 2014).  
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Together, these results demonstrate that 1) psoriasiform inflammation was 
successfully induced in C57BL/6 mice using IMQ, 2) qualitative clinical 
assessment of psoriasiform skin changes could be quantified during the 
course of IMQ application using the mPASI and 3) the newly developed mPASI 
correlated significantly with key clinically relevant histopathological 
parameters, that typify human psoriasis (Figure 3.4c-d).  
 
3.5.2 ACKR2 expression levels in the IMQ mouse model of 
psoriasiform inflammation. 
ACKR2 expression in human psoriasis is high in unaffected non-lesional skin 
that is remote from psoriatic plaques. In contrast, ACKR2 expression in 
psoriatic human plaques is relatively low (Singh et al. 2012). ACKR2 
expression patterns in murine psoriasiform inflammation has however not 
been studied previously. In order to determine whether the ACKR2 
expression patterns in the IMQ mouse model parallel those of human 
psoriasis, IMQ (or vehicle cream) was applied for either 3 or 6 days, with 
mice culled on day 4 or 7 respectively. ACKR2 mRNA expression was 
quantified by QPCR of whole skin RNA (Figure 3.5). In keeping with data from 
human psoriasis, ACKR2 transcript levels were significantly lower in 
psoriasiform plaques as compared to (non-inflamed) control cream treated 
contralateral skin. The differences were apparent and statistically significant 
on day 4, and appeared more pronounced on day 7 in this model. It should 
be noted however, that whilst ACKR2 is upregulated in human remote 
unaffected skin, similar upregulation in mouse skin remote from the IMQ-
treated site was not observed (Figures 3.5a and 3.5b).  
As previously discussed, topical IMQ/Aldara™ appears to induce psoriasiform 
inflammation through several mechanisms. For example, the excipient 
isostearic acid that is used to aid solubility in Aldara™ cream, has been 
shown to be capable of inducing inflammation even in the absence of IMQ 
(Walter et al. 2013). Hence, in order to determine whether the reduction of 
ACKR2 observed in IMQ-treated skin was a direct effect of imiquimod and/or 
due to exposure of the excipients in Aldara™ cream, murine skin explants 
(epidermis plus dermis) were treated with pure imiquimod in vitro. Explants 
were chosen rather than topical application of pure imiquimod as 1) an 
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Aldara™ equivalent, but isostearic acid free topical preparation is not 
available and 2) the trauma that would follow any injected imiquimod would 
likely introduce a confounding variable in the form of skin trauma, that 
could directly affect ACKR2 expression. Results showed that imiquimod alone 
was sufficient to significantly reduce ACKR2 transcript expression in murine 
skin in vitro, and that this effect appeared to be dose dependent (Figure 
3.6). Additionally, these in vitro data demonstrated that IMQ driven ACKR2 
downregulation was independent of infiltrating leukocytes and circulating 
factors e.g. cytokines (Figure 3.6). This finding was in keeping with the 
effect of IMQ cream on murine skin being, at least in part, driven by 
imiquimod, rather than another excipient of the IMQ/Aldara™ cream. 
 
3.5.3 ACKR2 expression in remote internal organs in the IMQ 
mouse model of psoriasiform inflammation. 
Whilst ACKR2 expression is elevated in unaffected remote non-lesional skin 
in patients with psoriasis, it is not known how ACKR2 expression is altered in 
internal organs in vivo. In order to better understand the effect of focal 
psoriasiform skin inflammation on the expression of ACKR2 in remote tissues, 
ACKR2 expression levels were determined in lymph nodes, spleen, heart and 
liver following IMQ induction of psoriasiform inflammation in mice. QPCR 
data showed that IMQ treatment was associated with a significant (albeit 
modest) increase in ACKR2 expression in non-draining inguinal lymph nodes 
(contralateral to the treated flank) on day 4, but the increase on the treated 
side was not statistically significant (Figure 3.7a). There were no significant 
differences in ACKR2 transcript levels in lymph nodes on either side on day 7 
(Figure 3.7b). IMQ treatment led to visible enlargement of the spleen of 
mice as previously described (results not quantified) (van der Fits et al. 
2009). Furthermore, a significant reduction in ACKR2 mRNA expression was 
observed in the spleen of IMQ, as compared to control cream treated mice. 
This was apparent on day 4 and persisted also on day 7 (Figure 3.7). ACKR2 
expression was significantly elevated in both the heart and liver of IMQ-
treated mice on day 7 (Figure 3.8b), whilst no such differences were 
observed in on day 4 (Figure 3.8a).  
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Together these data demonstrated that 1) IMQ induced psoriasiform plaques 
displayed reduced ACKR2 transcript expression as compared to control 
treated skin, which mimicked ACKR2 skin expression in human psoriatic 
plaques, 2) reduced ACKR2 expression in murine skin explants occurred in 
response to imiquimod, apparently also independently of excipients in 
Aldara™, at least in vitro, 3) IMQ treatment of skin was associated with 
decreased ACKR expression in the spleen on day 4 and 7, and 4) an increased 
expression of ACKR2 was observed in the heart and liver on day 7.  
 
3.5.4 Absence of ACKR2 was associated with more severe 
psoriasiform inflammation in the IMQ mouse model. 
To determine the role of ACKR2 in psoriasiform inflammation, ACKR2-/- mice 
were initially treated with IMQ to determine the basic dynamics of 
inflammation induction in the absence of ACKR2 (Figure 3.9). In ACKR2-/- 
mice, IMQ rapidly caused erythema, scaling and skin thickening, with an 
apparent plateauing of the mPASI score on day 4 (Figure 3.9a). In contrast, 
control cream treatment of ACKR2-/- did not cause any signs of 
inflammation in any mice (Figure 3.9a). mPASI scores in this initial 
experiment were suggestive of more severe inflammation as compared to 
previous experiments with WT mice at comparable time points (Figure 3.3). 
In order to confirm whether ACKR2-/- mice develop more severe 
psoriasiform inflammation, the response of ACKR2-/- and WT mice to IMQ 
was directly compared side-by-side. To this end, age matched ACKR2-/- and 
WT C57BL/6 mice were treated concurrently over a 4-day period. IMQ 
caused significantly more inflammation than control cream in both WT and 
ACKR2-/- mice, which reached significance from day 3 onwards as quantified 
by the mPASI (Figure 3.10). Notably, ACKR2-/- mice displayed significantly 
higher mPASI severity scores compared to WT, which reached statistical 
significance from day 3 onwards (i.e. after two single applications of IMQ) 
(Figure 3.10b).  
Importantly, the cutaneous application of IMQ is frequently associated with 
severe systemic features including dehydration, which has been shown to be 
more severe in C57BL/6 mice as compared to other strains (van der Fits et al. 
2009). For this reason, the weights of all treated mice were monitored in the 
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above experiments. IMQ treatment caused significant weight loss following 1 
single application of IMQ, which was more severe in ACKR2-/- mice as 
compared to WT at all time points (Figure 3.10B). Previous studies suggested 
mice treated with IMQ lost weight very rapidly and became moribund unless 
injected with saline (van der Fits et al. 2009). For this reason, mice in all the 
above experiments were given fruit puree and a soft diet ad libitum. No 
mice became moribund in these experiments, and weight loss was less than 
20% of the baseline in all mice (mice with weight loss greater than 20% were 
to be culled, as per applicable Home Office licences).  
In conclusion, the above experiments suggest that psoriasiform skin 
inflammation was significantly more severe in ACKR2-/- as compared to WT 
mice, both in terms of skin inflammation and in terms of systemic features 
as measured by weight loss. These data are in keeping with ACKR2 playing a 
key role in limiting psoriasiform inflammation in vivo. However, it is 
necessary to repeat these experiments, in order to ensure reproducibility, 
before firm conclusions can be drawn. 
 
3.5.5 Absence of ACKR2 was associated with enhanced 
epidermal thickening and basal keratinocyte 
hyperproliferation.  
Next, histological features of ACKR2-/- and WT mouse skin were analysed 
(both IMQ and control cream treated), to determine any histopathological 
differences. Previous studies have demonstrated that there are no 
histological differences between ACKR2-/- and WT mice at rest (Nibbs et al. 
2007), and similarly, no differences were observable between ACKR2-/- and 
WT mice in control cream treated skin in these experiments. However, in 
skin treated with IMQ, there was significantly increased skin thickening in 
ACKR2-/- as compared to WT mice (Figure 3.11 and enlarged views in Figure 
3.12). Additionally, psoriatic features such as parakeratosis (retention of 
nuclei in stratum corneum) and hyperkeratosis (thickened stratum corneum) 
were evident in IMQ treated murine skin, which is in keeping with 
psoriasiform histological changes having been successfully induced (Figures 
3.11 and 3.12). In order to examine the effect of IMQ on basal epidermal cell 
hyperproliferation (a hallmark of psoriasiform skin changes (Di Meglio et al. 
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2014)), the skin sections were additionally stained for the proliferation 
marker Ki67. In ACKR2-/- mice, there was a thicker layer of cells with nuclei 
staining for Ki67, which is in keeping with hyperproliferation. The 
differences between ACKR2-/- and WT mice were quantified in terms of 
epidermal thickness and thickness of the Ki67 positive cell layer, and 
differences were found to be statistically significant both on day 4 and 7 in 
this model. (Figures 3.11a and 3.11b) As discussed above, there was 
furthermore a significant direct correlation between epidermal thickness and 
thickness of the Ki67 positive basal cell layer, and the mPASI (Figure 3.4). 
 
3.5.6 ACKR2-/- mice demonstrated enhanced CD3+ T-cell 
positioning in epidermal skin layers in response to topical IMQ. 
Psoriasis is considered to be a predominantly T-cell driven inflammatory 
disorder, and the localisation of T-cells in the skin has previously been shown 
to be important for plaque development (Conrad et al. 2007). Furthermore, 
studies have demonstrated a role for ACKR2 in determining tissue 
localisation of both dendritic cells and macrophages (McKimmie et al. 2013; 
Lee et al. 2014). However, the role of ACKR2 in determining T-cell 
localisation in a model of psoriasis, has not been previously elucidated. As 
the absence of ACKR2 was associated with exaggerated psoriasiform 
inflammation in the IMQ model above, it was hypothesised that ACKR2, in its 
capacity as a scavenger of pro-inflammatory chemokines, could determine T-
cell localisation within the skin in psoriasiform inflammation. For these 
reasons, the effect of ACKR2 on CD3+ T-cell localisation was explored in the 
IMQ model. 
There were no differences at baseline between untreated ACKR2-/- and WT 
mice in terms of CD3+ T-cell numbers/localisation (data not shown). IMQ 
application to murine skin caused epidermal T-cell entry, which appeared 
more marked in ACKR2-/- mice as compared to WT (Figure 3.13). The 
percentage of CD3+ T-cells that localised in the epidermis was quantified, 
and a significantly higher percentage were localised in the epidermis of 
ACKR2-/- mice as compared to WT, both at day 4 and day 7 (Figure 3.14a). 
Additionally, in IMQ treated WT mice (grey bars), the proportion of CD3+ T-
cells localised in the epidermis decreased significantly between 4 and 7 
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days. In contrast, the proportion of CD3+ cells that localised in the epidermis 
of ACKR2-/- mice (black bars) were maintained between the two time points 
(Figure 3.14a). To convincingly demonstrate a difference, a comparison of 
absolute numbers of T-cells, rather than percentages would have been 
preferable. Accordingly, absolute numbers were recorded in subsequent 
experiments (Figure 4.13) and show no differences in total skin T-cells, but a 
clear increase in the proportion of CD3+ localising in the epidermis. This is 
perhaps to be expected, as previously published studies using the 
inflammatory phorbol ester TPA, have shown absolute numbers of T-cells in 
skin are similar in ACKR2-/- and WT, but their distribution within the skin is 
not (Jamieson et al. 2005). The proximity of CD3+ T-cells to the basement 
membrane was determined, but the difference between ACKR2-/- and WT 
was only apparent in the epidermis, rather than throughout all skin layers 
(Figure 3.14b).  
Together, these data supported a role for ACKR2 in determining cutaneous 
CD3+ T-cell localisation in vivo, in the IMQ model of psoriasiform 
inflammation. Specifically, ACKR2 played a role in determining T-cell entry 
into the epidermis, which has previously been shown to be critical for the 
development of psoriatic skin lesions (Conrad et al. 2007). 
 
3.5.7 A novel in vitro model of T-cell migration towards a 
chemokine stimulus.  
Whilst the above experiments demonstrated that ACKR2 is important for 
determining T-cell positioning in psoriasiform skin inflammation, the 
mechanism by which ACKR2 mediates this effect is unknown. Previous 
studies have demonstrated that ACKR2 expression is particularly high in basal 
keratinocytes in the unaffected skin of patients with psoriasis (Singh et al. 
2012). This previous observation, coupled with the known CC-chemokine 
scavenging capacity of ACKR2, led to the hypothesis that high ACKR2 
expression in basal epidermal keratinocytes enables such cells to act as a 
filter for any chemokines produced/released in the epidermis. This could 
then limit the formation of chemotactic CC-chemokine gradients emanating 
in the epidermis, and thereby restrict CD3+ T-cell entry in the epidermis. To 
test this hypothesis in a reductionist manner, a novel migration assay was 
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developed (Figure 3.15) to study the effect of ACKR2 expression in a barrier 
layer of keratinocytes (akin to that in the skin basement membrane), on the 
migration of human T-cells (in the ‘dermis’) towards a chemotactic 
chemokine gradient that originates above such a layer (in the ‘epidermis’).  
This new migration assay constituted three layers; an upper chemokine 
containing layer; a middle layer of ACKR2 expressing stromal cells; and a 
bottom layer containing activated T-cells.  To determine the function of 
ACKR2 in this system, the middle cell barrier layer was created using cells 
expressing different levels of ACKR2. Thus, the system recapitulated key 
aspects of the skin in a cell culture system, with the ACKR2 expressing 
stromal cells separating an ACKR2 ligand CC-chemokine (in the ‘epidermis’) 
and the active human T-cells (in the ‘dermis). In this model (summarised in 
Figure 3.15), human T-cells were isolated, expanded and stimulated in vitro 
from whole blood of healthy donors. T-cells were suspended in a semi-solid 
bovine skin collagen matrix. Primary human keratinocytes (in which ACKR2 
expression could be induced) or other cell types (as indicated in figures) 
were suspended in a semi-solid skin collagen matrix, and placed on top of 
the T-cell layer. This was carried out in a manner that enabled the formation 
of a clear sharp interface between the cell barrier layer and the T-cell layer 
(Figure 3.16b-c). Once set, a chemokine could be placed on top, the 
chamber sealed on all sides. Subsequently, a chemotactic gradient could 
form through the semi-liquid layers, with the keratinocyte layer forming a 
barrier between the migrating T-cells and the chemotactic stimulus. Using 
this model system it was possible to determine if ACKR2 in the KC layer 
could successfully scavenge/eliminate the chemokine, and thereby diminish 
T-cell migration towards the chemokine. The model recapitulated, in a 
reductionist manner, T-cell migration from the dermis towards the 
epidermis.  
Through tracking individuals T-cells by means of time-lapse photography, 
migration patterns of T-cells could be determined in detail (Figures 3.17 and 
3.18). Firstly, it was necessary to determine a suitable concentration of 
chemokine to use that caused directional migration of T-cells towards the 
chemokine stimulus (Figure 3.19). Although a number of chemokines are 
upregulated in psoriasis, CCL5 was chosen in these experiments, as it is both 
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highly expressed in the psoriatic epidermis (Singh et al. 2012), and is also 
known to bind ACKR2 (Sokol & Luster 2015; Raychaudhuri et al. 1999; 
Griffith, Sokol & Luster 2014; Mabuchi et al. 2012). A concentration of 160ng 
CCL5 per ml was found to cause optimal directional migration of T-cells 
towards the CCL5 layer. The accumulated distance migrated by all analysed 
T-cells was highest at both 160ng and 640ng CCL5/ml, but migration was 
only directional at 160ng/ml (Figures 3.19-3.20), though it should be noted 
that this optimisation experiment was performed once. 
 
3.5.8 A barrier layer of cells expressing ACKR2 regulated T-
cell migration towards a chemokine stimulus. 
Next, cells that expressed no ACKR2 (HEK293 cells) or very high levels of 
ACKR2 (ACKR2 transfected HEK293, kindly donated by Dr Kay Hewit) were 
placed at the interface between the activated (‘dermal’) T-cell layer and 
the ‘epidermal’ chemotactic CCL5 layer. Comparing T-cell migration towards 
a CCL5 stimulus in the presence of both HEK cell lines was necessary, in 
order to determine whether ACKR2 expression levels in the interface cell 
layer could measurably affect T-cell migration.  
As hypothesised, where ACKR2 is absent in the barrier layer (HEK293 cells), 
T-cell migration was significantly directional towards the CCL5 stimulus in 
experiments that were conducted once (Figure 3.21a), in keeping with the 
chemotactic gradient forming unhindered past the cell barrier layer 
separating the chemokine and the T-cells. In contrast, where ACKR2 
expression was high (in ACKR2 transfected HEK293 cells) T-cell migration was 
found to be non-directional (Figure 3.21b). This in turn is suggestive of 
ACKR2 scavenging of CCL5 by the barrier layer preventing the formation of a 
chemotactic gradient, and therefore loss of directionality in T-cells.  
Next, to better model human skin, the barrier layer was established using 
primary human keratinocytes (KC) from healthy donors (Figure 3.22), with 
the total cell volume (Volume = cell number x ([4/3]πr3) maintained the 
same as in experiments with HEKs. This was so as to not inadvertently 
prevent diffusion of chemokine by a cell layer that was too dense. Cultured 
healthy KCs have low expression of ACKR2 at rest, but this expression can be 
substantially upregulated by IFNγ treatment (Singh et al. 2012). Where 
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ACKR2 expression was relatively low (unstimulated KCs) significant 
directional migration of activated human T-cells was observed (Figure 
3.22a). This would be in keeping with chemotactic CCL5 gradient appeared 
to have formed freely past the barrier layer of ACKR2-low KCs. However, 
where ACKR2 expression was high (induced in this case by stimulation with 
IFNγ), directional T-cell migration was lost (Figure 3.22b). Together, these 
findings would be in keeping with the hypothesis that a high ACKR2 
expressing barrier layer of KCs (as seen at the basal epidermal layers in 
humans) can prevent the formation of chemokine gradients, and thereby 
limit T-cell migration into the epidermis. The current approach was 
employed as it (unlike e.g. transwell systems) enables more qualitative 
insights into T-cell migration, e.g. directionality. However, it is 
acknowledged that the above experiments need to be repeated further 
times, in order to ascertain reproducibility and sensitivity, and in order to 
provide further quantitative data on the effect that an ACKR2 high/low 
barrier layer may have on T-cell migration.  
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Figure 3.1 Schematic representation of the IMQ mouse model of 
psoriasiform inflammation. 
(a) mice were shaved 1 day prior to the first application of 5% imiquimod 
(Aldara™) cream, or control cream (Fagron™ Lanette cream with 20% 
Vaseline), onto each shaved skin site as per the diagram. 
(b) topical treatment was applied to one flank daily for 3 or 6 consecutive 
days, with cull on day 4 or 7 respectively. Contralateral flank skin acted 
as untreated control skin in both IMQ and control cream groups.  
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IMQ or control cream 
applied to shaved flank 
contralateral flank  
(remote skin) as 
untreated control skin 
SHAMS 2016 
	123 
 
 
 
 
Figure 3.2 Details of the modified PASI used to quantify the severity of 
psoriasiform pathology in murine skin. 
The modified PASI was used to quantify psoriasiform inflammation on mouse 
skin on a daily basis. The score is carried out over 3 parameters, yielding a 
total score of 0 (no inflammation) to 12 (most severe inflammation), as per 
the criteria detailed. 
 
 
 
parameter score criteria 
 
notes 
 
erythema 
0 
 
normal  
1 
 
pink  
2 
 
red  
3 
 
dark red  
4 
 
very dark red  
(changing to purple) 
 
 
scaling 
0 
 
normal  
 
 
1 
 
fine scale covering part 
of the lesion 
Scales <0.5mm, covering 
<50% of lesion 
 
2 
 
fine scaling covering 
most of the lesion 
Scales <0.5mm, covering 
≥50% of lesion  
 
3 
 
rough scaling covering 
most of the lesion 
Scales ≥0.5mm, covering 
≥50% of lesion 
 
4 
 
very rough, thick scaling 
covering most of the 
lesion 
Scales ≥1mm (or, several 
layers of scale), covering 
≥50% of lesion 
 
skin thickness 
0 
 
normal  
 
 
1 
 
some ridging of skin but 
dependent on posture 
ridging, but not apparent 
when mouse walking 
 
2 
 
some ridging of skin 
noticeable when moving 
 
 
 
3 
 
ridging is as deep as it is 
wide and noticeable 
when moving 
 
 
 
4 
 
very deep ridging 
noticeable when skin is 
stretched 
ridging apparent also 
upon manual stretching 
using digits 
total possible 
score 
 
12 
 
 
sum of all parameters 
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Figure 3.3 Modified PASI in wild-type mice treated with imiquimod 
cream.  
(a) Modified total PASI, across all parameter, in wild-type C57BL/6 mice 
treated with IMQ (dark blue line) or control cream (orange line) on one 
flank. n=6 mice per group. 
(b-d) modified PASI score for separate parameters the sum of which 
constituted the total PASI (erythema, scaling and thickness) 
Data are mean±SEM, statistical analysis is two-way ANOVA with repeated 
measures with Bonferroni post-test. * P<0.05, ** P<0.01, *** P<0.005, **** 
P<0.001. Data representative of two comparable experiments. 
 
a 
b 
i 
ii iv 
iii total modified PASI 
scaling score thickness score 
erythema score 
0 2 4 6 8
0
2
4
6
8
10
12
day of treatment
m
od
ifi
ed
 P
A
SI
 
Control 
IMQ
**
****
**** **** ****
0 2 4 6 8
0
1
2
3
4
day of treatment
m
od
ifi
ed
 P
A
SI
 
Control 
IMQ
**** **** **** ****
****
0 2 4 6 8
0
1
2
3
4
day of treatment
m
od
ifi
ed
 P
A
SI
 
Control 
IMQ
**** **** **** ****
0 2 4 6 8
0
1
2
3
4
day of treatment
m
od
ifi
ed
 P
A
SI
 
Control 
IMQ
**** ****
d c 
b a 
SHAMS 2016 
	125 
 
Figure 3.4 Correlation between modified PASI and histopathological changes, 
and psoriasiform changes in WT mice with imiquimod cream. 
(a) Correlation plot between severity of skin inflammation (modified PASI) and 
epidermal thickness of treated skin, in IMQ treated WT mice. 
(b) Correlation plot between severity of skin inflammation (modified PASI) and 
thickness of Ki67 positive basal keratinocyte layer (thickness between the 
basement membrane to uppermost Ki67 positive cell), in IMQ treated WT mice. 
(c) Wild-type mouse skin treated with control cream and; 
(d) Wild-type mouse skin treated with imiquimod cream for 3 days before day of 
cull, stained with H&E, demonstrating psoriasiform changes including; (black 
arrow) epidermal thickening, (red arrow) parakeratosis; retention of nuclei in 
stratum corneum and (blue arrow) hyperkeratosis. Scale bars 100µm. 
Data for (a) and (b) are derived from separate experiments. 
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Figure 3.5 Effect of topical IMQ treatment on ACKR2 expression in vivo. 
(a) Absolute ACKR2 mRNA expression normalised to 18S in flank skin treated 
with topical IMQ or control cream (treated) and contralateral untreated 
control flank skin (control skin), in mice treated for 3 days and culled on 
day 4. 
(b) Absolute ACKR2 mRNA expression normalised to 18S in flank skin treated 
with topical IMQ or control cream (treated skin) and contralateral 
untreated control flank skin (control skin), in mice treated for 6 days 
and culled on day 7. 
Line indicates mean, statistical analysis is Student’s t-test. * P<0.05, ** 
P<0.01, *** P<0.005, **** P<0.0001. Each time point performed once. 
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Figure 3.6 Treatment of explanted WT mouse skin with pure imiquimod 
in vitro. 
Absolute ACKR2 mRNA expression normalised to 18S in murine skin incubated 
in the presence of increasing concentrations of imiquimod for 24 hours. Data 
are mean±SEM, 6 explants per group, statistical analysis is one-way ANOVA. 
** P<0.01. Data from one experiment. 
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Figure 3.7 Effect of topical IMQ treatment on ACKR2 expression in 
inguinal lymph nodes and spleen. 
(a) Absolute ACKR2 mRNA expression normalised to 18S in inguinal lymph 
nodes (draining/treated and contralateral nodes), where flank was 
treated topical IMQ or control cream and spleen. Mice treated for 3 days 
and culled on day 4. 
(b) Absolute ACKR2 mRNA expression normalised to 18S inguinal lymph nodes 
(draining/treated and contralateral nodes), where flank was treated 
with topical IMQ or control cream and spleen. Mice treated for 6 days 
and culled on day 7. 
Line indicates mean, statistical analysis is one-way ANOVA (left hand 
graphs) and  Student’s t-test (right hand graphs). * P<0.05, ** P<0.01, *** 
P<0.005, **** P<0.0001. Each time point performed once. 
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Figure 3.8 Effect of topical IMQ treatment on ACKR2 expression the heart 
and liver. 
(a) Absolute ACKR2 mRNA expression normalised to 18S in the heart where 
flank was treated with topical IMQ or control cream and in liver. Mice 
treated for 3 days and culled on day 4. 
(b) Absolute ACKR2 mRNA expression normalised to 18S in the heart where 
flank was treated topical IMQ or control cream and in liver. Mice treated 
for 6 days and culled on day 7. 
Line indicates mean, statistical analysis is Student’s t-test. * P<0.05, ** 
P<0.01, *** P<0.005, **** P<0.0001. Each time point performed once. 
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Figure 3.9 Modified PASI in ACKR2-/- mice treated with imiquimod.  
(a) Modified total PASI, across all parameter, in ACKR2-/- mice treated with 
IMQ (orange line) or control cream (dark blue line) on one flank. n=4/3 in 
IMQ/control group respectively, and modified PASI score for separate 
parameters that constitute the total PASI (erythema, scaling and 
thickness) 
(b) Representative images of murine flank after 6 days treatment with 
control cream (pre-cull on day 7). 
(c) Representative image of murine flank after 6 days treatment with IMQ 
(pre-cull on day 7). 
Data are mean±SEM, statistical analysis is two-way ANOVA with repeated 
measures with Bonferroni post-test. * P<0.05, ** P<0.01, *** P<0.005, **** 
P<0.0001. Data representative of two comparable experiments. 
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Figure 3.10 Exaggerated psoriasiform inflammation in IMQ treated  
ACKR2-/- mice.  
(a) Images of wild-type (WT) mice treated for 3 days with control cream, 
IMQ and ACKR2-deficient mice similarly treated with IMQ. Mice were 
culled on day 4. 
(b) (top graph) Skin inflammation severity (modified PASI) (3 groups, n≥4 in 
each group). (bottom graph) Weight change compared to baseline 
(100%) throughout the treatments.  
Data are mean±SEM, statistical analysis is two-way ANOVA, Tukey’s 
multiple comparisons test). Data are representative of two similar 
experiments. * P<0.05, ** P<0.01, *** P<0.005, **** P<0.0001. Experiment 
performed once. 
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Figure 3.11 Exaggerated psoriasiform pathology in IMQ treated ACKR2-/- mice.  
(a) (histology) H&E stains of WT and ACKR2-deficient (KO) skin after 3 days of IMQ 
treatment. (graph) Quantification of epidermal thickness on day of cull after 3 or 6 
days of daily topical IMQ at x100 magnification. (all scale bars: 100µm; Statistics: 
one-way ANOVA).  
(b) (histology) Ki67 stain of the epidermis of WT and ACKR2-deficient (KO) skin after 3 
days of IMQ treatment. (graph) Quantification of the thickness of the Ki67 staining 
in the epidermal layer (x100 magnification). Ki67 staining is a measure of cellular 
proliferation and the data presented report the extent of Ki67 positivity, as 
demonstrated by the thickness of the Ki67 positive basal keratinocyte layer. 
Counter-stained with toluidine blue.  
All scale bars: 100µm. For the quantitative data in B and C, thickness of 1) the 
epidermal layer (basement membrane up to, but not including, stratum corneum) and 
2) the thickness of the Ki67 positive keratinocyte basal layer (basement membrane to 
uppermost cell membrane of last Ki67 positive cell) was measured across 9 sites, from 3 
separate sections from each skin sample, from each mouse (n=6). Each time point 
performed once. 
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Figure 3.12 Exaggerated psoriasiform pathology in IMQ treated ACKR2-/- 
mice; enlarged views of representative sections. 
(a) H&E stains of WT and  ACKR2-deficient (KO) skin after 3 days of IMQ 
treatment; x100 magnification for centre images (all scale bars: 100µm). 
Arrows point to examples of hyperkeratosis and parakeratosis. 
(b) Ki67 stain of the epidermis of WT and ACKR2-deficient (KO) skin after 3 
days of IMQ treatment. Counter-stained with toluidine blue. (all scale 
bars: 100µm). n=6 mice, experiment performed once. 
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Figure 3.13 CD3+ T-cells in epidermis of ACKR2-/- mice following IMQ 
treatment; enlarged views of representative sections. 
CD3+ staining in WT and ACKR2-deficient (KO) skin after 3 days of IMQ 
treatment, or control. Red arrows indicate epidermal CD3+ T-cells. The red 
line represents the dermal-epidermal junction (all scale bars: 100µm). 
Counter-stained with toluidine blue. n=6 mice, experiment performed once. 
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Figure 3.14 Enhanced epidermal CD3+ positioning in ACKR2-/- mice 
following IMQ treatment. 
(a) Epidermal CD3+ T-cell numbers as a percentage of total CD3+ cells in 
same field-of-view (x200 magnification). Quantification conducted over 9 
different sites across three separate sections from each lesion. 
(b) CD3+ T-cell distance from the basement membrane (shortest distance T-
cell to basement membrane) of WT and ACKR2-deficient epidermis after 
3 days of IMQ treatment. 
Data are mean±SEM, statistical analysis is two-way ANOVA with Tukey’s 
multiple comparisons test. * P<0.05, ** P<0.01, *** P<0.005, **** 
P<0.0001. Time point performed once. 
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Figure 3.15 Diagram of the design of the novel T-cell migration assay. 
(a) Diagram of the novel migration assay. T-cells and primary human 
keratinocytes (resting or activated) were added as described in the text. 
CCL5 was selected as a chemotactic stimulus and added to one side of 
the collagen gel and a gradient allowed to form through diffusion. T-cell 
migration towards the CCL5 gradient was imaged by time-lapse 
photography. Note that whilst represented in a sloping or vertical 
manner in this figure, the migration assays take place in slides mounted 
in a standard way on the microscope stage. Cellular migration therefore 
is in a horizontal plane in this assay. 
(b) Manufactured slides holding the layers depicted in (a). 
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Figure 3.16 Details of the novel T-cell migration assay. 
(a) Schematic side view of migration chamber. Cells and chemokines were 
added as indicated in the text, with the light blue representing the 
‘epidermis’, the pink cell layer the ‘basal epidermis’ and the brown T-
cell layer the ‘dermis.  
(b) Light microscopy image of completed layers, in order to illustrate that 
layers remained discrete and effectively separated. The interface layer 
is acellular in this specific example. 
(c) Light microscopy image of completed layers, illustrating the interface 
between HEK293 cells (used in subsequent migration experiments) and T-
cell layer, and the effective formation of a discrete cell barrier layer. 
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Figure 3.17 Details of the novel T-cell migration assay methodology. 
(a) Illustration of the standardised site where image was obtained for time-
lapse photography. 
(b) In order to reduce selection bias, all T-cells in the first field of view 
were tracked, until no longer within the field of view. Completely non-
motile T-cells (if encountered) were excluded, as their viability could 
not be determined. The tracks were plotted (see Figure 3.18) such that 
T-cells migrating towards the CCL5 stimulus (superior aspect of image) 
were marked black, and those migrating away from the stimulus were 
marked red. In addition to actual migration track, the data analysis 
software calculated 1) the direction of migration of each cell (blue 
arrow), 2) the Euclidian distance travelled (denoted d, from point x to 
y). 
CCL5 in liquid 
suspension 
cells in collagen 
matrix, 1.5mm 
thick 
activated 
human T-
cells in 
collagen 
matrix (2/3 
up the well) 
z
z
site of filming (square 
represents image) 
a 
b
x
y
d
z
z
SHAMS 2016 
	139 
 
Figure 3.18 Details of the novel T-cell migration assay methodology: 
schematic examples of migration plots. 
(a) Data are presented as a plot of all migration tracks, for each individual 
T-cell, with that T-cells migrating towards the CCL5 stimulus (superior 
aspect of image) marked black, and those migrating away from the 
stimulus marked red. 
(b) In addition, quantitative data are also represented as a circle plot, 
where a red line represents the composite direction of travel of all 
migratory cells, and the thickness of the blue circle is indicative of the 
quantity of migration in each direction. 
Statistical analysis of migration data is obtained through the Rayleigh 
test for vector data, where P<0.05 indicates that the cell migration is 
significant in the main direction of migration, as indicated by the red 
line in the circle plot. 
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Figure 3.19 Determination of optimal CCL5 concentration for migration 
assay. 
T-cell migration determined (no cellular interface layer) towards CCL5 layer 
with increasing concentrations of chemokine. Migration is presented as circle 
plots (column ‘a’) and as individual migration track plots (column ‘b’). Plots 
on the left of each set represent a composite circle plot of cumulative 
migration direction. The plot on the right displays individual tracks (black = 
towards CCL5, red = away from CCL5). Migration was assessed over 180 
minutes, and was performed once at each concentration of CCL5. Data 
derived from one experiment.  
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Figure 3.20 Accumulated distance travelled of all T-cells in one field-of-
view. 
Accumulated T-cell distance travelled (over 180 minutes) in presence of 
increasing concentrations of CCL5. Data derived form one experiment.  
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Figure 3.21 Effect of ACKR2 expression in barrier layer on T-cell 
migration. 
(a) Circle migration plots of T-cell migration towards CCL5 chemotactic 
layer (160ng/ml) with interface layer composed of HEK293 cells (no 
ACKR2) and;  
(b) HEK293 cells transfected with ACKR2 (high ACKR2 expression).  
Statistical analysis was the Rayleigh test for vector data, where P<0.05 
indicates that migration is significantly directional. Migration was 
assessed over 180 minutes. 
Data derived from one experiment. 
 
 
  
p = 0.0004* 
*Rayleigh test for vector data 
p = 0.03* 
*Rayleigh test for vector data 
HEK293 barrier (no ACKR2) HEK ACKR2 barrier a b 
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Figure 3.22 Effect of ACKR2 expression in barrier layer of primary human 
keratinocytes on T-cell migration. 
Plots on the left of each set represent a composite circle plot of cumulative 
migration direction. The plot on the right displays individual tracks (black = towards 
CCL5, red = away from CCL5). 
(a) T-cell migration towards CCL5 chemotactic layer (160ng/ml) with interface 
layer composed of non-inflamed low-ACKR2 expressing primary human 
keratinocytes. 67 cells migrating ‘up’ towards CCL5, 39 cells migrating ‘down’ 
away from CCL5.  
(b) T-cell migration towards CCL5 chemotactic layer (160ng/ml) with interface 
layer composed of IFNγ stimulated high-ACKR2 expressing primary human 
keratinocytes. 49 cells migrating ‘up’ towards CCL5, 42 cells migrating ‘down’ 
away from CCL5. 
Statistical analysis is the Rayleigh test for vector data, where P<0.05 indicates that 
migration is significantly directional. Migration was assessed over 180 minutes. Data 
derived from one experiment. 
ACKR2 high barrier 
P=0.63 
ACKR2 low barrier 
P<0.01 
a 
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3.6 Summary Chapter 3 
This chapter reports the development of a murine model of psoriasiform 
inflammation, which enabled the study of ACKR2 function in vivo, and the 
development and use of a novel T-cell migration assay, which enabled the 
study of ACKR2 function in disease-relevant cultured cutaneous cells. The 
well-established imiquimod (IMQ) model of psoriasiform inflammation (van 
der Fits et al. 2009) in C57BL/6 mice, demonstrated ACKR2 expression 
changes that are reminiscent of those seen in human psoriasis, with reduced 
expression of ACKR2 in psoriasiform plaques when compared to untreated 
skin. This model allowed the induction of psoriasiform lesions at discrete 
pre-determined sites, which in turn allowed comparisons to be made 
between inflamed skin and remote control tissues. However, and in contrast 
to human disease, induction of one psoriatic lesion through focal IMQ 
application alone, did not lead to an elevated ACKR2 expression in 
apparently unaffected remote skin. This discrepancy is addressed in detail in 
a later chapter in this thesis.   
This chapter also reported, for the first time, that ACKR2 was essential for 
the limitation of IMQ-induced psoriasiform skin inflammation in vivo. ACKR2-
/- mice displayed significantly exaggerated inflammation, increased 
epidermal thickening and enhanced keratinocyte (KC) proliferation at the 
basal epidermal layers, when compared to WT mice. These inflammatory 
changes observed in mice, are all features that typically characterise human 
psoriatic plaques (Di Meglio et al. 2014). Whether these differences were 
sustained is not known, due to the limited time frame of the presented 
experiments. It is possible that differences between ACKR2-/- and WT mice 
are lost over time, and that the observations are due to altered kinetics of 
disease induction. Longer-term comparisons between WT and ACKR2-/- mice 
would be required to determine whether the observed differences are 
sustained over time. Additionally, a novel murine clinical scoring system was 
developed, which was shown to significantly correlate with histological 
markers of psoriasiform skin change, including epidermal thickening and 
hyperproliferation. This scoring system (termed the modified Psoriasis Area 
Severity Index, mPASI) was broadly based on the principles of the Psoriasis 
Area Severity Index that is used in humans, both to guide therapy and in the 
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research setting (Fredriksson & Pettersson 1978). The mPASI was designed 
such that a score could be obtained rapidly in moving mice, and enabled 
close monitoring of the dynamics of skin inflammation, throughout the 
development of psoriasiform plaques. Further work is required to more 
comprehensively validate the mPASI in the context of typical anti-psoriatic 
therapies (e.g. ciclosporin and anti-TNF antibodies), and in order to quantify 
its sensitivity for detecting change in the degree of cutaneous inflammation 
in a wider range of contexts. 
Psoriasis is increasingly considered to be a systemic condition, associated 
with excess cardiovascular and hepato-metabolic co-morbidities (Di Meglio 
et al. 2014; Roberts et al. 2014), whilst previous work on the IMQ model 
showed an enlargement of the spleen of IMQ treated mice (van der Fits et al. 
2009). To determine the effect of focal psoriasiform skin inflammation on 
remote organs, ACKR2 mRNA expression was quantified in the heart, liver, 
spleen and skin draining lymph nodes in mice. Results show a significant 
differential regulation of ACKR2 in all the assessed organs, in response to 
one focal area of skin inflammation. There was an upregulation of ACKR2 
mRNA in the heart and liver, and in contrast, reduced ACKR2 expression in 
the spleen in the IMQ model. The functional significance of these 
observations was not explored as part of this thesis, and future studies will 
need to determine whether this differential regulation in remote organs is 
sustained, in which cells the upregulation occurs and whether it modulates 
inflammatory responses in those tissues. Because the spleen mass increased 
so substantially following IMQ application, it is not possible to say whether 
this decrease in spleen ACRK2 was due to influx of non-ACKR2 expressing 
cells (i.e. dilution of ACKR2 signal), or if the decrease represented a 
decrease in cellular expression.  
Psoriasis is a T-cell (notably Th1/Th17) driven condition (Di Meglio et al. 
2014). To examine T-cells in this model of psoriasis, murine skin was stained 
for CD3+ T-cells in order to determine the effect of ACKR2 expression on T-
cell positioning. Previous studies have shown that there are no significant 
differences in cutaneous T cells between ACKR2-/- and WT mice at rest 
(Jamieson et al. 2005). This chapter showed that CD3+ T-cells infiltrated skin 
of both ACKR2-/- and WT mice in response to topical IMQ. However, whilst 
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CD3+ cells were largely excluded from the epidermis in WT mice, in ACKR2-
/- mice a large proportion of CD3+ T-cells localised in the epidermis. Indeed, 
previous studies have shown that psoriasiform inflammation is critically 
dependent on T-cell migration from the dermis into the epidermis in vivo 
(Conrad et al. 2007), and these new data suggest that ACKR2 plays a role in 
excluding CD3+ T-cells from the epidermis. This observation may explain the 
difference in severity of psoriasiform inflammation between ACKR2-/- and 
WT mice, when treated with IMQ.  
The mechanism by which ACKR2 regulates T-cell migration in this context is 
not well defined, and a novel 3-dimensional in vitro model of T-cell 
migration in skin was thus developed to address this deficiency. By using this 
model, this chapter reported, that ACKR2 expressed by a primary human 
keratinocyte layer (as seen in the epidermis) may be capable of regulating 
migration of active human T-cells towards a chemotactic psoriasis-associated 
CC-chemokine stimulus. This could possibly be due to ACKR2 
scavenging/internalisation/degradation of the CC-chemokine signal (Graham 
& McKimmie 2006), which could disrupt the formation of a chemotactic 
gradient, and further experiments are needed to test this hypothesis. The 
interpretation of the data is limited by the migration experiments having 
been performed once with HEK cells and once more with keratinocytes, and 
it would be important to repeat these migration experiments several times, 
to ensure the finding are reproducible and to provide more quantitative 
results, before definitive conclusions can be drawn. 
Overall, the reported data demonstrated that key human psoriatic ACKR2 
patterns could be replicated in mice by using the IMQ model of psoriasiform 
inflammation. Furthermore, ACKR2 was essential for limiting psoriasiform 
skin inflammation in vivo, and for excluding CD3+ T-cells from the epidermis 
that in turn are critical for psoriatic plaque development (Conrad et al. 
2007). Using a novel in vitro T-cell migration assay, data suggest that KC 
expressed ACKR2 may regulate T-cell migration towards a chemotactic 
chemokine stimulus, though further repeat experiments are necessary in 
order to draw firm conclusions. These findings would place ACKR2 in a 
central position in the regulation of psoriasiform inflammation in vivo. 
However, more work is necessary to understand the significance of ACKR2 
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differential regulation away from the site of skin inflammation. Additionally, 
more work is required to understand how ACKR2 might influence the 
migration of specific leukocyte subsets that play a role in psoriasis 
pathogenesis.   
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4 Focal psoriasiform inflammation limits the 
spread of inflammation to remote tissues in vivo, in 
ACKR2-dependent manner. 
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4.2 Hypotheses 
• Psoriasis associated T-cell-derived cytokines regulate ACKR2 expression 
in primary human keratinocytes 
• IFNγ production is deficient in the IMQ model of psoriasiform 
inflammation 
• The lack of remote skin ACKR2 upregulation in the IMQ model is due to a 
relative deficiency in circulating ACKR2-inducing cytokines. 
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• The lack of remote skin ACKR2 upregulation in the IMQ model of 
psoriasiform inflammation can be overcome by administering specific 
psoriasis-associated ACKR2 inducing cytokines exogenously. 
• Upregulation of ACKR2 in remote unaffected skin (away from the 
psoriasiform plaques) limits the spread of psoriasiform inflammation in 
vivo. 
 
 
4.3 Aims 
the aims of this chapter were to; 
• Determine the cytokines that regulate systemic ACKR2 upregulation 
• Explore the effect of systemic ACKR2 induction on the skin’s propensity 
to become inflamed 
• Determine the effect of focal psoriasiform inflammation on remote 
ACKR2 expression, and propensity to inflammation. 
• Determine the mechanism by which systemic ACKR2 upregulation 
modulates inflammation at sites remote from the initial site of 
inflammation 
 
 
4.4 Introduction 
Studies have shown that remote apparently unaffected human skin in 
psoriasis (‘remote’ in this context meaning in all apparently unaffected skin, 
away from psoriatic plaques) express high levels of ACKR2 (Singh et al. 
2012). However, neither 1) the mechanism by which this remote 
upregulation occurs nor 2) the significance of these observations have been 
shown. In all but the most severe cases of psoriasis, most of the patients’ 
skin is unaffected. Thus, high ACKR2 expression apparently occurs over very 
large areas of skin (Griffith, Sokol & Luster 2014), which in turn would 
suggest that the mechanism(s) that underpin(s) skin ACKR2 upregulation in 
psoriasis functions on a systemic level. Furthermore, previous work has 
demonstrated that the Th1 cytokine IFNγ is a potent inducer of ACKR2 
expression in primary human keratinocytes (Singh et al. 2012). Soluble T-cell 
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derived cytokines would be plausible inducers of such widespread systemic 
ACKR2 upregulation (in an ‘endocrine’ manner), as such cytokines are 
expressed not only where they are produced (in local tissues into which T-
cells have infiltrated), but are also detected in the systemic circulation 
(Lowes et al. 2014). The relative contribution of key psoriasis-associated 
Th1/Th17 cytokines on KC (as the principal ACKR2 expressing cell in the skin) 
has been relatively unexplored. Taken together, it was hypothesised that T-
cell derived soluble cytokines, produced in psoriatic plaques, could mediate 
an upregulation of ACKR2 through their release into the circulation.  
Work in our laboratory has previously identified high levels of IFNγ (a potent 
inducer of ACKR2 in vitro (Singh et al. 2012)) in the circulation of patients 
with psoriasis, but not in healthy controls (Supplementary Figure 4.1). 
Concurrently, previous work in our laboratory failed to detect IFNγ in the 
circulation of IMQ treated mice, which suggests that the IMQ model of 
psoriasiform inflammation is deficient in this particular cytokine, in 
comparison to human psoriatic disease. Indeed, studies that compare the 
IMQ model to other murine models of psoriasiform inflammation (e.g. K14-
AREG and K5-Stat3C models) also demonstrate that the IMQ model is 
relatively deficient in IFNγ (Swindell et al. 2011). These findings in mice are 
in stark contrast to previously published human data, where IMQ application 
to human skin was associated with a significant increase in IFNγ (as well as 
other psoriasis-associated cytokines such as TNF, IL-16 and IL-23 (Vinter et al. 
2014)). As discussed in the previous chapter, whilst topical IMQ on murine 
skin led to a reduction of ACKR2 expression in the psoriasiform plaque, there 
was no upregulation in apparently normal remote skin in the same mice. If 
indeed circulating IFNγ does account for remote ACKR2 upregulation in 
psoriasiform inflammation, the lack of IFNγ release in the IMQ mouse model 
may account for the apparent lack of remote ACKR2 upregulation observed 
previously. 
The in vivo effect of ACKR2 is anti-inflammatory. Thus, the hypothesis that 
IFNγ leads to ACKR2 upregulation in apparently unaffected skin would imply 
that IFNγ acts as an inducer of anti-inflammatory mechanisms in this 
particular context. This is arguably counter-intuitive, considering that IFNγ is 
generally considered to be a pro-inflammatory Th1 cytokine. However, early 
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studies suggested that some (albeit not all) patients with psoriasis as well as 
psoriatic-arthritis showed a degree of improvement in their disease when 
given recombinant IFNγ (Morhenn 1987; Fierlbeck & Rassner 1990). IFNγ has 
since also been used in a trial setting for the treatment of other conditions 
with an immune pathogenesis, including atopic dermatitis and rheumatoid 
arthritis (Stevens et al. 1998; Veys et al. 1997). The mechanism by which 
IFNγ may have such a therapeutically beneficial effect in the context of 
inflammatory disorders has however not been understood. Given 1) the high 
capacity that ACKR2 has for pro-inflammatory chemokines, 2) the potent 
ACKR2 induction demonstrated with the use of IFNγ in vivo and 3) previous 
trials suggesting that IFNγ could be therapeutically beneficial in psoriasis, it 
was hypothesised 1) that circulating IFNγ would lead to upregulation of 
ACKR2 in unaffected skin and 2) that this upregulation would protect 
unaffected skin against the spread of psoriasiform inflammation. However, 
using IFNγ for the purpose of treating inflammation in the clinic is likely to 
be associated with unacceptable off-target effects, as well as injection site 
reactions (Johnson-Huang et al. 2012). Such challenges notwithstanding, 
IFNγ remains a useful research tool as a potent inducer of ACKR2, in 
experimental models exploring therapeutic ACKR2 modulation. 
 
 
4.5 Results 
 
4.5.1 Th1 and Th17 cytokines upregulate ACKR2 expression in 
skin. 
Psoriasis is considered a predominantly Th17/Th1 driven condition (Lowes et 
al. 2014), but the effect and relative contribution of individual Th17/Th1 
cytokines on the regulation of ACKR2 have not been explained. Determining 
which cytokines regulate ACKR2 expression is essential in understanding how 
ACKR2 is systemically upregulated in clinically unaffected skin in psoriasis. 
Keratinocytes are the main ACKR2 expressing cells in the skin (Singh et al. 
2012), and major players in the pathogenesis of psoriasis (Nestle, Kaplan, et 
al. 2009). The importance of T-cells in psoriasis pathogenesis is illustrated by 
the efficacy of T-cell directed therapies currently in use, which target 
SHAMS 2016 
	153 
predominantly Th17 and Th1 cytokines (Di Meglio et al. 2014). It was 
therefore hypothesised that Th1 and Th17 products (singly and/or in 
combination) were inducers of ACKR2. Thus, in order to explore the role of 
T-cell products on keratinocyte ACKR2 expression, T-cells were isolated from 
healthy human donors, grown in the presence of IL-2 and activated using 
CD2/CD3/CD28 beads and the tissue culture supernatant collected. The 
tissue culture supernatant, that contained secreted cytokines from the 
activated T-cells, significantly increased ACKR2 transcript expression in 
healthy human keratinocytes grown in vitro, in a dose-dependent manner 
(Figure 4.1a). To better understand the role of T-cells and specific T-cell 
cytokines in a more relevant human psoriasis disease model, a collaboration 
was established with colleagues in the Netherlands (E. van den Bogaard and 
J, Schalkwijk, Radboud University), who have developed a humanised in 
vitro skin equivalent model of psoriasis (van den Bogaard et al. 2013). In this 
model (summarised in Figure 4.1b, and carried out by the Radboud 
University team), healthy human donor skin was enzymatically 
decellularised, leaving a dermal connective tissue scaffold. Keratinocytes 
were then grown on top of this scaffold (hence constituting the epidermal 
equivalent), and the dermal component populated from beneath with 
activated T-cells. This led to changes in the skin equivalents that are similar 
to human psoriasis in terms of histological appearance, transcriptional 
changes as well as in the response to typical anti-psoriatic therapies (van 
den Bogaard et al. 2013). This model more closely mimics human psoriasis 
than keratinocyte tissue culture monolayers, and enables the study of 
individual cell types and cytokines in a reductionist manner. In this skin 
equivalent model of psoriasis, ACKR2 transcript levels were increased when 
activated T-cells were allowed to enter the skin equivalents (Figure 4.1c). 
These findings support a role for T-cells in regulating ACKR2 expression in 
psoriasis. The T-cell dependency of ACKR2 upregulation in this model was 
further confirmed through treating the skin equivalents with the anti-T-cell 
calcineurin inhibitor ciclosporin (Figure 4.1d). Treatment of skin equivalents 
with ciclosporin for 4 days significantly inhibited ACKR2 upregulation as 
compared to untreated skin equivalent controls, further underlining the T-
cell dependency of the ACKR2 upregulation observed. In contrast, treatment 
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with retinoic acid (an inhibitor of keratinocyte proliferation, and a common 
class of drugs used in the treatment of psoriasis (Di Meglio et al. 2014)) did 
not significantly alter ACKR2 expression (Figure 4.1d). 
 
4.5.2 IFNγ is the principal T-cell derived cytokine inducer of 
ACKR2 expression. 
Next, the relative contribution of key Th1 and Th17 cytokines in the 
regulation of ACKR2 was determined in healthy human primary keratinocytes 
(both singly and in combination). Both Th1 and Th17 cytokine combination 
‘cocktails’ (as defined in the figure legend) increased ACKR2 expression, but 
the effect was not additive or synergistic (Figure 4.2a). In these in vitro 
experiment, Th1 cytokines were the strongest inducers of ACKR2 expression, 
though Th17 cytokines also significantly upregulated ACKR2 mRNA expression 
(Figure 4.2a). To better understand the role of individual cytokines, healthy 
human primary keratinocytes were stimulated with individual key (psoriasis 
associated) Th1 and Th17 cytokines (Figure 4.2b). The data showed that IFNγ 
was the most potent single inducer of ACKR2 expression, to levels in keeping 
with previously published data (Singh et al. 2012). To confirm the central 
role of IFNγ relative to other T-cell products, primary human keratinocytes 
were stimulated with activated T-cell tissue culture supernatant that had 
been incubated with increasing concentrations of neutralising IFNγ 
antibodies (Figure 4.2c). Neutralisation of IFNγ in the tissue culture 
supernatant from activated T-cells, almost entirely eliminated the ACKR2 
inducing effect on keratinocytes in a dose dependent manner. This finding is 
in keeping with IFNγ being the main T-cell derived inducer of ACKR2. Taken 
together, these data demonstrate that 1) ACKR2 upregulation in 
keratinocytes and in psoriasiform skin equivalents, occurs in a T-cell 
dependent manner, 2) Th1/Th17 cytokines are potent inducers of ACKR2 
expression, and 2) IFNγ is the most potent single-agent inducer of ACKR2 
transcript expression identified to date, in human primary keratinocytes in 
vitro. 
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4.5.3 IFNγ upregulates cutaneous ACKR2 expression when 
administered exogenously in vivo. 
Given the above data showing that IFNγ is a potent inducer of ACKR2 
expression, it was therefore hypothesised that circulating IFNγ could 
explain, at least in part, the systemic upregulation of ACKR2 observed in skin 
remote from the psoriatic plaques in humans (Singh et al. 2012). However, 
previous work in this group failed to detect circulating IFNγ in mice treated 
with IMQ (unpublished data, by Dr Mark Singh), suggesting that the IMQ 
model (in its basic configuration) would not recapitulate the high circulating 
levels of IFNγ observed in humans with psoriasis. Thus, the IMQ model 
apparently differs significantly from human disease in its lack of circulating 
IFNγ. Indeed, using the IMQ mouse model of psoriasis, QPCR data showed 
that treatment with IMQ did not lead to an increase in transcript levels of 
IFNγ in skin, draining lymph nodes or the spleen (Figure 4.3a). For these 
experiments, Bunyavirus infected murine skin (as a known potent inducer of 
IFNγ) was used as a positive control, to confirm that lack of IFNγ response 
was not an inherent deficiency of the mice used. Virus infection of murine 
skin confirmed that high levels of IFNγ could be induced (Figure 4.3a). ELISA 
experiments failed to show any detectable IFNγ protein in the skin of either 
control or IMQ treated mice (Figure 4.3b). Additionally, ELISA experiments 
did not detect any IFNγ protein in IFNγ-treated mice, which is likely due to 
the relatively short half-life of exogenously administered recombinant IFNγ 
in vivo, making it difficult to detect protein at the time of cull (the day after 
the last injected dose).  
Next, having demonstrated that the IMQ model is deficient in IFNγ, 
experiments were designed to determine whether IFNγ upregulates ACKR2 in 
vivo (as had been demonstrated in vitro in Figure 4.2b). To this end, 
exogenous recombinant IFNγ was administered systemically in mice. In 
keeping with the above human in vitro cell culture data of keratinocytes, 
data confirmed that systemic treatment with injected recombinant IFNγ in 
vivo led to a significant increase in ACKR2 expression in murine skin (Figure 
4.3c). 
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4.5.4 Induced ACKR2 upregulation limits psoriasiform skin 
inflammation in vivo. 
ACKR2 is a scavenger of pro-inflammatory CC-chemokines that is upregulated 
in unaffected skin of patients with psoriasis, but relatively deficient in the 
psoriatic plaques themselves. It was thus hypothesised that elevated ACKR2 
expression could protect against the spread of psoriasiform inflammation; 
high ACKR2 expression could limit inflammation through CC-chemokine 
scavenging, thereby limiting T-cell infiltration into skin. In contrast, it was 
hypothesised that focally deficient ACKR2 expression could enable 
unrestricted inflammation through the free formation of chemotactic CC-
chemokine gradients. However, IFNγ expression appears to be deficient in 
the IMQ model (Figure 4.3a-b), but could be mimicked through exogenous 
IFNγ administration. Experiments were therefore designed to test whether 
induction of ACKR2 expression protects against inflammation, in the context 
of psoriasiform inflammation in vivo. Mice were initially treated with 
exogenous recombinant IFNγ, before and during application of IMQ, in order 
to upregulate ACKR2 expression, as had been shown (Figure 4.3c). 
Mice were injected with IFNγ twice daily for 24 hours before the first 
application of IMQ in order to upregulate ACKR2 expression (the 
experimental model is represented schematically in Figure 4.4a). IFNγ 
injections continued twice daily for the duration of IMQ treatment, due to 
the short half-life of IFNγ in vivo. After the second application of IMQ, data 
showed that IFNγ co-treated mice (high ACKR2 expression in skin) displayed 
significantly less psoriasiform inflammation in response to IMQ, compared to 
control treated mice, as measured by the modified PASI (Figure 4.4b-c). This 
effect was sustained, and remained both clinically and statistically 
significant, until the day of cull. In this experiment, systemic IFNγ alone 
caused no clinically apparent skin changes in mice that were not treated 
with IMQ (Figure 4.4c). To further explore the role of ACKR2 in limiting the 
severity of psoriasiform inflammation, skin ACKR2 expression was correlated 
with the modified PASI score. This demonstrated a significant inverse 
correlation, where higher skin ACKR2 expression was associated with lower 
mPASI scores (Figure 4.4d).  
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In order to confirm that the observed effect was indeed mediated by ACKR2, 
experiments were additionally conducted in ACKR2-/- mice. Data showed 
that IFNγ in ACKR2-/- mice did not confer a protective effect against IMQ 
mediated psoriasiform inflammation, compared to WT (Figure 4.5). Indeed, 
at one time point (day 3) IFNγ appears to enhance inflammation (Figure 4.5) 
and it is hypothesised that in the absence of ACKR2, the pro-inflammatory 
effects of IFNγ could outweigh any anti-inflammatory effects. However, it 
would be important to repeat these experiments and continue to model for 
longer in order to more fully characterise the effect of IFNγ in ACKR2-/- 
mice. Concurrently, and in order to explore the protective effect of IFNγ on 
the secretion of psoriasis-associated chemokines, skin from mice was 
incubated in the presence of protease inhibitors, to collect secreted 
chemokines. The chemokine levels were quantified using ELISA, and 
demonstrated that IFNγ administered with topical IMQ limited not only 
clinical inflammation but suppressed the production of the T-cell attracting 
CC-chemokines CCL5 and CCL20 as well as the psoriasis associated Th17 
cytokine IL-17 (Figure 4.6). Whilst CCL5 is a ligand of ACKR2, CCL20 is not. 
This suggests that the observed reduction in CCL5, and CCL20 in the context 
of IFNγ-induced ACKR2 upregulation, is not necessarily a result of ACKR2 
scavenging. Instead, ACKR2 upregulation is associated with a general 
reduction in inflammation, as evidenced by a reduction in both ACKR2- and 
non-ACKR2 ligands, as well as IL-17. 
 
4.5.5 IFNγ co-administered with topical IMQ in mice, leads to 
a remote upregulation of ACKR2. 
As previously discussed, previous studies show that ACKR2 expression is 
relatively deficient in human psoriatic plaques (Singh et al. 2012). Data 
showed that topical application of IMQ replicates human ACKR2 expression 
patterns in inflammatory plaques, as demonstrated by a reduction in ACKR2 
transcript in IMQ treated- as compared to control cream treated mouse skin 
(Figure 4.7a, orange data points). It was hypothesised that it is the focal 
psoriatic plaques in humans, that drive remote ACKR2 upregulation, and that 
this occurs through IFNγ, (that is the most potent ACKR2-inducing Th1/Th17 
cytokine identified to date). However and in contrast to this hypothesis, in 
SHAMS 2016 
	158 
the IMQ model focal IMQ failed to differentially regulate remote ACKR2 
expression in skin (Figure 4.7b, orange data points). However, as previously 
outlined, the expression of IFNγ (both in skin and circulation) is deficient in 
the IMQ model. We therefore hypothesised that elevated IFNγ in the 
circulation was necessary for the psoriasiform inflammation to drive remote 
ACKR2 upregulation. For this reason, and in order to more closely model 
human psoriasis (where IFNγ is elevated in the circulation), mice were 
treated with systemically injected IFNγ (as in Figure 4.4a), and the ACKR2 
expression in remote skin quantified. Data showed that IFNγ co-administered 
in this manner increased ACKR2 expression in control treated skin as before 
(Figure 4.7a, filled blue data points). Strikingly, induction of a psoriasiform 
plaque in skin, with concurrent systemic IFNγ led to a substantial increase in 
ACKR2 expression in remote skin (Figure 4.7b, blue data points). This stands 
in contrast to IMQ alone, that did not upregulate ACKR2 in remote skin 
(Figure 4.7b, open orange data points). Together, these experiments 
demonstrated that where IFNγ was administered alongside topical IMQ, the 
human ACKR2 skin expression patterns could be modelled in mice (high 
ACKR2 in remote unaffected skin, low ACKR2 expression in plaques). 
 
4.5.6 Remotely upregulated ACKR2 protects against the 
spread of psoriasiform cutaneous inflammation. 
The clinical significance of increased ACKR2 expression in remote apparently 
unaffected skin of patients with psoriasis has been unknown. Data presented 
previously in this thesis have demonstrated that induced ACKR2 expression 
limited psoriasiform inflammation, may have modulated T-cell migration 
towards a pro-inflammatory chemokine stimulus, and restricted CD3+ T-cell 
positioning in the epidermis (Chapter 3, Figure 3.13). For these reasons, it 
was hypothesised that ACKR2 upregulation in remote skin, would protect 
against the spread of psoriasiform inflammation to those sites. To test this 
hypothesis, a ‘two-hit’ IMQ model was established (summarised in Figure 
4.8a), in which remote ACKR2 upregulation was achieved through treatment 
of the right mouse flank with IMQ together with systemic IFNγ injections. 
This protocol had been shown to increase ACKR2 expression in remote skin 
(Figure 4.7b). Having achieved remote ACKR2 upregulation in the same 
SHAMS 2016 
	159 
manner, a second site (contralateral flank or ear) was treated with IMQ (the 
protocol is summarised in Figure 4.8a).  
Again, and as shown in above experiments (Figure 4.4b), IFNγ limited 
psoriasiform inflammation at the first IMQ treated site (Figure 4.8b). 
Critically, and in keeping with the above hypothesis, the induction of one 
lesion in this model with systemic IFNγ, protected remote skin against the 
spread of psoriasiform inflammation (Figure 4.8c). Whilst exogenously 
administered IFNγ is protective against imiquimod-induced psoriasiform 
inflammation during and for a period after administration, data from day 8 
of the model (Figure 4.8b) suggests there may be enhanced inflammation in 
the IFNγ-treated as opposed to the control-treated group. This does not 
reach statistical significance, and further experiments, where the model is 
maintained for longer that 8-days would be helpful in determining whether 
IFNγ will have pro-inflammatory effects longer-term, after an initial 
protective period. It is possible that whilst IFNγ-induced ACKR2-upreglation 
is protective in the initial stages, the pro-inflammatory pathways induced by 
IFNγ become more dominant at later time points, thus overcoming any early 
anti-inflammatory effects. Additionally, longer-term experiments with 
continued IFNγ injections would be required to determine whether the effect 
of IFNγ in terms of limiting mPASI/psoriasiform inflammation only occurs in 
the early stages of this model, or whether the loss of protection in terms of 
psoriasiform inflammation at the time of cull, is due to cessation of IFNγ 
injections in the presented experiments.   
Whilst above experiments suggest that high ACKR2 expression is associated 
with reduced psoriasiform inflammation, it is important to demonstrate that 
any protective effect observed from IFNγ administration is indeed dependent 
on the presence of ACKR2.	 Therefore, in order to confirm that these 
observations were dependent on ACKR2, experiments were conducted in 
ACKR2-/- mice, using ear skin as a second site of inflammation. However, in 
ACKR2-/- no protective effect was afforded by induction of a previous 
psoriasiform lesion alongside systemic IFNγ (Figure 4.8d and 4.9), as had 
been seen in WT mice (Figure 4.7c). These data suggest that the protective 
effects that result from IMQ/systemic IFNγ on remote skin are ACKR2-
dependent, though further work and repeat experiments are required (e.g. 
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also using non-ear skin as a second site in ACKR2-/- mice) to verify these 
findings. In addition, an elevation of ACKR2 transcript expression in the 
remote skin site was confirmed by QPCR (Figure 4.10a). At present, reliable 
staining of murine skin for ACKR2 is not possible using available antibodies. 
Thus, in order to confirm the location of ACKR2 upregulation in skin, skin 
was split into dermal and epidermal compartments and successful separation 
confirmed by demonstrating elevated involucrin expression (a keratinocyte 
differentiation marker). QPCR data confirm that ACKR2 induction 
predominantly occurs in the epidermal compartment, which is in keeping 
with previous data demonstrating epidermal keratinocytes as the main site 
of ACKR2 expression in human skin (Singh et al. 2012). 
Histopathology showed that IFNγ limited thickening, epidermal CD3+ T-cell 
infiltration and epidermal hyperproliferation (as measured by Ki67 staining) 
of IMQ treated mouse skin both at the first flank lesions (Figure 4.11a), and 
also at the second lesion (Figure 4.11b). Quantification of the difference 
between PBS control and IFNγ treated mice (in terms of epidermal 
thickening, thickness of the Ki67 positive epidermal layer (a marker of 
proliferation) and the proportion of CD3+ T-cells in the epidermis), 
confirmed that these differences were significant (Figures 4.12a-b). 
Immunohistochemical staining for the proliferation marker Ki67 revealed a 
significantly thicker layer of proliferating basal keratinocytes in mice treated 
with IFNγ as compared to PBS control treated mice in both the first (Figure 
4.12a) and second lesions (Figure 4.12b). Furthermore, proportionately 
fewer CD3+ T-cells were localised in the epidermis in IFNγ as compared to 
PBS control treated mice, both in the first lesion, and in the second induced 
lesion (Figures 4.12c-d). Critically, there were no significant differences 
between IFNγ and PBS treated mice in terms of total numbers of CD3+ cells 
in the skin (epidermis plus dermis), indicating that the epidermal differences 
are specifically a function of CD3+ exclusion from the epidermis, where 
ACKR2 is upregulated (Figures 4.12c-d). Immunohistochemical analyses in 
above experiments had been limited to CD3+ cells only. However, several 
cell sub-types play a role in the pathogenesis of psoriasis and in order to 
better understand the cell infiltrate in the skin in this model, skin sections 
were additionally stained for CD3+, CD4+, CD8+, CD25+ and FoxP3 positive 
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cells. Cells counted both in whole skin including dermis and epidermis 
(Figure 4.13a) and the epidermis alone (Figure 4.13b), in order to determine 
whether there were differences in the treatment groups in terms of 
leukocyte positioning in skin. Whilst no significant differences were found 
between the treatment groups in terms of absolute cell numbers in 
epidermis plus dermis (Figure 4.13a), a significantly higher proportion of 
CD3+ cells were found in the epidermis in imiquimod treated ACKR2-/- mice, 
as compared to wild-type mice.  Though data did not reach statistical 
significance, results suggest that the relative exclusion of T-cells appear to 
be predominantly skewed against CD4+ cells. The significance of this finding 
is unclear, and whilst CD4+ and CD8+ both play an important role in 
psoriasis, their relative contribution and importance to pathogenesis is 
controversial. Further studies are required to fully understand the difference 
in the relative exclusion of different leukocyte sub-populations in the 
context of psoriasiform inflammation, and the significance this would have 
for the development of psoriasiform plaques. Attempts were also made to 
stain for RORγt cells in these experiments, given the importance of Th17 
cells in psoriasis. However, despite numerous antibodies and staining 
methods, none of the strategies employed were successful in staining 
reliably for RORγt cells, which needs to be addressed in future experiments.  
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Figure 4.1 Differential expression of ACKR2 in skin is dependent on products 
of activated T-cells. 
(a) Absolute ACKR2 mRNA expression in primary human keratinocytes treated 
with conditioned medium from activated or non-activated (resting) human 
T-cells (compared to fresh medium (nil), or diluted 1:8-1:2 in fresh 
medium). 
(b) Schematic representation of the psoriasiform in vitro skin equivalent model 
set-up. 
(c) Relative ACKR2 mRNA expression in in vitro human skin equivalents of 
psoriasis, with increasing numbers of infiltrating activated human CD4+ T-
cells (M=million). 
(d) Fold change ACKR2 mRNA expression in vitro human skin equivalents of 
psoriasis after 2-4 days of T-cell migration into the skin equivalents and 
following treatment with all-trans retinoic acid (RA, 10-6M) or ciclosporin A 
(CsA, 400ng/ml).  
Human skin equivalent work was carried out by our collaborators as described in section 
2.4.8 (Dr Ellen van den Bogaard and Prof Joost Schalkwijk, at Radboud University Nijmegen, 
the Netherlands), n=3-5. 
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Figure 4.2 Th1/Th17 cytokines upregulate ACKR2 expression, with IFNγ being 
the single most potent ACKR2 inducing T-cell product. 
(a) Relative ACKR2 mRNA expression in in vitro ‘skin equivalents’ treated with 
cytokine combinations; Th1 cytokines; IL-1α+TNFα+IFNγ: Th17 cytokines; IL-
17+IL22. IL-1α 30ng/ml: IFNγ 500U/ml: TNFα 30ng/ml: IL-17 100ng/ml: IL-22 
100ng/ml: Statistics is Student’s t-test. * P<0.05, ** P<0.01. 
(b) Relative ACKR2 mRNA expression in in vitro ‘skin equivalents’ treated with 
individual cytokines; IL-1α 30ng/ml: IFNγ 500U/ml: TNFα 30ng/ml: IL-17 
100ng/ml: IL-22 100ng/ml: Statistics is Student’s t-test. * P<0.05, ** P<0.01. 
(c) Absolute ACKR2 mRNA expression in primary human keratinocytes treated with 
conditioned medium from activated human T-cells diluted 1:8, with added 
increasing concentrations of neutralising anti-IFNγ antibodies, compared to 
untreated keratinocytes. Significance was assessed using two-way ANOVA with 
Tukey’s multiple-comparisons-test. **** P<0.0001. Orange *; compared to NIL. 
Black *; compared to no anti-IFNγ, but with conditioned active T-cell medium. 
Cell culture experiments in (a) and (b) was carried out by our (Dr Ellen van den Bogaard 
and Prof Joost Schalkwijk, at Radboud University Nijmegen, the Netherlands), n=3-5.  
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Figure 4.3 The IMQ mouse model of psoriasis is not associated with 
increased IFNγ transcript/protein in skin. 
(a) Absolute ACKR2 mRNA expression in dorsal mouse skin, draining lymph 
node and spleen, 24 hours after treatment with control cream, IMQ or 
systemic Bunyavirus infection. *** P<0.005. n=6 mice per group. 
(b) Concentration of IFNγ, in mouse skin on day 5 following twice daily IFNγ 
(20,000 U intraperitoneally [i.p.]) on days 1-4, topical control or IMQ on 
days 2-4, as compared to PBS vehicle control/carrier cream (naïve) 
mouse skin, as measured by ELISA (n=6/group). (Undertaken with the 
assistance of Dr G. Wilson) 
(c) Absolute ACKR2 mRNA expression in dorsal skin of mice that were 
untreated, or treated with systemic IFNγ (20,000U i.p. per day for 4 
days, n=6). Significance was determined using Student’s t-test. Data 
derived from one experiment. 
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Figure 4.4 IFNγ induced ACKR2 expression in mice protects against IMQ 
induced psoriasiform skin inflammation. 
(a) Schematic representation of the experimental model in which mice were 
injected with IFNγ or PBS negative control. 
(b) Skin inflammation severity (3 groups of n=6 in each group). Arrows 
indicate first day of IFNγ/PBS injections and IMQ/control cream. 
Treatments continued until the day before cull. 
(c) Representative images of wild-type (WT) mice (top) IFNγ (20,000U 
2x/day) plus control cream; (middle) PBS plus IMQ and (bottom) IFNγ 
plus IMQ. Treatments were for 3 days and mice culled on day 4. 
(d) Correlation of cutaneous ACKR2 expression and skin inflammation 
severity. **** P<0.0001. Data representative of two comparable 
experiments.  
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Figure 4.5 IFNγ failed to protect against IMQ induced psoriasiform skin 
inflammation in ACKR2-/- mice. 
Modified total PASI, across all parameter, in ACKR2-/- and WT mice treated 
with IMQ on one flank, plus either systemic IFNγ or PBS control. 
Data are mean±SEM, statistical analysis is two-way ANOVA with Tukey’s 
multiple comparisons test. n=6, ** P<0.01. Data from one experiment. 
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Figure 4.6 Induced ACKR2 expression in mice limits production of 
psoriasis-associated soluble CC-chemokines. 
(a,b) Concentration of CCL5 and CCL20, in mouse skin on day 5 following 
twice daily IFNγ (20,000 U i.p.) on days 1-4, topical control or IMQ on 
days 2-4, as compared to PBS vehicle control/carrier cream (naïve) 
mouse skin, as measured by ELISA (n=6 mice). (Undertaken with the 
assistance of Dr G. Wilson) 
(c)  Absolute CCL20 expression, normalised to 18S, in mouse skin 3 days of 
control cream or IMQ in WT or ACKR2 deficient (KO) mice.  
(d)  Concentration of IL-17, in mouse skin. Methodology as in a-b above. 
Statistics: one-way ANOVA with Tukey’s post-test. *P<0.05, **P<0.01, 
***P<0.005. Each experiment performed once.  
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Figure 4.7 Human psoriatic ACKR2 expression patterns can be 
successfully modelled in vivo by topical IMQ at one site plus injected IFNγ 
in mice. 
Comparison of ACKR2 expression in;  
(a) topically treated skin and  
(b) remote untreated control skin of IMQ treated mice in the presence or 
absence of subcutaneous IFNγ administration (10,000U IFNγ per day) n=6 
in all groups. Significance was assessed using one-way ANOVA with 
Tukey’s multiple comparisons test. * P<0.05, ** P<0.01, *** P<0.005, **** 
P<0.0001.  Data representative of two comparable experiment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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Figure 4.8 Focal psoriasiform inflammation protected remote unaffected skin 
from the spread of inflammation. 
(a) Diagram of experimental design. 
(b) Inflammation severity of initial psoriasiform lesions: Mice were treated with 
20,000U IFNγ 2xdaily or vehicle (black arrows) and IMQ 1xdaily (grey arrows) to 
right flank. This was stopped, and;  
(c) inflammation induced by daily IMQ treatment at the second site (mice were 
culled on day 8) was assessed. Data representative of two comparable 
experiments. 
(d) Absolute increase in ear thickness, where ear was used as the second site for 
IMQ application. 
Statistics: two-way ANOVA (a-c) and one-way ANOVA (d) *P<0.05, **P<0.01, 
***P<0.005, ****P<0.0001. n=6 mice. Experiment performed once. 
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Figure 4.9 Focal psoriasiform inflammation plus IFNγ did not protect 
remote unaffected ear skin from the spread of inflammation in the 
absence of ACKR2. 
Representative images of H&E, Ki67 and CD3 staining of mouse ears, in 
which psoriasiform lesions had been induced on flank alongside concurrent 
systemic IFNγ at 20,000U per day per mouse (n=6). 
(a) WT mouse ear 
(b) ACKR2-/- ear 
The dark red arrows indicate CD3+ T-cells in epidermis, with the dark red 
line representing the dermal-epidermal junction. All scale bars 100µm. 
Experiment performed once. 
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Figure 4.10 ACKR2 is essential for focal psoriasiform inflammation 
protecting remote unaffected skin from the spread of inflammation. 
(a) ACKR2 expression (normalised to 18S) in the second IMQ-induced lesions, 
where the first lesion was induced with concurrent PBS (grey bar) or IFNγ 
(black bar). Statistics: Student’s t-test. n=6 mice. Data representative of 
two comparable experiment. 
(b) ACKR2 expression in distal epidermis (orange) and dermis (blue). 
Epidermal/dermal separation confirmed by QPCR for involucrin (grey 
bars). Statistics:  Student's t-test, Tukey’s multiple comparisons test. 
*P<0.05, ****P<0.0001. n=6 mice. Experiment performed once.  
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Figure 4.11 IFNγ induced ACKR2 expression limits epidermal thickening 
and limits epidermal CD3+ T-cell positioning. 
Representative images of (i) H&E, (ii) Ki67 and (iii) CD3+ staining of: 
(a) The initial IMQ-induced lesion on right mouse flank, with concurrent PBS 
control or systemic IFNγ at 20,000U per day per mouse and; 
(b) The second IMQ-induced lesion initiated following cessation of the initial 
IMQ/IFNγ or PBS treatment.  
In (iii) the dark red arrows indicate CD3+ T-cells in epidermis, with the 
dark red line representing the dermal-epidermal junction. All scale bars 
100µm. Experiment performed once. 
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Figure 4.12 IFNγ  induced ACKR2 expression is associated with limited epidermal 
thickening and restricted epidermal CD3+ T-cell positioning: quantitative data. 
Quantification of H&E, Ki67 and CD3+ staining of: 
(a) The initial IMQ-induced lesion on right mouse flank, with concurrent PBS control or 
systemic IFNγ at 20,000U per day per mouse and; 
(b) The second IMQ-induced lesion initiated following cessation of the initial IMQ/IFNγ or 
PBS treatment. 
(c) The first IMQ-induced lesion on right mouse flank, with concurrent PBS control or 
systemic IFNγ (20,000U per day per mouse).  
(d)  The second IMQ-induced lesion following cessation of systemic PBS or IFNγ treatment.   
In (a-b) for the quantitative data, thickness was measured across 9 sites, from 3 
separate sections from each skin sample.  
Quantification of CD3+ cell numbers (mean of 3 separate fields-of-view per mouse) in 
(c+d): (left hand graphs) Total numbers of CD3+ T-cells in whole skin (dermis and 
epidermis) and (right hand graphs) Numbers of CD3+ T-cells specifically located in the 
epidermis. *P<0.05, **P<0.01, ***P<0.005. n=6 mice. Experiment performed once. 
a b
PB
S 
IFN
γ 
0
20
40
60
80
ep
id
er
m
al
 th
ic
kn
es
s 
(µ
m
)
*
PB
S 
IFN
γ 
0
5
10
15
20
25
%
 C
D
3+
 e
pi
de
rm
al
 T
-c
el
ls ***
PB
S 
IFN
γ 
0
10
20
30
40
K
I6
7+
 th
ic
kn
es
s 
(µ
m
) **
PB
S 
IFN
γ 
0
20
40
60
80
ep
id
er
m
al
 th
ic
kn
es
s 
(µ
m
)
***
PB
S 
IFN
γ 
0
10
20
30
40
K
I6
7+
 th
ic
kn
es
s 
(µ
m
) **
PB
S 
IFN
γ 
0
5
10
15
20
25
%
 C
D
3+
 e
pi
de
rm
al
 T
-c
el
ls ***
PB
S 
IFN
γ 
0
3
6
9
12
15
C
D
3+
 c
el
l c
ou
nt
 in
 d
er
m
is
 p
er
 F
O
V
P<0.001
PB
S 
IFN
γ 
0
20
40
60
80
100
C
D
3+
 c
el
l c
ou
nt
 in
 s
ki
n 
pe
r F
O
V NS
PB
S 
IFN
γ 
0
3
6
9
12
15
C
D
3+
 c
el
l c
ou
nt
 in
 d
er
m
is
 p
er
 F
O
V
P<0.05
PB
S 
IFN
γ 
0
15
30
45
60
75
90
C
D
3+
 c
el
l c
ou
nt
 in
 s
ki
n 
pe
r F
O
V NS
c d 
SECOND LESION FIRST LESION  
    
*** 
    
* 
SHAMS 2016 
	174 
 
Figure 4.13 Immunohistochemical characterisation of immune cells in 
skin. 
Markers used: CD3+ for T-cells: CD4+ for helper T-cell: CD8+ for cytotoxic T-
cells: CD25+ for activated T-cells and FoxP3 for regulatory T-cells. 
(a) Median cell numbers as per same field-of-view (FOV) of whole skin (x200 
magnification) after 3 days of treatment with IMQ (±systemic IFNγ 
20,000 U daily). (Statistics: one-way ANOVA with Tukey’s multiple 
comparisons test). Quantifications carried out using 6 FOV per skin 
sample.  
(b) Median cell numbers as per same field-of-view of epidermis (x200 
magnification) after 3 days of treatment with IMQ (±systemic IFNγ 
20,000 U daily). (Statistics: multiple t-test with Holm-Sidak multiple 
comparison correction. ** P<0.01).  
Quantifications carried out using 6 FOV per skin sample. n=6 mice. 
Experiment performed once. 
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Supplementary Figure 4.1 Supplied by Dr Mark Singh. IFNγ levels were 
increased in patients with psoriasis as compared to healthy controls. 
Plasma cytokine levels in healthy controls (n=10)  
versus patients with psoriasis (n=50), assessed.  
Significance was determined by Mann-Whitney U test. *** P<0.005. 
Experiment performed once. 	  
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4.6 Summary Chapter 4 
This chapter reports the identification of IFNγ as an inducer of epidermal 
ACKR2 expression in vivo, and thus enabled the assessment of therapeutic 
ACKR2 induction in a murine model of psoriasiform inflammation. ACKR2 
induction in vivo protected against the development of psoriasiform 
inflammation. Furthermore, induction of one psoriasiform skin plaque, lead 
to upregulation of ACKR2 in remote unaffected skin in the IMQ mouse model, 
and protected unaffected skin from the further spread of inflammation. 
Previous studies have shown a relatively deficient expression of the CC-
chemokine scavenging atypical chemokine receptor ACKR2 in psoriatic 
plaques. In contrast, ACKR2 expression in unaffected remote skin (‘remote’ 
from psoriatic lesions) is upregulated in patients with psoriasis (Singh et al. 
2012). The mechanism and significance of this observation has not been 
previously understood. Psoriasis is considered a predominantly Th1/Th17 
driven systemic inflammatory disorder, with elevated levels of Th1/Th17 
cytokines in the circulation (Di Meglio et al. 2014). Given the apparently 
widespread upregulation of ACKR2 in those with psoriasis, it was thus 
hypothesised that T-cells and soluble Th1/Th17 cytokines could differentially 
regulate ACKR2 expression. To test this hypothesis, the effect of T-cell 
products on ACKR2 expression was assessed. Results showed that soluble T-
cell products from activated human T-cells were potent inducers of ACKR2 
expression in keratinocytes (KC). The T-cell dependency of ACKR2 
upregulation in skin was further confirmed through the use of a novel 
previously validated humanised in vitro 3D model of psoriasis (‘skin 
equivalents’), in collaboration with colleagues at Radboud University, 
Nijmegen, the Netherlands (van den Bogaard et al. 2013). In brief, this 
model involved culturing primary human keratinocytes on a decellularised 
human dermal matrix, into which active human T-cells were allowed to 
infiltrate. The resulting skin equivalent bears significant similarities to 
human psoriasis, both in phenotype and gene expression (van den Bogaard et 
al. 2013). Using this in vitro model of human psoriasis, data confirmed that 
T-cell infiltration of this skin model was necessary for ACKR2 upregulation in 
the skin equivalents. Additionally, targeting T-cells therapeutically using the 
calcineurin inhibitor ciclosporin, significantly limited the ACKR2 upregulation 
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associated with T-cell infiltration into the skin equivalents. Therapeutic 
targeting of KC proliferation, instead of T-cells, through the use of retinoids 
did not significantly reduce ACKR2 expression. Together, the data suggest a 
role for T-cells in the differential regulation of ACKR2 in both cultured 
primary human KC and in an in vitro model of psoriasis.    
Whilst psoriasis is driven by Th1/Th17 cytokines (Di Meglio et al. 2014), the 
relative contribution of different Th1/Th17 cytokine products has not 
previously been assessed. For this reason, Th1/Th17 cytokines were tested 
(both singly and in combination) using healthy primary human keratinocyte 
monolayers. Data showed that Th1 and Th17 cytokine combinations both 
significantly upregulated ACKR2 expression in skin equivalents. Antibody 
neutralisation of IFNγ in active human T-cell supernatant obliterated the 
ACKR2 inducing effect of T-cell products, suggesting that the T-cell 
mediated ACKR2 upregulation is predominantly driven by IFNγ. Therefore, it 
was hypothesised that IFNγ released into the circulation from inflammatory 
psoriatic plaques, could upregulate ACKR2 expression in vivo. However, our 
data showed that IFNγ expression is not induced in the IMQ mouse model 
(transcript or protein). This is a significant deficiency of this model 
compared to both other murine models of psoriasis and human skin (Swindell 
et al. 2011; Vinter et al. 2014). This deficiency notwithstanding, the IMQ 
model remains a readily available model, and offers the advantage of 
psoriasiform lesion being inducible at specific, pre-determined skin sites. To 
address the lack of systemic ACKR2 upregulation in the IMQ model, next WT 
mice were treated with systemic recombinant IFNγ. Data demonstrated, for 
the first time, that cutaneous ACKR2 expression (as assessed through QPCR) 
could be induced on a systemic level through exogenously administered IFNγ. 
Having established a method by which ACKR2 expression could be induced, 
initial experiments were designed to determine if induction of ACKR2 could 
prevent the development of psoriasiform lesions. Results showed that IFNγ 
administered the day before IMQ (to upregulate ACKR2 prior to IMQ 
application) and throughout IMQ treatment, significantly limited the severity 
of skin inflammation in WT mice. In keeping with the reduced clinical 
severity of psoriasiform inflammation that was achieved with IFNγ 
administration, experiments also confirmed a reduction in the production of 
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CCL5 (a T-cell chemotactic, psoriasis-associated ACKR2 ligand), CCL20 and 
IL-17 in IFNγ as apposed to control treated mice, following application of 
IMQ. Experiments using IFNγ combined with topical IMQ were additionally 
performed in ACKR2-/- to assess the ACKR2-dependency of the observations. 
Results showed that IFNγ did not confer a protective effect against IMQ 
induced inflammation in ACKR2-/- as compared to WT mice. Unexpectedly, 
at one time point (day 3) inflammation was enhanced in IFNγ treated mice 
with IMQ treated skin. This would be in keeping with IFNγ having both pro- 
and anti-inflammatory effects in vivo; it is possible that where ACKR2 is 
absent, IFNγ cannot exert its anti-inflammatory effect through ACKR2 
upregulation, which shifts the balance in favour of the pro-inflammatory 
effects of IFNγ. This in turn, could have been manifest as enhanced 
psoriasiform inflammation in these experiments. Further experiments would 
however be necessary, to determine the mechanism of such pro-
inflammatory effects. 
As previously discussed, in humans with psoriasis, there is reduced ACKR2 
expression in psoriatic plaques, but elevated levels in remote unaffected 
skin (Singh et al. 2012). Next, experiments were conducted to determine 
whether the human psoriatic ACKR2 expression patterns (both in inflamed 
and remote skin) could be replicated in the IMQ model. As in human disease, 
induction of psoriatic plaques through the use of IMQ was associated with a 
reduction of ACKR2 mRNA expression in the plaque itself. IMQ alone did not 
lead to an upregulation of remote ACKR2 in mice, however as IFNγ  appears 
to be deficient in the IMQ model and is the most potent inducer of ACKR2 
identified to date, it was hypothesised that concurrent administration of 
recombinant injected IFNγ could overcome the lack of remote ACKR2 
upregulation in the IMQ model. Data confirmed this hypothesis; systemic IFNγ 
plus IMQ applied to one flank, was associated with a substantial increase in 
ACKR2 mRNA expression in remote unaffected skin, as compared to IFNγ 
alone. These data imply that there are factors, possibly released by the 
psoriasiform plaque, that synergise with the ACKR2 induction caused by IFNγ. 
Furthermore, results highlight a novel mechanism by which inflammation in 
vivo could be spatially restricted; It was hypothesised that induction of one 
psoriasiform lesion in the context of IFNγ associated inflammation (as in 
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human psoriasis), leads to a remote upregulation of ACKR2. Upregulated 
remote ACKR2 in turn, acts to limit the spread of inflammation. This 
hypothesis was confirmed through experiments where a second skin site was 
treated with IMQ, following the establishment of a first lesion with 
IMQ/concurrent IFNγ in order to upregulate ACKR2 remotely; specifically, 
inflammation was significantly limited at the second IMQ treated site. There 
was significantly reduced epidermal thickening, Ki67 epidermal staining and 
restricted CD3+ epidermal entry at the second induced lesion where ACKR2 
expression was elevated. These results were dependent on ACKR2, as repeat 
experiments in ACKR2-/- mice showed that, in contrast to WT mice, IMQ plus 
systemic IFNγ did not protect remote sites against IMQ driven inflammation 
in ACKR2 deficient mice.  
Lastly, in order to better understand the T-cell infiltrate in IMQ treated skin, 
skin sections from IMQ treated WT, ACKR2-/- and WT+ IFNγ mice, were 
stained for CD3+, CD4+, CD8+, CD25+ and FoxP3 positive cells. Whilst there 
were no significant differences between the treatment groups in terms of 
the total number of cells positive for the above markers in whole skin, 
differences were striking when the proportion of infiltrating skin cells that 
localised in the epidermis were determined. Data showed that the epidermal 
exclusion of T-cells in WT/WT+ IFNγ is predominantly skewed against CD4+ 
cells, in contrast to ACKR2-/- mice.  
In conclusion, data presented in this chapter highlight ACKR2 as being 
important not only to restrict skin inflammation at the first psoriasiform 
lesion, but also in limiting the further spread of inflammation beyond the 
first skin lesion. This provides a novel mechanism by which psoriasiform 
inflammation may be spatially restricted in vivo, and highlights ACKR2 
induction as a novel therapeutic approach in the treatment of psoriasiform 
inflammation. 
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5 Psoriasis associated microRNAs regulate 
expression of ACKR2 in human primary 
keratinocytes and lymphatic endothelial cells. 
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5.6 Summary Chapter 5 
 
 
5.2 Hypothesis 
• Psoriasis-associated microRNAs are negative regulators of ACKR2 
expression in keratinocytes (KC) and lymphatic endothelial cells (LEC) 
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5.3 Aims 
The aims of this chapter were to; 
• Identify microRNAs capable of differentially regulating ACKR2 in primary 
human keratinocytes and lymphatic endothelial cells 
• Determine whether identified microRNAs bind directly to the 3’-UTR of 
ACKR2 
 
 
5.4 Introduction 
ACKR2 expression is relatively deficient in psoriatic plaques. In contrast, 
ACKR2 expression in clinically unaffected remote skin (remote from 
inflammatory psoriatic lesions) is relatively high (Singh et al. 2012). ACKR2 
acts as a scavenger of pro-inflammatory CC-chemokines, and has a role in 
limiting excessive/deleterious inflammation in vivo (Nibbs et al. 2007). It 
was hypothesised that the high ACKR2 expression in unaffected remote skin 
in psoriasis (where it is mainly expressed in the lower epidermis (Singh et al. 
2012)) prevents excessive inflammation and thus psoriatic plaque 
development. In keeping with this hypothesis, previous chapters of this 
thesis demonstrated that a lack of ACKR2 enhanced CD3+ T-cell positioning 
in the epidermis and exaggerated psoriasiform inflammation in the IMQ 
mouse model (chapter 3). In contrast, where ACKR2 expression was induced 
in vivo, skin was significantly protected against psoriasiform inflammation 
(Chapter 4). However, the mechanism by which ACKR2 expression is 
relatively decreased in psoriatic plaques is not known. Insights into the 
molecular mechanism(s) by which ACKR2 downregulation is controlled, will 
aid in our understanding of the reasons why ACKR2 expression is focally 
deficient (e.g. in plaques). In addition, this could help provide a possible 
novel therapeutic target in limiting psoriasiform inflammation. 
MicroRNAs have emerged as the most abundant class of gene regulators, and 
have been implicated in a range of inflammatory disease processes. They 
predominantly act as negative regulators of gene expression at a post-
transcriptional level (Pasquinelli 2012). Specifically, microRNAs bind their 
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mRNA target 3’-utranslated region (3’-UTR), and lead to the degradation of 
their mRNA target (microRNA biosynthesis and target interactions are 
represented schematically in Supplementary Figure 5.1). Typically, one 
microRNA binds multiple mRNA targets, and the same mRNA 3’-UTR can be 
targeted by numerous microRNAs; this promiscuity introduces a significant 
degree of complexity in microRNA/target interactions and subsequent gene 
expression (Eulalio & Mano 2015). Recent studies have shown that a large 
number of microRNAs are differentially expressed in psoriasis, with many 
being significantly overexpressed in the psoriatic plaques (Sonkoly et al. 
2007). Given their abundance as negative regulators of gene expression, 
microRNAs are thus plausible regulators of ACKR2 expression. There exist 
bioinformatics tools, that enable in silico predictions of which microRNAs 
might target any specific mRNA 3’-UTR. Such databases use microRNA-mRNA 
complementarity as well as microRNA conservation across species, in order 
to predict the likelihood of binding in vivo (Ekimler & Sahin 2014). It was 
therefore hypothesised that microRNAs capable of negatively regulating 
ACKR2 mRNA via binding to the 3’-UTR could be identified through studying 
microRNAs that are both 1) differentially expressed in psoriasis (where 
ACKR2 expression is diminished in plaques) and 2) are predicted to bind the 
ACKR2 3’-UTR in silico. Particular emphasis was placed on keratinocytes 
(KCs) and lymphatic endothelial cells (LECs), as these are the skin cells in 
which ACKR2 expression is particularly high and of direct relevance to skin 
inflammation (Griffith, Sokol & Luster 2014; McKimmie et al. 2013; Griffith, 
Sokol & Luster 2014).  
 
 
5.5 Results 
 
5.5.1 Three microRNAs, predicted to bind the ACKR2 3’-UTR 
are differentially expressed in psoriatic lesions. 
Though cytokines have been identified that upregulate of ACKR2 (e.g. Th1 
and Th17 cytokines, see Chapter 3), the precise molecular mechanisms 
whereby ACKR2 is downregulated are not known. In particular, we do not 
understand the molecular mechanisms by which ACKR2 expression is reduced 
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within psoriatic plaques, where ACKR2 expression is relatively deficient as 
compared to unaffected skin of patients with psoriasis (Singh et al. 2012). 
MicroRNAs are generally considered the largest class of regulators of gene 
expression, but their role in regulating ACKR2 has remained unexplored. In 
order to identify possible microRNA regulators of ACKR2 expression, the 
bioinformatics database TargetScan was used to identify possible microRNA 
targets. Results were filtered such that only microRNAs that are broadly 
conserved amongst vertebrates would be identified, in order to increase the 
likelihood of identified microRNA species being biologically relevant. 
Through this search strategy, 16 microRNAs were identified that were both 
1) predicted to bind the 3’-UTR of human ACKR2, and 2) were broadly 
conserved amongst vertebrates (Figure 5.1). The more negative the ‘total 
context score’ becomes, the more likely that this miRNA is predicted to bind 
to the 3’-UTR. In Figure 5.1, the miRNAs are ranked in descending likelihood 
of binding the ACKR2 3’-UTR 
Previously published studies have identified numerous microRNAs that are 
differentially expressed in psoriatic skin, though their role in psoriasis 
pathogenesis has remained relatively unknown (Sonkoly et al. 2007; Zibert et 
al. 2010). As microRNAs are predominantly negative regulators of gene 
expression, emphasis was placed on microRNAs that were upregulated in the 
psoriatic plaque (where ACKR2 expression is comparatively reduced). In this 
manner, by comparing 1) the list of microRNAs that are predicted to bind the 
3’-UTR of ACKR2 in silico and 2) microRNAs previously shown to be 
differentially regulated in psoriasis, it was possible to identify 3 single 
microRNAs that were present in both lists; miR-10, miR-146 and miR-203. 
Interestingly, each of these miRNAs had a particularly high in silico likelihood 
of regulating ACKR2 (Figures 5.2 and 5.3). Additionally, all three microRNAs 
have been shown to play roles in skin homeostasis and inflammation (Xue et 
al. 2011; Saba et al. 2014; Primo et al. 2012), thus making them plausible 
candidates as ACKR2 regulators. miR-146 and 203 had been previously shown 
to be upregulated in psoriatic lesions (where ACKR2 expression is limited). In 
contrast, miR-10 is upregulated in unaffected skin, but has a particularly 
high predictive score for binding ACKR2. For the above reasons, these three 
SHAMS 2016 
	185 
microRNAs were selected for further evaluation as possible regulators of 
ACKR2 expression. 
 
5.5.2 A microRNA transfection protocol was developed for use in 
primary human cells. 
In order to ensure successful transfection of cells, first the appropriate 
concentration of microRNA to be complexed with transfection reagent was 
determined. This was to ensure that the delivered concentration would be 
tolerated by primary cells without causing cell death, whilst also enabling 
efficient delivery of microRNAs to the cytoplasm. The cell types tested were 
those with apparently highest ACKR2 expression in skin; healthy human 
primary keratinocytes (KC) and lymphatic endothelial cells (LEC) (Griffith, 
Sokol & Luster 2014; McKimmie et al. 2013). A microRNA concentration of 
10nM has been previously used in the literature with human cells, that were 
transfected at 70% cell confluence (Sonkoly et al. 2009). This previously used 
protocol was taken as the starting point in developing transfection protocols. 
Three concentrations of microRNAs were initially tested in pilot 
experiments; transfection reagent without microRNA, 10nM and 30nM;. 
Whilst transfection reagent (RNAiMax) alone, and microRNA at 10nM caused 
no cell death or discernible morphological changes in confluent cell 
monolayers of KC or LEC, cells were not viable/adherent after 24 hours upon 
treatment with 30nM microRNA (data not quantified). Interestingly, cells 
were viable if 10nM of several different microRNAs were used up to a total of 
30nM (see below for details). A maximum of 10nM of each type of microRNA 
was thus used for subsequent experiments presented below. 
As demonstrated in chapter 3 of this thesis, inflamed cells upregulate ACKR2 
expression. In order to determine whether microRNAs are capable to reduce 
ACKR2 expression also in the context of upregulated ACKR2, microRNAs were 
transfected into both healthy and inflamed cells. In order to ensure that 
microRNAs were successfully transfected into both normal and inflamed 
cells, initially healthy KC and KC treated with IFNγ (to upregulate ACKR2) 
were transfected with miR-146b for 24h and the reduction of the expression 
of previously validated miR-146b targets (IRAK1 and TRAF6) determined by 
QPCR (Figure 5.4a-b). As predicted, 10nM miR-146b led to a significant 
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reduction in the expression of IRAK1 and TRAF6, both in untreated (Figure 
5.4a) and IFNγ treated KC (Figure 5.4b) at 24 hours. IFNγ is a potent inducer 
of ACKR2 expression, and IFNγ treated cells were included in order to ensure 
that the microRNA-induced repression of gene expression would also be 
evident in the context of high ACKR2 expression. Next, the optimal duration 
of transfection was determined using KC, with cells treated with 10nM miR-
146b for 8, 24 and 48h. Expression of IRAK1 (Figure 5.5a) as well as TRAF6 
(Figure 5.5b) mRNA were significantly reduced at all time points with miR-
146b as compared to scrambled miR control (Figure 5.5). In the case of 
ACKR2 however (Figure 5.6), scrambled miR control was associated with an 
increased ACKR2 expression at 48h as compared to 24h. This would be in 
keeping with the process of transfection itself being associated with an 
upregulation of ACKR2 at 48h. This in turn could be possible marker of 
confounding off target effects of the transfection process at 48h. Therefore, 
24h was chosen at the duration of transfection that 1) led to the most 
apparent reduction in ACKR2 expression, but 2) with no apparent 
upregulation of ACKR2 due to the process of microRNA transfection. 
Together, these results demonstrated that microRNA could be successfully 
delivered into the cytoplasm of KC.  
 
5.5.3 miR-146b and miR-10b reduce the expression of ACKR2 
mRNA in primary human KC and LEC respectively. 
Having shown, at least in principle, utilising KC and previously validated miR 
targets, that functional microRNAs can be delivered intracellularly, next 
both KC and LEC were transfected with the main microRNAs identified as 
potentially targeting ACKR2; miR-10a, miR-146b and miR-203. It is 
acknowledged that whilst viability of both KC and LEC was determined, 
optimisation of microRNA dose and duration of transfection was conducted in 
KC alone, and the protocol extrapolated to LECs. Optimisation should be 
conducted separately in LECs and further cell types in the future.  
Primary cells from at least two separate healthy donors were used for all 
subsequent experiments, with 3 replicates being used per experiment (tissue 
culture wells or tissue culture flasks). Data showed that miR-146b 
significantly suppressed ACKR2 mRNA expression in KC as compared to 
SHAMS 2016 
	187 
scrambled miR control (Figure 5.7a), with data being representative of two 
separate experiments. In contrast, miR-146b inhibitor (also known as 
antagomirs) did not influence ACKR2 expression.  This is suggestive of there 
being low levels of miR-146b expression in KC in non-inflamed contexts 
(Figure 5.7a)  
The above in silico analyses predicted that miR-146a and miR-146b both bind 
the ACKR2 3’-UTR with the same CT score (Figure 5.1). However, previous 
studies report different results for differential expression of miR-146a and b 
in psoriasis, which would suggest non-redundant roles (Sonkoly et al. 2007). 
Thus, in order to determine whether any apparent differences exist between 
miR-146a and miR-146b, the two were directly compared. Results showed 
that both miR-146a and miR-146b reduced ACKR2 mRNA expression in KC 
after 24 hours compared to scrambled miR control, with no significant 
differences between the two variants (Figure 5.7b). Thus, miR-146a and miR-
146b when transfected on their own, resulted in down-regulation of ACKR2 
transcript levels.  
Next, the other microRNAs identified above (miR-10b and miR-203) as well 
as specific miR inhibitors, were then tested for their ability to down-regulate 
ACKR2 in KC, both singly or in combination with each other and miR-146b 
(maximum concentration of any one species 10nM). Results were not 
statistically significant for either miR-10b or 203 or combinations in KCs, 
with the exception of a reduction in ACKR2 expression with miR-203 inhibitor 
(Figure 5.8b), and an increase with miR-146/203 in combination (Figure 
5.8f). Thus, although miR-146 on its own reduced ACKR2 transcript levels, 
when used in combination with the other two microRNAs, there was no 
change in ACKR2. It noteworthy that whilst miR-146b alone reduced ACKR2 
expression and miR-203 alone did not alter ACKR2 expression, together they 
cause a paradoxical increase in ACKR2 expression (Figure 5.8f). Complex 
interactions between microRNAs have been described in the literature 
(including synergisms and antagonism), but remain poorly understood and 
characterised (Vasudevan et al. 2007). It is possible that the miR-146/203 
effect represents such a synergistic effect, though this particular interaction 
remains uncharacterised, and is based on a relatively modest effect and 
limited data. 
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Next the selected microRNAs were transfected into primary healthy human 
LECs, singly and in combination (Figure 5.9). Only miR-10b significantly 
reduced ACKR2 mRNA expression in LECs (Figure 5.9a), with data being 
representative of two separate experiments. Additionally, transfection of 
miR-203 inhibitor was associated with a significant increase in ACKR2 
expression in vitro (Figure 5.9c), This would be in keeping with miR-203 
potentially playing a role in limiting ACKR2 expression in healthy (non-
inflamed) LECs.  
In conclusion, the inhibition of ACKR2 mRNA expression was most substantial 
with miR-146a/b in KC and miR-10b in LEC. For this reason, these two 
microRNAs were therefore selected for further study, as detailed below, in 
each respective cell type. 
 
 
5.5.4 A Dual-Glo™ Luciferase Assay was optimised to determine 
whether miR-10b/miR-146b modulate ACKR2 expression through 
directly binding the ACKR2 3’-UTR. 
MicroRNAs exert their effect on mRNA/gene expression principally through 
binding the 3’-UTR of their transcript target. Thus, a dual-glo luciferase 
assay was optimised, in order to determine whether the microRNAs that 
reduce ACKR2 expression in KC and LEC, interact directly with the 3’-UTR of 
ACKR2 transcript. The principles of this assay, which enables quantification 
of microRNA to 3’-UTR transcript binding, are schematically summarised in 
Figure 5.10. In brief, the 3’-UTR of ACKR2 was cloned and inserted into a 
reporter vector containing two luciferase genes (Figure 5.10).  The assay is 
based on the assumption that the presence of the ACKR2 3’-UTR downstream 
of the luciferase should enable quantification of miR interactions with the 
ACKR2 3’-UTR by assessing luciferase expression. To obtain this luciferase 
reading, cells were assayed for their ability to generate bioluminescence 
upon addition of Firefly luciferase bioluminescence substrate (and 
subsequently normalised to Renilla luciferase). 
Following insertion of the ACKR2 3’-UTR into the Dual-Glo plasmid, it was 
sequenced, to ensure the sequence was intact and putative microRNA 
binding sites were unaffected (Figure 5.11a-b). Two single nucleotide 
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insertions and one deletion were noted, but were not located near any 
predicted microRNA binding sites (Figure 5.11). It was deemed that these 
changes were unlikely to affect binding of the miRNA to its putative RNA 
target. The reporter vector was transfected into HEK293 cells. Stable 
transfectants were selected using neomycin and clonal populations isolated 
as single colonies isolated in the presence of G418 (Figure 5.12). Firstly, to 
determine that these new luciferase-expressing clones could be transfected 
with microRNAs and that this led to gene expression changes, the expression 
of IRAK1 was determined in stable HEK transfectants. This showed that miR-
146b downregulated IRAK1 in the stable transfectants (two different clones 
tested), thereby confirming that miR-146 could be successfully transfected 
into HEK cells (Figure 5.13).  
Next, experiments were designed to determine whether transfection with 
miR-146b and miR-10a could also decrease luciferase expression, and so 
demonstrate that they interact directly with the ACKR2 3’-UTR transcript 
(Figure 5.14). These data show that these miRNAs could bind to the 3’-UTR 
transcript of ACKR2, as a measurable and significant decrease in 
bioluminescence was observed in ACKR2 3’-UTR-containing HEK293 cells, 
using two different stable HEK293 transfected clones. Inhibition of this signal 
by the presence of ACKR2 3’-UTR in the plasmid following transfection of the 
miR suggest that these miR do bind to the ACKR2 3’-UTR, and that this 
binding can inhibit the expression of the upstream ACKR2 gene (Figure 5.14). 
Importantly, both miR-146 and miR-10 were able to reduce the luciferase 
expression driven from ACKR2 3’-UTR constructs.  
 
5.5.5 Cytoplasmic ACKR2 can be visualised in ACKR2 
transfected HEK293 cells through immunofluorescent antibody 
staining. 
Although ACKR2 scavenging entails ACKR2 cycling from the cell surface to 
the cytoplasm, the bulk of ACKR2 in cells at any given time is localised in the 
cytoplasm, specifically in recycling endosomes (Blackburn et al. 2004) Data 
above demonstrate that microRNA transfection (miR-146b in KC, and miR-
10b in LEC) reduce ACKR2 mRNA expression (Figure 5.7 and 5.9). In order to 
examine the effect of miR-146 and miR-10 on ACKR2 protein expression and 
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localisation in cells, published ACKR2 immunofluorescent staining protocols 
(Singh et al. 2012), were firstly optimised. HEK293 cells that had been 
previously generated to stably express ACKR2 were stained for ACKR2 and 
compared with transfected HEK293 cells (that do not express ACKR2) as 
negative controls. Confocal immunofluorescent images confirmed that ACKR2 
could be clearly visualised in the cytoplasm of HEK-ACKR2 cells (Figure 
5.15). In contrast, non-transfected HEK293 cells that were negative for 
ACKR2 when similarly stained, did not stain for ACKR2. A degree of green 
background staining throughout the cytoplasm was noted in ACKR2 deficient 
cells, but this staining was faint, and diffuse compared with ACKR2 
transfected HEK293 cells (Figure 5.15). 
 
5.5.6 miR-146b transfection of KC and miR-10b transfection of 
LEC reduce cytoplasmic ACKR2 expression.  
Next, in order to determine qualitative changes in ACKR2 subcellular 
localisation, a protocol was optimised to enable staining of ACKR2 in KC 
monolayers grown in polycarbonate chambers. KC were grown as confluent 
cell monolayers (Figure 5.16a), and fixed using methanol prior to 
immunofluorescent staining. There was a consistent degree of cytoplasmic 
staining even with isotype control antibodies, but again this staining was 
faint, evenly distributed throughout the cytoplasm, and non-punctate 
(Figure 5.16b). In order to determine the effect of miR-146b on ACKR2 
expression and localisation, confluent KC monolayers were transfected for 24 
hours. The cell medium was changed after 24 hours, but the KC incubated 
for a further 24 hours prior to fixing with methanol. This was due to the long 
half-life of ACKR2 protein; whilst a reduction in ACKR2 mRNA was observed 
after 8-24 hours of transfection (as previously presented), it was anticipated 
that a discernible reduction, or change in localisation, in cytoplasmic ACKR2 
protein would take longer to be evident. Bright green punctate cytoplasmic 
staining was observed in KC transfected with negative scrambled miR control 
(Figure 5.17a). The staining was more marked in the peri-nuclear region and 
often in an asymmetrical fashion, which would be in keeping with higher 
ACKR2 levels in the endoplasmic reticulum (Figure 5.17a). In future 
experiments, it would be useful to perform co-stains with markers of early 
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and late endosomal compartments. In contrast, where KC had been 
transfected with miR-146b, there was a loss of ACKR2 staining throughout 
the cytoplasm, although the peri-nuclear staining was still evident (Figure 
5.17b). These findings paralleled mRNA data presented above. 
To investigate the effect of miR-10b on LECs, LECs that had been grown as 
confluent cell monolayers were transfected for 24 hours (Figure 5.18a). As 
previously, cells were incubated for a further 24 hours after the medium was 
changed. Similar to KC, there was a degree of faint/hazy green staining with 
isotype antibody control staining (Figure 5.18b). In contrast, ACKR2 staining 
was more pronounced and more granular where LECs had been transfected 
with scrambled miR control (relatively high ACKR2) as compared to miR-10b 
(Figure 5.18c-d). Following transfection with miR-10b, cytoplasmic green 
fluorescence levels were more in keeping with the fluorescent levels seen 
with isotope antibody background staining (Figure 5.18b). Overall, the level 
of fluorescence was apparently lower than KC, which is likely a reflection of 
lower ACKR2 expression in LEC as compared to KCs. Since images were 
obtained using a confocal microscope, the fact that LECs are substantially 
flatter/thinner than KC when grown as monolayers should not have made a 
substantial difference on the degree of green staining. The granular staining 
in LEC was again more marked to one side of the peri-nuclear cytoplasm 
(akin to what was observed in KC), which became especially apparent at 
higher magnification (Figures 5.19a-b), especially when compared to miR-
10b transfected LECs (Figures 5.20a-b).  
Taken together, immunofluorescent staining of cultured cell monolayers did 
enable staining for ACKR2, that appeared granular and more pronounced in 
the peri-nuclear area in the cytoplasm in both KC and LEC. Furthermore, 
transfection with miR-146b in KC and miR-10b in LEC lead to an apparent 
reduction in ACKR2 staining in both cell types, at 48 hours. This suggests that 
the aforementioned microRNAs not only lead to a reduction in ACKR2 mRNA 
expression in these cells, but possibly also a reduction in ACKR2 protein. It 
would also have been useful to quantify these changes, and numerical data 
pooled from multiple experiments would have strengthened the argument. In 
future experiments, the Zeiss software could be used to quantify the 
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fluorescence associated with ACKR2, across different experiments, and at 
different sites along the slide.  
 
5.5.7 miR-146b transfection of KC and miR-10b transfection of 
LEC reduce ACKR2 protein expression by Western Blot. 
Previous studies have demonstrated successful ACKR2 detection using 
Western Blotting (Blackburn et al. 2004). Western Blots enable relatively 
easy quantification of protein expression (through band densitometry), but 
also yield useful information about the ACKR2 protein (Blackburn et al. 
2004).  Previous studies have shown that ACKR2 does not appear as one 
isolated band on Western blots (Blackburn et al. 2004). Instead, several 
bands appear, that have been attributed to different levels of e.g. 
glycosylation and multimerisation state (Blackburn et al. 2004). In order to 
gain a better understanding of the effect of microRNAs on ACKR2 expression, 
cells were again grown as confluent monolayers and transfected with 
microRNAs for 24 hours, then incubated for a further 24 hours. To ensure 
that ACKR2 could be successfully identified using Western Blotting, lysates 
from ACKR2 transfected HEK293, and ACKR2-deficient HEK293 were studied. 
This revealed two darker bands (at 55kDa and 38kDa) and a stack of 3 more 
faint bands at 41/45/49 kDa (Figure 5.21). This appearance is in keeping 
with previously published data (Blackburn et al. 2004). Based on the 
predicted size of ACKR2 and previous studies, it is likely that the band at 
49kDa represented the non-glycosylated form of ACKR2, and the darker band 
at 55kDa a glycosylated form, and smaller bands ACKR2 fragment(s).  
Subsequently, KC were transfected with miR-146b prior to lysis. Throughout 
the experiments, ACKR2 transfected HEK293 and untransfected HEK293 cells 
were used as positive and negative controls respectively, and run on the 
same gel as other samples. Blots demonstrated bands in KC that are broadly 
similar to those observed in the positive HEK293 control (Figure 5.22). The 
main band at 49kDa appeared more faint where the KC has been transfected 
with miR-146b, which is keeping with both QPCR and the 
immunohistochemistry data. Though other bands appear more faint in miR-
146b treated KC, the difference appeared more marked for the 49kDa band, 
which suggested that miR-146b induced ACKR2 reduction does not affect all 
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protein forms of ACKR2 equally. The functional significance of this however 
remains to be determined. Additionally, bands appear at approximately 
100kDa (in contrast to HEK293 transfectants), and as previous studies 
suggest, these could represent dimerised or glycosylated variants of ACKR2.  
Using ImageJ, the density of the bands were quantified, and normalised to 
the beta-tubulin loading control (Figure 5.23). Given the multiple bands that 
likely represented ACKR2, choosing one single band is challenging and might 
yield misleading results. To reduce the risk of this, analysis was conducted in 
two alternative ways; 1) densitometry of all bands likely to represent ACKR2 
in KC (Figure 5.23a, bands marked in black), and 2) densitometry of the 
bands most likely to represent ACKR2 at 40-50kDa and also the dimerised 
form (Figure 5.23a, bands marked in red). Either approach yields a 
comparable reduction of band density (adjusted to the loading control) of 
approximately 20% (Figure 5.23b). It is acknowledged that quantification of 
less than three blots limits the conclusions that can be drawn, and in future 
experiments, it would be helpful to quantify change in band density in three 
or more blots, in order to yield more robust and reproducible results. 
Next, LECs were transfected with miR-10b. As the amount of ACKR2 was 
anticipated to be less than KC, in addition to miR-10b/scrambled miR control 
treated LECs, LECs were included that had been treated with IFNγ (for 24h 
during the time of miR transfection, and then incubated for a further 24 
hours), in order to upregulate ACKR2 expression. As in KCs, bands were 
generally more faint in miR-10b transfected LECs, which suggested that 
protein expression levels were reduced (Figure 5.24), although further 
repeat experiments are needed before drawing firm conclusions. 
Furthermore, the bands were more marked in IFNγ treated LECs, which 
suggested that ACKR2 protein expression was successfully induced in these 
cells (Figure 5.25). The differences between the different treatments were 
more apparent in the 49kDa band, and in the 38kDa band in LECs. This would 
be in keeping with KCs and LECs expressing ACKR2 with distinct 
glycosylation/fragmentation patterns. 
As in KC, adjusted densitometry was employed, using two different 
methodologies akin to those used for KC above; 1) densitometry of all bands 
likely to represent ACKR2 in LEC (Figure 5.26a, bands marked in black), and 
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2) densitometry of the bands most likely to represent ACKR2 at 40-50kDa and 
also the dimerised form (Figure 5.26a, bands marked in red). Either method 
of quantification was associated with a reduction of band density adjusted 
for loading control, of approximately 20-25% (Figure 5.26), but further 
repeat experiments are required in order to draw more certain conclusions 
about the effect of microRNA transfection on the quantity of ACKR2 protein, 
notably in the context of relatively small changes in apparent band density.   
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Figure 5.1 TargetScan in silico predictions of microRNAs potentially 
binding the ACKR2 3’-UTR 
Table of microRNAs that are broadly conserved amongst vertebrates that are 
predicted (in descending order of likelihood, less negative Total Context 
Score) to bind the human ACKR2 3’-UTR. 
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Figure 5.2 Summary of microRNAs predicted to bind the ACKR2 3’-UTR 
with associated microRNA specific data from previous psoriasis 
publications  
The 10 microRNAs most likely to target ACKR2 included in the diagram, with 
relevant findings in two papers given in the right hand column; miR-10, miR-
146 and miR-203 were all differentially regulated in psoriasis (previous array 
data). 
 
  
 
miR 
(broadly conserved  
among vertebrates) 
Total  
Context 
Score 
 
regulation in psoriasis 
miR-10abc/10a-5p 
 
-0.57 miR-10b 1.32-fold up-regulated in PN1 
miR-10a 0.67-fold down-regulated in 
PP2 
miR-490-3p 
 
-0.29 n/a 
 
 
miR-146ac/146b-5p 
 
-0.26 miR-146a 3.10-fold upregulated in PP, 
miR-146b-59 up-regulated 2.73-fold[Q] 
miR-146a 3.30-fold up-regulated in PP2 
miR-146b up-regulated 3.31-fold in PP2 
miR-203 
 
-0.19 2.02-fold up-regulated in PP1 
5.86-fold up-regulated in PP2 
 
miR-210 
 
-0.15 n/a 
 
 
miR-24/24ab/24-3p 
 
-0.15 1.51-fold and 1.41 up-regulated in PP 
and PN respectively1 
 
miR-122/122a/1352 
 
-0.13 n/a 
 
 
miR-103a/107/107ab 
 
-0.13 1.04-fold up-regulated in PP1 
 
 
miR-145 
 
-0.10 n/a 
 
 
miR-375 
 
-0.09 n/a 
 
 
PP – psoriatic lesion (plaque) PN – normal (clinically unaffected) psoriatic skin 
 
1 Zibert J.R. et al. MicroRNAs and potential target interaction sin psoriasis. J Dermatol Sci 58(3), (2010) 
2 Sonkoly E. et al. MicroRNAs: novel regulators invovled in the pathogeneis of psoriasis? Plos 
One 2(7), e610 (2007) 
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Figure 5.3 Three microRNAs (miR-10, miR-146 and miR-203) are 
predicted to bind the ACKR2 3’-UTR and are differentially expressed in 
psoriasis.  
Diagrammatic representation of microRNAs that are predicted to bind the 
ACKR2 3’-UTR in silico, and that have ben shown to be differentially 
expressed in psoriasis in array studies. 
 
 
  
miR-10 
miR-146 
miR-203 
16 miRs (broadly 
conserved in 
vertebrates)  
predicted to bind 
to the ACKR2 
3’-UTR. 
(TargetScan v6.2) 
47 miR 
differentially 
expressed in PP 
versus NN (Zibert 
et al. J Derm Sci 
2010) 
 
29 miR 
differentially 
expressed in PP 
versus NN 
(Sonkoly et al. J 
PLOS One 2007) 
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Figure 5.4 MicroRNAs can be successfully transfected into primary human 
keratinocytes. 
Absolute quantification of IRAK/TRAF6 mRNA (previously validated miR146b 
targets) in primary healthy human keratinocytes that are  
(a) unstimulated 
(b) stimulated with 100ng/ml of human recombinant IFNγ prior to 
transfection 
Keratinocytes were transfected for 24 hours prior to lysis and RNA 
extraction. All microRNAs transfected at 10nM. Significance was assessed 
using Student's t-test. * P<0.05, ** P<0.01, *** P<0.005, **** P<0.0001. 
Each validation experiment performed once. 
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Figure 5.5 MicroRNAs can be successfully transfected into primary human 
keratinocytes at 8, 24 and 48-hour time points.  
Absolute quantification of;  
(a) IRAK1 and;  
(b) TRAF 6 (both previously validated miR146b targets) in primary healthy 
human keratinocytes 
Keratinocytes were transfected for 24-48 hours, prior to lysis and RNA 
extraction. All microRNAs at 10nM. Significance was assessed using 
Student's t-test. * P<0.05, ** P<0.01, *** P<0.005, **** P<0.0001. Each 
time point performed once. 
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Figure 5.6 miR-146b transfection of primary human keratinocytes for 24-
48 hours leads to reduction in ACKR2 mRNA, relative to control miR. 
Absolute quantification of gene expression in primary human keratinocytes 
following transfection with miR-146b for 8, 24 or 48 hours prior to RNA 
extraction and QPCR for ACKR2. 
Keratinocytes were transfected for 24-48 hours, prior to lysis and RNA 
extraction. microRNAs at 10nM, control is scrambled microRNA. Significance 
was assessed using Student's t-test * P<0.05, ** P<0.01. 8h and 48h time 
points performed once, 24h time point performed three times. 
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Figure 5.7 miR-146a as well as miR-146b transfection of primary human 
keratinocytes for 24 hours leads to reduction in ACKR2 mRNA.  
Absolute quantification of;  
(a) ACKR2 following transfection of KC with miR-146b or miR-146b inhibitor. 
Representative of three experiments. 
(b) ACKR2 following transfection of KC with miR-146a and miR-146b 
Keratinocytes were transfected for 24 hours, prior to lysis and RNA 
extraction. Data from (a) and (b) are from different experiments and cell 
donors. All microRNAs at 10nM. Significance was assessed by one-way 
ANOVA. * P<0.05, ** P<0.01. Comparison performed once. 
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Figure 5.8 miR-10 and miR-203 do not differentially regulate ACKR2 
expression in keratinocytes. 
Absolute quantification of ACKR2 in primary human keratinocytes following 
transfection of primary human keratinocytes with various microRNAs (singly 
and in combination) for 24 hours. All microRNAs transfected at 10nM, unless 
otherwise stated. Significance was assessed using one-way ANOVA with 
Tukey’s post-test. * P<0.05. Experiment performed once. 
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Figure 5.9 miR-10b reduces ACKR2 mRNA expression in lymphatic 
endothelial cells. 
Absolute quantification of ACKR2 in primary human LECs following 
transfection with various microRNAs (singly and in combination) for 24 hours. 
All at 10nM. Significance was assessed using one-way ANOVA with Tukey’s 
post-test. * P<0.05. Data representative of one experiment (except miR-10b, 
performed twice) 
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Figure 5.10 Schematic representation of Dual-Glo™ Luciferase reporter 
assay. 
(Undertaken with the assistance of Dr F. Schütte). THe 3’-UTR of ACKR2 was cloned 
and inserted into a reporter vector containing two luciferase genes.  This assay is 
works on the principle that the presence of the ACKR2 3’-UTR downstream of the 
luciferase enables quantification of miR interactions with the ACKR2 3’-UTR by 
assessing luciferase expression. To obtain this luciferase reading, cells are assayed 
for their ability to generate bioluminescence upon addition of Firefly luciferase 
bioluminescence substrate and normalised to Renilla luciferase. Note D6 is 
synonymous with ACKR2. 
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Figure 5.11 Schematic representation of Dual-Glo™ Luciferase reporter 
vector showing results of sequencing of the ACKR2 3’-UTR. 
Insertion/deletion and predicted microRNA binding sites highlighted. 
Sequencing performed once. Note D6 is synonymous with ACKR2. 
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Figure 5.12 Representative images of stable transfected HEK293 clones. 
Stable HEK293 transfectants, expressing luciferase plasmid constructs, were 
selected using neomycin and clonal populations cultured from single colonies 
isolated in the presence of G418. Three different clones were grown.  
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Figure 5.13 miR-146b can be successfully transfected into HEK293 cells 
Absolute quantification of IRAK1 mRNA as assessed by QPCR in HEK293 cells 
following transfection of two different stable HEK293 populations (named 
‘1C’ and ‘1P’) with miR-146b (purple bars) as compared to scrambled control 
(blue bars). Experiment performed once per HEK293 population. 
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Figure 5.14 miR-146b and miR-10b bind directly to the ACKR2 3’-UTR. 
Results from Dual-Glo™ luciferase reporter assay, measuring bioluminescence 
following addition of substrate for Firefly luciferase (bioluminescence 
inversely proportional to microRNA 3’-UTR binding) normalised to Renilla 
luciferase. Results are from two different stable transfected HEK293 
populations (‘1C’ and ‘1P’) following transfection of HEK293 cells with miR-
10b and miR-146b (singly and combination) and scrambled miR control. 
Statistics: one-way ANOVA, results mean±SEM. Assay performed twice. 
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Figure 5.15 ACKR2 in ACKR2 transfected HEK293 can be visualised 
through fluorescent antibody staining. 
Representative immunofluorescence in ACKR2 transfected HEK293 cells (high 
ACKR2) and HEK 293 cells (no ACKR2) grown as confluent monolayers. 
Experiment performed once, two wells per stain.  
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Figure 5.16 Isotype control antibody staining of primary human 
keratinocyte monolayers. 
(a) Representative bright-field image of KC grown as confluent monolayer 
(b) Representative immunofluorescence of KC grown as confluent 
monolayers, stained with isotype control antibody. Experiment 
performed once, two wells per stain. 
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Figure 5.17 Reduced cytoplasmic ACKR2 following miR-146b transfection 
of KC, as visualised by immunofluorescent antibody staining. 
Representative immunofluorescence microscopy images of confluent 
monolayers of keratinocytes 48 hours after transfection with; 
(a) scrambled miR control 
(b) miR-146b.  
Results representative of two comparable experiments, four wells per 
stain/treatment.  
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Figure 5.18 Reduced cytoplasmic ACKR2 levels following miR-10b 
transfection of LEC, as visualised through immunofluorescent antibody 
staining. 
(a) Representative bright-field image of LEC grown as a confluent monolayer 
Representative immunofluorescence microscopy images of confluent 
monolayers of LECs 48 hours after transfection with; 
(b) scrambled miR control, isotype antibody stain  
(c) scrambled miR control, stained for ACKR2 
(d) miR-10b, stained for ACKR2 
Results representative of two comparable experiments, four wells per 
stain/treatment. 
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Figure 5.19 Cytoplasmic ACKR2 following scrambled miR control 
transfection of LEC, as visualised by immunofluorescent antibody 
staining. 
(a) Representative image of LEC grown as confluent monolayer, stained for 
ACKR2. 
(b) Enlarged part of above image, illustrating punctate ACKR2 staining 
(arrows). 
Results representative of two comparable experiments, four wells per 
stain/treatment. 
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Figure 5.20 Reduced cytoplasmic ACKR2 following miR-10b transfection 
of LEC, as visualised through immunofluorescent antibody staining. 
(a) Representative image of LEC grown as confluent monolayer, transfected 
with miR-10 and stained for ACKR2. 
(b) Enlarged part of above image, illustrating relative absence of granular 
ACKR2 staining. 
Results representative of two comparable experiments, four wells per 
stain/treatment. 
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Figure 5.21 ACKR2 protein bands can be visualised using Western 
blotting. 
ACKR2 antibody stain of Western blot, with protein lysate from HEK293 (no 
ACKR2, left lane) and ACKR2 transfected HEK293 cells (high ACKR2). Equal 
loading was assessed by Ponceau-S staining, and staining for β-tubulin. Data 
representative of 3 comparable experiments. 
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Figure 5.22 Reduced ACKR2 protein following transfection of KC with 
miR-146b. 
Western blots of ACKR2 expression in KC 48h after transfection with 
scrambled control miR or miR-146b, compared to β-tubulin (control). ACKR2 
controls and transfected samples were run on the same gel – difference in 
exposure is due to coverage of HEK293 lanes with extra film to avoid over-
exposure. 
(a) Staining for ACKR2 
(b) Staining for β-tubulin as loading control 
(c) ACKR2 staining for HEK293 lanes, with different exposure to better 
illustrate ACKR2-associated bands. 
Data representative of two comparable experiments 
Same HEK ACKR2 lane as 
above with different exposure 
to better delineate bands 
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Figure 5.23 Reduced ACKR2 protein following transfection of KC with 
miR-146b as quantified through band densitometry. 
Western blots quantified through band densitometry, with ACKR2 normalised 
to β-tubulin band intensity, using two approaches illustrated in  
(a) densitometry of all bands within black bracket, and bands most likely to 
represent ACKR2 within red brackets 
(b) densitometry of Western blots of KC treated with either miR-146 or 
scrambled control miR 
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Figure 5.24 Reduced ACKR2 protein following transfection of LEC with 
miR-10b. 
Western blots of ACKR2 expression in LEC 48h after transfection with 
scrambled control miR or miR-10b, compared to β-tubulin (loading control). 
HEK293 ACKR2 positive and negative controls and transfected LEC samples 
were run on the same gel.  
Data representative of two comparable experiments 
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Figure 5.25 Reduced ACKR2 protein following transfection of LEC with 
miR-10b, and increased ACKR2 protein following treatment with IFNγ. 
Western blots of ACKR2 expression in LEC 48h after transfection with 
scrambled control miR or miR-10b, compared to β-tubulin (control). LEC 
treated with 100ng/ml IFNγ, to upregulate ACKR2, were used as a positive 
control.  
Data representative of two comparable experiments (interferon treatment 
performed once) 
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Figure 5.26 Reduced ACKR2 protein following transfection of LEC with 
miR-10b as quantified through band densitometry. 
Western blots quantified through band densitometry, with ACKR2 normalised 
to β-tubulin band intensity, using two approaches illustrated in  
(a) densitometry of all bands within black bracket, and bands most likely to 
represent ACKR2 within red brackets 
(b) densitometry of Western blots of LEC treated with either miR-10b or 
scrambled control miR, and LECs treated with IFNγ in order to 
upregulate ACKR2. All bands (equivalent of bands marked in red brackets 
above) used for densitometry of these samples. 
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Supplementary Figure 5.1 Summary of miRNA biosynthesis 
Compiled with information from; (Carthew & Sontheimer 2009; Kim et al. 
2009). Pre-microRNA is synthesised in the nucleus with Exportin 5 facilitating 
its entry into the nucleus. There, cleavage of the pre-microRNA yields a 
microRNA duplex, after which the mature miRNA strand complexes with 
effector proteins (to form a so called RNA-induced silencing complex, RISC), 
whilst the complementary miRNA is degraded, miRNA, as part of the RISC 
will then interact with its mRNA target, leading eventually to mRNA 
degradation.  
SHAMS 2016 
	222 
5.6 Summary Chapter 5 
This chapter reports for the first time, the identification of microRNAs that 
bind directly to the ACKR2 3’-UTR and reduce expression of ACKR2 in 
primary human keratinocytes (KC) and lymphatic endothelial cells (LEC). 
Specifically, miR-146b downregulates ACKR2 in KC, and miR-10b 
downregulates ACKR2 in LEC, and are shown to bind directly to the ACKR2 
3’-UTR. 
Several cytokines are known to differentially regulate ACKR2 expression in 
vitro, and previous chapters in this thesis demonstrate a role for IFNγ in the 
upregulation of ACKR2 in vivo. However, the molecular mechanisms by which 
ACKR2 expression is regulated have not been determined. MicroRNAs are 
small RNA fragments that regulate gene expression at a post-transcriptional 
level, and have emerged as the most abundant class of gene regulators 
(Pasquinelli 2012). Previous array data demonstrated that a large number of 
microRNAs are differentially expressed in psoriasis (Sonkoly et al. 2007), but 
relatively little has been known about their potential roles in psoriasiform 
inflammation.  
Bioinformatic databases exist that enable in silico predictions of which 
microRNAs may bind specific mRNA 3’-UTRs (Ekimler & Sahin 2014). Through 
the use of the database TargetScan, this thesis identified several microRNAs 
that were predicted to bind the ACKR2 3’-UTR in silico. Three of these were 
also differentially expressed in psoriasis in previously published array 
studies; miR-10, miR-146 and miR-203 (Sonkoly et al. 2007; Zibert et al. 
2010). These microRNAs were selected for further study as possible negative 
regulators of ACKR2 expression. A protocol was subsequently developed in 
KC that would enable the successful transfection of primary human cells 
with microRNAs. Using previously validated miR-146 targets (IRAK1/TRAF6) 
successful transfection was confirmed using the developed protocol. KC and 
LEC were transfected with all three microRNAs, both singly and in 
combination, and data showed that miR-146a/b and miR-10b significantly 
downregulated ACKR2 mRNA expression in KC and LEC respectively; for this 
reason subsequent experiments were performed with miR-146 in KC and miR-
10 in LEC. It is noteworthy that miR-10b has been shown to be upregulated 
in unaffected psoriatic skin (where ACKR2 expression is relatively high); it is 
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possible that ACKR2 expression would be yet higher without such 
upregulation, but further studies are required to determine the role of miR-
10 in vivo. ACKR2 transcript was reduced by approximately one third in each 
cell type, which is in keeping with previous data of miR-induced mRNA 
repression (Bartel 2004; Bartel 2009). It is acknowledged that the absolute 
change in ACKR2 mRNA copy number is small, and the current experiments 
did not assess the biological significance of this change. Future work will 
need to determine whether the observed reduction in ACKR2 expression in 
KC and LEC does indeed translate into a difference in 1) ACKR2 ligand 
scavenging and 2) subsequent cell infiltration and inflammation. 
Furthermore, it is likely that there exists heterogeneity in KC responses to 
microRNA transfection, and for this reason, using a larger number of donors 
in the future would yield more robust results, and would enable the degree 
of heterogeneity to be determined. 
Next, in order to confirm that the observed mRNA reduction was due to miR-
146b/miR-10b binding directly to the ACKR2 3’-UTR, a dual-glo Luciferase 
assay was utilised. In brief, the ACKR2 3’-UTR was cloned into a dual-
luciferase reporter vector, and stable HEK293 transfectants generated. 
HEK293 transfectants were subsequently transfected with microRNAs, and 
any reduction in bioluminescence upon addition of the substrate for Firefly 
luciferase would be indirectly proportional to direct microRNA binding of the 
ACKR2 3’UTR. Renilla luciferase bioluminescence was subsequently used for 
normalisation in the same experiments. Results confirmed that both miR-10b 
and miR-146b bind directly to the ACKR2 3’-UTR, which would be in keeping 
with the mRNA reduction previously demonstrated being due to a direct 
effect of microRNA binding to the ACKR2 3’-UTR. 
Subsequently, the effect of microRNA on ACKR2 protein expression was 
determined by means of immunofluorescent microscopy. Primary human KC 
and LEC were transfected with miR-146b/miR-10b respectively as well as 
scrambled miR as control. In healthy KC transfected with miR control 
punctate ACKR2 staining was evident throughout the cytoplasm. This was in 
keeping with previous studies, that demonstrated that most ACKR2 protein 
(90%) is found in the cytoplasm (Blackburn et al. 2004). Transfection of the 
cells with miR-146b and miR-10b in KC and LEC respectively confirmed that 
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the microRNAs reduced ACKR2 expression in the cells, as suggested by the 
reduction in cytoplasmic ACKR2 staining 48 hours post transfection. These 
results were largely qualitative, and future repeat studies would be required 
in order to quantify the findings.  
In order to quantify the reduction in ACKR2 protein, KC and LECs were again 
transfected with microRNAs, but this time the protein expression was 
assessed by Western blotting. In keeping with previously published studies, 
ACKR2 appeared not as a single band on Western Blotting, but as several 
bands, likely representing different states of glycosylation and dimerisation. 
Reduction in band density was assessed through densitometric analysis 
(adjusted to the β–tubulin loading control). Transfection of miR-146b in KC 
and miR-10b in LEC was associated with a reduction of approximately 20% in 
Western Blot band intensity 48h post transfection, which is broadly in 
keeping with the degree of mRNA reduction observed with QPCR in this 
thesis. One limitation of the above experiments is that there was no 
assessment of the functional effect of the reduction in ACKR2 mRNA and 
protein. As ACKR2 has a high capacity for chemokine scavenging through re-
cycling (Galliera, Galliera, et al. 2004), it could be that compensatory 
mechanism will come into play, enabling more rapid cycling, thus 
overcoming the reduction in ACKR2 protein in the cytoplasm. It is 
acknowledged that the effect of microRNA transfection on ACKR2 expression 
in KC and LEC appears relatively modest, as assessed by Q-PCR, 
immunofluorescent microscopy and Western Blots. It is unclear whether the 
observed differences are fully reproducible, and whether they translate into 
a biologically meaningful change in ACKR2 function, and further experiments 
will need to assess in detail the effect that microRNAs have on chemokine 
scavenging and overall inflammation. A further limitation of the above 
experiments, is that microRNA transfection possibly delivers 
supraphysiological levels of microRNAs. Thus, whilst the data demonstrate 
that the microRNAs bind the ACKR2 3’-UTR and reduce ACKR2 mRNA 
expression in vitro, the role of these microRNAs in vivo cannot be 
determined through these experiments alone. 
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6 Tensile stretching of inflamed KC and LEC 
differentially regulates expression of ACKR2. 
 
 
6.1 Contents 
6.2 Hypothesis 
6.3 Aims  
6.4 Introduction 
6.4.1 An in vitro model of repeated tensile trauma of primary human 
keratinocytes. 
6.4.2 Tensile trauma of inflamed KC led to a rapid reduction in ACKR2 
mRNA expression. 
6.4.3 Tensile trauma of inflamed KC led to a significant increase in miR-
146a and miR-146b expression. 
6.4.4 Tensile trauma of LEC did not affect ACKR2 expression. 
6.4.5 Incisional trauma of remote unaffected skin of mice in the IMQ 
mouse model of psoriasiform inflammation led to a downregulation 
of ACKR2. 
6.6 Summary Chapter 6 
 
6.2 Hypothesis 
• Tensile trauma of skin cells downregulates ACKR2 expression 
 
6.3 Aims 
The aims of this chapter were to; 
• Develop a model whereby the effect of tensile stress on primary human 
skin cells that express ACKR2 could be assessed 
• Assess the effect of tensile stress on primary human cells 
• Determine whether expression of ACKR2 interacting miRs correlate with 
tensile trauma 
 
6.4 Introduction 
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As previously discussed, published data have demonstrated that ACKR2 
expression is relatively deficient in psoriatic plaques (Singh et al. 2012). 
Additionally, it has previously been shown by us that tape stripping of 
clinically unaffected skin in patients with psoriasis leads to a rapid reduction 
of ACKR2 transcript expression in the skin (Singh et al. 2012). This finding is 
of particular relevance, as it might provide a possible mechanism for a 
phenomenon described in psoriasis called ‘koebnerisation’. Koebnerisation is 
well-documented in psoriasis, and is a process by which simple trauma to 
unaffected skin of those with psoriasis, can trigger the development of 
psoriatic plaques at the site of trauma (Weiss et al. 2002; Camargo et al. 
2013). Several forms of trauma can lead to koebnerisation, including surgical 
incisions, as well as uni- and bi-axial skin stretching (Alolabi et al. 2011) 
(Verma 2009) (Reid Vender & Ronald Vender 2015). In many patients, 
psoriatic lesions tend to develop at those cutaneous sites that most regularly 
receive minor trauma, such as the elbows. This, coupled with our previous 
observations that; 1) in the absence of ACKR2, cutaneous inflammation is 
exaggerated and 2) tape stripping leads to a rapid downregulation of ACKR2 
in human skin, led to the hypothesis that trauma-induced downregulation of 
ACKR2 could be one trigger that precipitates the development of an 
inflammatory cutaneous lesion in psoriatic patients. The mechanism(s) by 
which this trauma-induced downregulation occurs, might provide insights 
into the molecular mechanism by which ACKR2 downregulation occurs in 
plaques. 
 
6.4.1 An in vitro model of repeated tensile trauma of primary 
human keratinocytes. 
Tape stripping of clinically unaffected human skin of patients with psoriasis 
leads to a rapid downregulation of ACKR2. However, the effect of tape 
stripping on healthy skin is two-fold; 1) it causes removal of the stratum 
corneum and damages the barrier function of skin and 2) It induces mild 
trauma of the skin. Due to report of stretching triggering koebnerisation 
(Verma 2009) (Reid Vender & Ronald Vender 2015), and as psoriasis has a 
particular predilection for sites that undergo repeated stretching in daily life 
(e.g. knees, elbows, skin folds, see Figure 1.4), emphasis was initially placed 
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on the effect of tensile trauma on the expression of ACKR2 in skin cells. In 
order to specifically determine the effect of tensile cell trauma on ACKR2 
expression, a reductionist in vitro model was developed that would enable 
the effect of repeated tensile trauma on ACKR2 expression in primary human 
cells to be studied. The model developed was based on the FlexCell™ 
International FX5000 machine, whereby primary human cells are grown on 
silicone membranes in a 6-well format. The membrane can subsequently be 
subjected to repeated bi-axial cyclical tension in vitro, with pre-determined 
degree of tension, stretch wave-form, and cycle number (this model is 
summarised in Figures 6.1 and 6.2).  
Experimental data presented in previous chapters demonstrated that KC and 
LEC can be successfully grown as confluent monolayers on uncoated 
polycarbonate plastic, as per the cell provider’s instructions (PromoCell 
GmbH, Heidelberg, Germany). However, it was noted during the 
optimisation steps in this chapter that neither KC nor LEC adhered to 
uncoated silicon membranes (images of LECs grown on different substrates in 
Figure 6.3, demonstrating that LECs form confluent monolayers on 
polycarbonate and fibronectin coated silicone, but fail to adhere on silicone 
even when coated with attachment factor). KC and LEC required Collagen 1 
and Fibronectin coated silicone respectively, in order to adhere (and 
critically, remained fully adherent after 12h of cyclical stretching). In order 
to ensure that growth on these alternative substrates had no unexpected 
effects on ACKR2 expression, KC and LECs were grown on Collagen 1 and 
Fibronectin respectively, and baseline ACKR2 expression determined by 
QPCR. Data showed that there was a modest but significant increase in KC 
ACKR2 expression (Figure 6.4a), and a decrease in LEC ACKR2 expression 
where cells were grown on coated silicon as compared to uncoated 
polycarbonate tissue culture plates (Figure 6.4b).  
 
6.4.2 Tensile trauma of inflamed KC leads to a rapid reduction 
in ACKR2 mRNA expression. 
In order to examine the effect of tensile trauma on KC, confluent KC 
monolayers grown on Collagen I coated silicon were subjected to stretching 
for 12h during which the membrane was stretched by 15% every 0.8 seconds 
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(0.8Hz) (Figure 6.2). Cells were rested for a further 12h (broadly similar to 
the time point used in tape stripping experiments in humans (Singh et al. 
2012)) before lysis and RNA extraction. QPCR data showed no difference in 
ACKR2 expression between healthy primary human KC stretched for this 
duration of time, and non-stretched control KC (Figure 6.5a).  
It should be noted that these primary human cells are derived from healthy 
donors and are grown in the absence of typical psoriasis-associated factors. 
Psoriasis patients have elevated T-cell cytokines including IFNγ that 
correlates with elevated ACKR2 in unaffected skin. To better model human 
psoriasis where KCs exist in the context of systemic inflammation, KCs were 
treated with either tissue culture supernatant from activated human T-cells 
or recombinant IFNγ and then exposed to tensile stress for 12h at 0.8Hz. In 
contrast to non-inflamed KC (Figure 6.5a), tensile trauma of T-cell 
supernatant pre-treated KC led to a significant decrease in ACKR2 expression 
(Figures 6.5b). This was also the case for IFNγ pre-treated KC, suggesting 
that KC with elevated ACKR2 display tensile stress induced downregulation 
of expression.  
In order to determine whether the observed effect was due to IFNγ in the T-
cell supernatant, T-cell supernatant was incubated with anti-IFNγ antibodies 
prior to being used to stimulate KC. However, treatment of the T-cell 
supernatant with IFNγ neutralising antibodies did not diminish this effect, 
suggesting that soluble T-cell products in addition to IFNγ can mediate 
ACKR2 upregulation (Figure 6.5b). It remains to be determined what the 
factors are, beyond IFNγ that upregulate ACKR2, and enable ACKR2 
downregulation upon application of tensile stress. This can be achieved e.g. 
through testing of specific T-cell cytokines, or systematic neutralisation of 
likely cytokine mediators in active T-cell supernatant. 
 
6.4.3 Tensile trauma of inflamed KC led to a significant 
increase in miR-146a and miR-146b expression. 
In this thesis (Chapter 4), it has previously been shown that miR-146a/b bind 
directly to the ACKR2 3’-UTR and downregulate ACKR2 mRNA expression.  
miR-146 is also upregulated in psoriatic lesions according to previous studies 
(Sonkoly et al. 2007; Zibert et al. 2010).  In order to determine whether 
SHAMS 2016 
	230 
there was a possible link between these observations, miR-146a/b expression 
levels were quantified by QPCR in inflamed KCs, and were expressed as fold-
change relative to non-inflamed healthy KC controls. Where inflamed KC 
were subjected to tensile trauma, there was an over 100-fold induction of 
miR-146a and a lesser (albeit still substantial and significant) induction of 
miR-146b (Figure 6, black bars), relative to static KC (Figure 6.6, grey bars). 
Given the demonstrated effect that these microRNAs have on ACKR2 
expression, it is thus possible that the reduction of ACKR2 expression in 
inflamed KC that follows tensile trauma is mediated, at least in part, 
through upregulation of miR-146a/b. These experiments did not however 
assess whether the observed association between elevated miR-146/ACKR2 is 
causative, and future studies will need to repeat these experiments in the 
presence of anti-miR-146 in order to determine its role in the 
downregulation of ACKR2 in inflamed KC upon flexing. 
 
6.4.4 Tensile trauma of LEC did not affect ACKR2 expression. 
As shown above, flexing of KC pre-treated with both IFNγ and tissue culture 
supernatant from activated human T-cells was associated with a reduction in 
the expression of ACKR2. However, flexing did not affect ACKR2 expression 
in KC where ACKR2 expression had not been induced in this manner. Thus, it 
was appropriate to similarly induce ACKR2 expression in LEC prior to tensile 
trauma. Therefore, in order to study the effect of flexing on LEC, first the 
response of KC and LEC to key psoriasis associated cytokines was compared 
(Figures 6.7a-b). The data revealed that, in keeping with previously 
published data, LECs express higher amounts of ACKR2 mRNA compared to 
KC at rest, and that KC and LEC differ in their responsiveness to key pro-
inflammatory cytokines (Figures 6.7a-b). Specifically, the response of LEC to 
IFNγ is more modest (albeit still significant, Figure 6.7b), with the strongest 
single cytokine inducer of ACKR2 expression in LEC amongst the cytokines 
tested being IL-6 (Figure 6.7b). Future experiments will however need to 
include the Th17 cytokine IL-17 as a key psoriasis-associated cytokine, which 
was not included in these experiments. Next the response of LEC to tissue 
culture supernatant from activated human T-cells was assessed (Figure 
6.7c). Supernatant from non-activated T-cells had no effect on ACKR2 
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expression in LEC, but active T-cell supernatant significantly upregulated 
expression of ACKR2 (Figure 6.7c). 
Next, having demonstrated that both IFNγ and T-cell supernatant 
upregulated ACKR2 in LECs, experiments were designed to assess the effect 
of flexing on LECs, that were untreated, or pre-treated with IFNγ (Figure 
6.8a) and activated T-cell supernatant (Figure 8b), prior to flexing for 12h at 
0.8Hz. Data showed that there was no effect on ACKR2 expression in LECs 
from flexing in LECs that were untreated, IFNγ stimulated or stimulated with 
T-cell supernatant (Figures 6.8a-b). Thus, the response of inflamed KC and 
LEC to tensile stress appears to be different, even where cells have been 
similarly pre-treated. This is in keeping with the results in previous chapters 
in this thesis, in which the major pathological finding exhibited by ACKR2-
deficient mouse skin is the aberrant positioning of inflammatory T-cells in 
the epidermis.  
 
6.4.5 Incisional trauma of remote unaffected skin of mice in 
the IMQ mouse model of psoriasiform inflammation led to a 
downregulation of ACKR2. 
Previous chapters demonstrated that human psoriatic expression patterns of 
ACKR2 could be successfully replicated in a modified form of the IMQ mouse 
model of psoriasiform inflammation. Specifically, application of IMQ to flank 
skin on one side plus systemically administered IFNγ together caused an 
upregulation of ACKR2 in remote unaffected skin. As discussed above, 
previously published data also showed that tape stripping of unaffected 
human psoriatic skin (where ACKR2 expression is high) led to a rapid 
reduction in ACKR2 transcript levels (Singh et al. 2012).  
As described above, in vitro stretching of inflamed KCs led to a 
downregulation of ACKR2. Thus, in order to examine whether cutaneous 
trauma to psoriatic mouse skin could similarly lead to ACKR2 
downregulation, mice were treated with IMQ to one flank plus systemic IFNγ 
in order to upregulate remote ACKR2 (the experimental protocol is 
schematically represented in Figure 6.9a) and the effect of trauma on ACKR2 
expression determined.  To do this a second site on the contralateral flank 
was then subjected to superficial incisional trauma (just down to the dermis) 
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using a sterile surgical blade, and the expression of ACKR2 determined by 
means of QPCR. Data showed that incisional trauma in vivo led to a rapid 
(within 24h) reduction of ACKR2 expression. These results parallel the results 
observed upon tape stripping in patients with psoriasis. Thus, data suggest 
that trauma induced modulation of ACKR2 can in principle be successfully 
modelled in mice, which if developed further would enable the further study 
of the mechanisms that underpin trauma induced differential ACKR2 
expression in vivo. However, the presented data were generated from one in 
vivo experiment, and larger experiments are required in order to be able to 
draw firmer conclusions about the effects of trauma in the context of a 
mouse model of psoriasis. Importantly, it is also acknowledged that 
incisional trauma does differ significantly from tensile trauma, but the work 
was undertaken within the restrictions of the available applicable Home 
Office licences. It would also be helpful to determine the role of microRNAs 
in the regulation of murine ACKR2 expression in this context. However, there 
are no clear miR-146 orthologs in mice, and the murine ACKR2 3’-UTR is 
significantly different to the human equivalent, and is therefore likely 
regulated by a set of microRNAs that are different to that in humans.  
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Figure 6.1 Schematic diagram of the cell flexing system used in this 
study. 
Schematic representation of the FLexCell™/BioFlex™ cell tension/flexion 
system. 
(c) Cells were grown as confluent monolayers on coated silicone membranes 
(Collagen 1 for KC, Fibronectin for LEC) 
(d) Cyclical tension was applied to the silicone membrane by means of 
adjustable vacuum (12h at 0.8Hz) 
(e) Top view of individual chamber (6-well format) upon application of 
tensile stress 
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Figure 6.2 Diagrammatic representation of the waveform used for the 
application of tensile stress. 
The FlexCell™ system enables adjustment of the duration, rate and 
waveform of the stretching applied. This study used a ½ sine waveform with 
15% effective stretching of the membrane, at 0.8Hz for 12 hours. 
 
  
½ Sine waveform 
12h total (≈54000 cycles) 
15
%
 e
ffe
ct
iv
e 
st
re
tc
h 
0.8Hz 
SHAMS 2016 
	235 
 
Figure 6.3 Representative bright field microscope images of primary 
human lymphatic endothelial cells (LEC) grown on different substrates. 
(a) LEC grown as firmly adherent confluent monolayers on uncoated tissue 
culture polycarbonate (as per cell supplier’s instructions) 
(b) Image illustrating the failure of LECs to attach to silicone, even with the 
pre-treatment of the membrane with Attachment Factor (Sigma). LECs 
also failed to attach to untreated silicone. 
(c) Image illustrating firm adhesion of LEC to Fibronectin coated silicone. 
Cells were always inspected at the end of experiments to ensure that 
they remained attached.  
Data from one experiment, with n=3 wells per substrate. 
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Figure 6.4 Effect of cell growth on Collagen 1 and Fibronectin on ACKR2 
expression. 
Absolute quantification of ACKR2 mRNA, normalised to TBP in;  
(a) Healthy human primary KC grown on Collagen 1 coated silicone for 96 
hours. 
(b) Healthy human primary LEC grown on Fibronectin coated silicone for 96 
hours. 
Significance was assessed using Student's t-test. Data derived from one 
experiment, with n=3 wells per substrate. 
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Figure 6.5 Effect of tensile stress on ACKR2 expression by primary human 
keratinocytes (KC). 
Absolute quantification of ACKR2 mRNA, normalised to TBP, in keratinocytes  
(a) Healthy human primary KC that remained static, or were subjected to tensile 
stress (flexed) at 0.8Hz for 12h, and then allowed to rest for 12h prior to cell 
lysis and RNA extraction. 
(b) Healthy human primary KC that remained static, or were subjected to tensile 
stress (flexed) at 0.8Hz for 12h, and then allowed to rest for 12h prior to cell 
lysis and RNA extraction. KC were treated with either 1) tissue culture 
supernatant from activated human T-cells (1:8 dilution in fresh medium), 2) 
100ng/ml recombinant human IFNγ, or 3) tissue culture supernatant from 
activated human T-cells plus neutralising anti-IFNγ antibodies, overnight prior 
to flexing at 0.8Hz for 12hours. Black bars; non-flexed static controls, grey bars 
flexed cells. 
Significance was assessed using One-way ANOVA. N=3 wells. Data representative of 
two comparable experiments (anti-interferon antibodies used once). 
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Figure 6.6 Effect of tensile stress on miR-146 expression in inflamed 
keratinocytes. 
Fold change in miR-146a and miR-146b expression as assessed by QPCR, and 
normalised to scrambled miR treated static KCs. KC were treated with tissue 
culture supernatant from activated human T-cells (1:8 dilution in fresh 
medium) overnight prior to flexing at 0.8Hz for 12hours. Experiment 
performed once. 
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Figure 6.7 Cytokine treatment of healthy human primary keratinocytes and 
lymphatic endothelial cells. 
Absolute quantification of ACKR2 mRNA, normalised to TBP following 
(a) Treatment of healthy primary human keratinocytes with cytokine for 24 hours 
with IFNγ 10ng/ml; IL-1α 10ng/ml; IL-6 2ng/ml (pre-complexed with 10ng/ml 
sIL-6R); TGF-β 10ng/ml.  
(b) Treatment of healthy primary human lymphatic endothelial cells (LEC) for 24 
hours with IFNγ 10ng/ml; IL-1α 10ng/ml; IL-6 2ng/ml (pre-complexed with 
10ng/ml sIL-6R); TGF-β 10ng/ml.  
(c) Treatment of LEC with tissue culture supernatant from activated and inactive 
human T-cells (dilutions as indicated in figure) 
Statistics: one-way ANOVA with Tukey’s multiple comparisons test. * P<0.05, ** 
P<0.01, **** P<0.0001. Each experiment performed once, n=3 wells per treatment. 
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Figure 6.8 Effect of tensile stress on ACKR2 expression by lymphatic 
endothelial cells.  
Absolute quantification of ACKR2 mRNA levels in lymphatic endothelial cells 
(LEC), normalised to TBP following 
(a) no treatment, or treatment of LEC with IFNγ at 100ng/ml overnight, 
prior to flexing at 0.8Hz for 12h. 
(b) Treatment of healthy primary LEC overnight with tissue culture 
supernatant from activated human T-cells (diluted 1:8 with fresh 
medium) prior to flexing. 
Statistics: (a) one-way ANOVA with Tukey’s multiple comparisons test 
and (b) Student’s t-test. **** P<0.0001. Experiment performed once. 
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Figure 6.9. Effect of incisional skin trauma in vivo on ACKR2 expression 
(a) Diagrammatic representation of the experimental design. One shaved 
mouse flank was treated with topical imiquimod (Aldara™ cream) daily 
for 3 days, with concurrent systemic IFNγ injections at 20,000U twice 
daily as indicated. This protocol had been previously shown to 
significantly upregulate ACKR2 expression in remote contralateral flank 
skin. Subsequently, and area was incised (down to superficial dermis), 
and the mice culled 24 hours later. Similarly treated mice that had not 
had their skin incised acted as a negative control. 
(b) Absolute quantification of ACKR2 mRNA normalised to 18S in untreated 
whole mouse skin and  incised skin. 
Statistics: Paired Student’s t-test *** P<0.005. The data presented represents 
one experiment. 
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6.5 Summary Chapter 6 
This chapter reports for the first time that tensile trauma of inflamed human 
KC leads to a rapid reduction in ACKR2 expression. Concurrently, it reports 
that tensile trauma substantially upregulated the psoriasis-associated miR-
146. This miR was shown, in the previous chapter, to bind the ACKR2 3’-UTR 
and downregulated ACKR2 in keratinocytes (KC).  
Previous studies have shown that expression of ACKR2 is elevated in 
clinically unaffected skin of patients with psoriasis. Concurrently, expression 
of ACKR2 is relatively deficient in psoriatic plaques, although the mechanism 
for this downregulation had not been elucidated. Indeed, previous chapters 
of this thesis demonstrated that a lack of ACKR2 in vivo enables unrestricted 
CD3+ T-cell entry into the epidermis, and enhanced psoriasiform 
inflammation. Previous work has shown that tape stripping of unaffected 
psoriatic skin in humans leads to a rapid (24h) downregulation of ACKR2 
expression in the traumatised skin.  
Importantly, trauma as a downregulator of ACKR2 expression could provide, 
for the first time, a mechanism for so called koebnerisation. Koebnerisation 
is a phenomenon that has been described in psoriasis (and some other skin 
conditions) where trauma to unaffected skin leads to the development of 
skin lesions associated with the underlying condition. Furthermore, it is 
noteworthy, that psoriatic plaques tend to have a predilection for body sites 
that undergo repeated (tensile) stress due to day-to-day movement, e.g. 
elbows and knees. For these reasons, this chapter set out to examine the 
effect of tensile trauma on ACKR2 expression in the main ACKR2 expressing 
cells in the skin; keratinocytes (KC) and lymphatic endothelial cells (LEC). To 
enable this, a reductionist in vitro model of tensile skin trauma was 
developed, that enabled the study of tensile stress in isolation. It is however 
acknowledged that skin trauma has many elements, including compressive 
force, whilst incisional trauma is associated with complex wound repair 
processes. 
In order to study the effect of cell tension on ACKR2 expression, the 
FlexCell™ FX5000 system was used, which enables repeated cyclical 
stretching of cells grown on flexible silicon membranes. Using this approach, 
both KC and LEC were subjected to tensile trauma, but this was found to 
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have no effect on ACKR2 expression in healthy cells. However, psoriasis is 
widely considered to be a systemic inflammatory disorder, with significant 
changes also in apparently unaffected skin (Xie et al. 2014).  Furthermore, 
there are elevated levels of Th1/Th17 cytokines in the circulation of patients 
with psoriasis (need reference). Thus, in order to better recapitulate the in 
vivo situation, KC and LEC were both pre-treated with IFNγ or conditioned 
medium from activated human T-cells, both of which are known to 
upregulate ACKR2. When such inflamed KC and LECs were subjected to the 
same degree of tensile trauma, there was a rapid and significant reduction in 
ACKR2 expression in KC but not in LEC. These results are in keeping with 
cyclical tensile trauma in the context of inflammation reducing ACKR2 
expression on KC. 
Additionally, the preceding chapter of this thesis demonstrated that the 
psoriasis-associated miR-146 bound directly to the 3’-UTR of ACKR2 and 
downregulated its expression at transcript and protein level. Results in this 
chapter demonstrated that there was a substantial and significant increase 
in the expression of miR-146a/b in inflamed KC that had been subjected to 
tensile trauma, as compared to static KC. It is possible that it is this 
upregulation of miR-146a/b that drives the downregulation of ACKR2, 
although further studies (e.g. using antagomirs in similar future 
experiments) are required to ascertain whether this association is causative. 
Critically, these findings outlined in this and previous chapters provide for 
the first time a possible molecular mechanism for koebnerisation. It is 
hypothesised that cutaneous trauma leads to a rapid downregulation of 
ACKR2 in apparently unaffected skin; the downregulation in turn enables 
unrestricted T-cell recruitment (due to deficient ACKR2 scavenging of pro-
inflammatory CC-chemokines), and unrestricted inflammation.  
Whilst it is known that tape stripping of human unaffected psoriatic skin 
leads to a downregulation of ACKR2, there have been no animal models in 
which this can be further studied. In this chapter, preliminary results show 
that incisional trauma led to a rapid downregulation of ACKR2 in apparently 
unaffected skin of mice, in the well-established IMQ mouse model of 
psoriasis. The model outlined in this chapter, if further developed and 
validated, might enable the detailed study of koebnerisation in vivo in the 
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future. It is additionally noteworthy, that IFNγ administered systemically in a 
mouse model of psoriasis in previous chapters, was associated with reduced 
psoriasiform inflammation in WT, but not ACKR2 deficient mice. It is thus 
possible, that trauma to skin cells in the context of IFNγ associated 
inflammation, would lead to a reduction of ACKR2 expression and thus 
enhanced inflammation. This hypothesis is still to be explored in vivo in 
future studies. 
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7 General discussion 
 
Chemokines are chemotactic cytokines and have emerged as the principal 
regulators of leukocyte migration and inflammation (Griffith, Sokol & 
Luster 2014). The atypical chemokine receptor 2 (ACKR2, formerly D6) 
binds most pro-inflammatory CC-chemokines, but in contrast to 
conventional chemokine receptors, does not signal through G proteins 
upon ligand binding. Instead, ACKR2 internalises and helps degrade CC-
chemokines. In doing so, ACKR2 acts as a chemokine scavenger that has a 
known role in regulating inflammation in vivo (Weber et al 2004). In the 
absence of ACKR2, inflammatory responses are dysfunctional in a number 
of in vivo models, although the mechanistic basis by which ACKR2 
functions is still to be clarified (Di Liberto et al. 2008; Nibbs & Graham 
2013; Nibbs et al. 2007; Berres et al. 2009). 
Previous studies have shown a marked difference in ACKR2 expression in 
human psoriatic plaque skin, as compared to apparently unaffected skin 
from the same individuals. ACKR2 is particularly highly expressed in basal 
epidermal keratinocytes (KC) in non-lesional skin of psoriatic patients 
(Singh et al. 2012). Given the capacity of ACKR2 for scavenging pro-
inflammatory CC-chemokines, it was hypothesised that high ACKR2 
expression protects against inflammation. In contrast, it was hypothesised 
that reduced ACKR2 expression in psoriatic patients could lead to 
exaggerated responses to exogenous inflammatory cues and thus 
precipitate the development of a psoriasiform plaque. One such known 
exogenous cue is trauma, which can trigger the development of psoriatic 
lesions (so called koebnerisation) in some patients. Indeed, we have 
previously shown trauma to psoriatic skin to trigger a rapid down-
regulation of ACKR2 expression in the skin (Singh et al. 2012).  
In order to study the role of ACKR2 in vivo, a mouse model suitable for 
assessing differential ACKR2 expression in skin was established. 
Specifically, the well-established imiquimod (IMQ) mouse model was 
chosen as the basis for this model, as it shares key similarities with human 
psoriasis, enables the induction of psoriasiform plaques at specific skin 
sites, and is typically conducted in the same strain into which ACKR2-/- 
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mice are back-crossed (C57BL/6) (van der Fits et al. 2009). In this model, 
repeated application of the imiquimod cream Aldara™ leads to the rapid 
induction of psoriasiform skin plaques in wild-type (WT) C57BL/6 mice 
(van der Fits et al. 2009). In order to examine whether human ACKR2 
expression patterns could be replicated in the IMQ model, ACKR2 mRNA 
expression was determined in whole skin. Data showed that ACKR2 
expression in IMQ treated mouse skin was reduced (analogous to the 
relative ACKR2 deficiency seen in human psoriatic plaques (M. D. Singh et 
al. 2012)). Additional ex vivo whole mouse explant studies suggested that 
the active drug imiquimod, rather than another component of Aldara™ 
cream alone, can reduce ACKR2 expression in a dose-dependent manner. 
This is of significance, as there is an increasing recognition that Aldara™ 
cream modulates immune responses through other mechanisms than that 
induced by imiquimod alone (Walter et al. 2013). 
In order to study, in detail, the dynamics of psoriasiform skin changes in 
this mouse model, a new scoring system of severity of psoriasiform 
inflammation was developed. This was broadly based on the human 
Psoriasis Area Severity Index (Fredriksson & Pettersson 1978), and is 
henceforth termed mPASI (0=normal skin, 12=most severe inflammation). 
Though some scoring systems of psoriasiform change in mice have been 
used in the literature, the criteria for scoring are often inadequately 
detailed/lacking altogether, and the scores are not validated against 
objective histopathological changes (van der Fits et al. 2009). In order to 
validate the mPASI defined here, the score was shown to significantly 
correlate with both epidermal thickening and KC hyperproliferation (as 
measured by staining for the cell proliferation marker Ki67). This is in 
keeping with the novel mPASI being a reliable clinical marker of 
histological features seen in psoriasiform inflammation in vivo.  
IMQ induced rapid psoriasiform inflammation in WT C57BL/6 mice in these 
experiments. Whilst there are no differences in skin histology between 
ACKR2-/- and WT mice at rest (Nibbs et al. 2007), data showed that IMQ 
induced rapid psoriasiform skin changes that are significantly more severe 
in ACKR2-/- mice as compared to WT mice. Human psoriasis is 
characterised by both increased epidermal thickening, hyperkeratosis and 
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keratinocyte hyperproliferation (Griffiths & Barker 2007). In keeping with 
human psoriasis, IMQ treatment in mice led to significant epidermal 
thickening (acanthosis), enhanced hyperkeratosis and enhanced KC 
proliferation in ACKR2-/- and WT mice. Importantly, quantification of 
histological skin changes demonstrated significantly more severe psoriasis-
associated changes in ACKR2-/- as compared to WT mice. Furthermore, 
the mPASI score increased more quickly, and reached a higher total, in 
ACKR2-/- as compared to WT mice. Overall, these results are in keeping 
with ACKR2 playing a role in limiting psoriasiform inflammation in a 
human disease-relevant murine model of psoriasis. 
Psoriasis is increasingly considered to be a systemic condition, associated 
with excess cardiovascular and hepato-metabolic co-morbidities (Di Meglio 
et al. 2014; Roberts et al. 2014). For instance, prognosis of those with 
psoriasis is significantly worse following a myocardial infarction (Ahlehoff 
et al. 2011), and there is an increased prevalence of fatty liver disease in 
those with psoriasis (Roberts et al. 2014). Additionally, previous work on 
the IMQ model showed an enlargement of the spleen of mice treated with 
IMQ (van der Fits et al. 2009). For these reason, ACKR2 mRNA expression 
was additionally assessed in the heart, liver, spleen and skin draining 
lymph nodes in mice. Results showed a significant upregulation of ACKR2 
in the heart and liver at day 7 in this model. Also, there was a significant 
increase in ACKR2 mRNA in non-draining (contralateral) inguinal lymph 
nodes of mice treated with IMQ, though this increase was small. In 
contrast, ACKR2 expression in the spleen is significantly reduced both at 
Days 4 and 7 in this model. The functional implications of these findings 
have yet to be determined and it will be important to explore whether 
reduced ACKR2 in remote tissues affect predisposition to inflammatory 
disorders. Relatively poor prognosis following a myocardial infarction (as 
seen in psoriasis (Ahlehoff et al. 2011)) may indicate aberrant regulation 
of inflammation, and it is possible that whilst ACKR2 expression is 
increased in e.g. the heart and liver in order to help limit inflammation, 
this increase may be insufficient to adequately limit inflammation. 
Additionally, it would be helpful to determine the precise site within the 
heart and liver where ACKR2 expression is increased, which may provide 
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insights into the possible functional relevance of its differential regulation 
in these organs. This is however not achievable at present e.g. through 
immunohistochemistry, as no antibodies are available that reliably detect 
ACKR2 in mice. One possibility would be to perform laser capture of 
specific tissue compartments, on which QPCR for ACKR2 transcript could 
be performed. Additionally, it would be interesting to induce 
inflammation in the heart and liver of mice in which ACKR2 expression has 
been induced, to assess the functional relevance of these observations in 
vivo. It should also be highlighted that whilst psoriasis is a chronic life-
long disorder in humans, the observations here are over a relatively short 
period (7 days), and further longer-term time points would give us a 
better understanding of the long-term effects of skin inflammation on 
heart and liver tissue ACKR2 expression. Assessing the relevance of 
reduced ACKR2 expression in the spleen is more challenging, as a 
considerable amount of transcript is likely derived from leukocytes. These 
in turn are known to express ACKR2 (Graham & Locati 2013), and their 
migratory and heterogeneous nature makes analysis of ACKR2 expression 
in the spleen (and indeed lymph nodes) challenging. 
Psoriasis pathology is a T-cell (notably Th1/Th17) driven condition (Di 
Meglio et al. 2014). In order to examine T-cells in the mouse IMQ model of 
psoriasis, mouse skin was stained for CD3+ T-cells and the effect of ACKR2 
on T-cell positioning determined. Previous studies have shown that there 
are no significant differences between ACKR2-/- and WT mice at rest 
(Jamieson et al. 2005). Results here showed that whole skin CD3+ T-cell 
numbers are increased in the skin of both ACKR2-/- and WT mice upon 
treatment with IMQ. However, whilst CD3+ cells were largely excluded 
from the epidermis in WT mice, a high proportion of CD3+ T-cells were 
able to migrate and become positioned in the epidermis at both day 4 and 
7 in ACKR2-/- mice in this model. Indeed, psoriasiform inflammation is 
critically dependent on T-cell migration from the dermis into the 
epidermis in vivo (Conrad et al. 2007), and these data suggest that ACKR2 
plays a role in excluding CD3+ T-cells from the epidermis. These data 
suggest, for the first time, that ACKR2 plays a role in excluding T-cells 
from the epidermis during (IMQ-induced) psoriasiform inflammation. 
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Whilst previous studies have shown that the application of the phorbol 
ester TPA onto dorsal skin of ACKR2-/- mice leads to more florid 
inflammation compared to WT mice and a relative T-cell exclusion from 
the epidermis (Jamieson et al. 2005). However, whilst TPA that used in 
that particular study is an irritant, it does not induce inflammation that 
resembles psoriasis in C57BL/6 mice (either WT or ACKR2-/-).  
The mechanism by which ACKR2 regulates the above observed T-cell 
epidermal localisation is not known. However, it is known that ACKR2 is 
predominantly expressed in basal epidermis/KCs (Singh et al. 2012), and 
that ACKR2 has the capacity to scavenge pro-inflammatory CC-chemokines 
(Weber et al 2004). KCs form a confluent proliferating cell layer that 
separates the dermis from the epidermis. CC-chemokines released in the 
epidermis thus need to form a chemotactic gradient that extends past the 
basal KCs, and into the dermis, in order to effectively recruit CC-
chemokine receptor expressing leukocytes into the epidermis. It was 
hypothesised that ACKR2 expression by KCs creates defined areas of skin 
tissue that lack bioavailable inflammatory CC-chemokines, and so 
preventing the influx of leukocytes. In order to test whether ACKR2 
expressed by KC can limit T cell migration past the dermal-epidermal 
interface, we established a novel in vitro model of T-cell migration. 
Whilst numerous chemokines are associated with psoriasis, CCL5 was 
selected as it is 1) associated with psoriasis pathogenesis and 2) is known 
to bind ACKR2 and 3) can attract inflammatory T-cells (CCL20 was not 
chosen for study as it is not bound by ACKR2). Data presented here 
suggest that high-ACKR2 expressing cells (both ACKR2 transfected HEK293 
cells and IFNγ treated primary human KC), when placed between a CCL5 
containing collagen matrix and T cells, restricted T-cell migration towards 
the CCL5 stimulus. In contrast, where ACKR2 expression is absent (HEK293 
cells) or low (resting primary human KCs), T-cell migration and 
directionality towards the source of CCL5 across the cellular layer appears 
unaffected. This would in keeping with ACKR2 acting to prevent the free 
formation of a chemotactic CCL5 gradient, however, this experiments was 
performed once, and should be repeated to ensure the results are 
reproducible before drawing firm conclusions.  
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These observations in turn would tie in with the in vivo observations, that 
CD3+ T-cells are excluded from the epidermis in psoriasiform 
inflammation where ACKR2 is expressed, but can enter unrestricted in 
ACKR2-/- mice. It would be helpful for such experiments to be repeated 
with a broader range of psoriasis associated CC-chemokines that are also 
known to bind ACKR2 in order to more comprehensively understand in 
which contexts ACKR2 expression can restrict epidermal T-cell entry in 
the manner described above. 
ACKR2 expression is relatively deficient in psoriatic plaques (Singh et al. 
2012), and it has been shown in this thesis that a lack of ACKR2 is 
associated with more severe psoriasiform inflammation. In order to 
understand the molecular mechanism by which ACKR2 expression is 
negatively regulated, microRNAs were identified in silico that were 
predicted to bind the ACKR2 3’-UTR and that were shown to be 
differentially regulated in previous publications. MicroRNAs are, in the 
main, negative regulators of gene expression, bind the 3’-UTR of their 
mRNA target and lead to its degradation (Pasquinelli 2012). Data showed 
that miR-146 and miR-10 reduce ACKR2 mRNA and protein expression in 
keratinocytes (KC) and lymphatic endothelial cells (LEC) respectively and 
that they bind directly to the ACKR2 3’-UTR. The functional significance 
of the degree of reduction is however unknown. This is the first time a 
negative regulator of ACKR2 expression has been identified.  
Our previous data additionally showed that simple skin trauma (in the 
form of tape stripping, where adhesive tape is repeatedly attached to skin 
and peeled off) of clinically unaffected human skin in patients with 
psoriasis, reduced ACKR2 mRNA expression (Singh et al. 2012). 
Additionally, it is recognised that psoriatic plaques have a predilection for 
skin that undergoes repeated tension, e.g. skin overlying elbows and 
knees (Lebwohl 2003). An in vitro model was therefore developed that 
enabled the study of the effect of tensile trauma on primary human skin 
cells. Results showed that tensile trauma of inflamed KC led to a rapid 
downregulation of ACKR2 expression. Additionally, there was a concurrent 
substantial and significant (>100-fold) upregulation of miR-146 in such 
cells that have been subjected to tensile stress. It is possible that miR-146 
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upregulation is a mechanism by which ACKR2 expression is reduced focally 
in skin that has been traumatised. It would be helpful to determine the 
causality of this association, for instance through the use of antagomirs to 
inhibit miR-146 upregulation upon the application of tensile cell stress. 
Whilst reductionist tensile stress experiments in vitro provide insights into 
the specific effects of tensile stress on cells, they will not fully capture 
the complex cell-cell interactions in vivo. Preliminary in vivo experiments 
in mice did however also suggest that trauma to skin (albeit in the form of 
incisional injury, rather than tape stripping), where ACKR2 expression had 
been previously induced, led to a rapid downregulation of ACKR2 
expression. This provides the basis of an animal model in which negative 
ACKR2 regulation (and koebnerisation) can be studied in vivo, and could 
be expanded to test specifically the effect of tensile trauma in vivo. 
However, this model needs to be further validated and developed. 
Experiments were, in general, conducted such that multiple techniques 
were used to demonstrate a specific finding. For instance, the effect of 
microRNAs on ACKR2 expression was demonstrated by Q-PCR of primary 
human cells, by immunocytochemistry of primary cell monolayers and by 
Western blotting (Chapter 5). It is acknowledged however, that where 
specific experiments were performed once in the thesis, the results 
should be treated with some caution. Indeed, it is important for further 
experiments to be undertaken to ascertain their reproducibility, before 
drawing firm conclusions. For experiments that assayed gene expression, 
further repeats would also enable more reliable comments to be made 
about the extent of up/down-regulation e.g. for Western blot experiments 
and immunocytochemistry (Chapter 5). This is also the case for leukocyte 
migration experiments in Chapter 3. 
For cell culture experiments (Chapters 5 and 6), all experiments were 
performed as 3 replicates (e.g. tissue culture wells, tissue culture flasks), 
and individual biological samples analysed by quadruplicate by Q-PCR. 
However, it should be borne in mind that there are inherent biological 
differences between individuals, and though cell culture experiments 
were in general performed with primary cells from at least two different 
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human donors, increased donor numbers would have enabled a more 
thorough assessment on whether the presented data are generalizable.  
In the laboratory where this work was performed, no litter-mates were 
available for the ACKR2-/- mice used (Chapters 3, 4 and 6). The control 
mice were therefore purchased, and it is acknowledged that (although 
they were one the same strain) differences could exist between the 
ACKR2-/- and purchased WT in terms of e.g. microbiota, diet and living 
environment prior to the experiments. Attempts were made to limit this 
source of bias, through co-housing the mice for at least one week prior to 
experiments. In future experiments, it would be helpful to breed and 
house control littermates alongside ACKR2-/- mice, to reduce this 
potential confounding variable. 
For many experiments, ACKR2-/- numbers available were extremely 
limited (due to substantial difficulties with breeding adequate mouse 
numbers, and multiple users in the group). In particular, for key 
experiments where ACKR2-/- and WT mice were directly compared 
(Chapter 4) it would be important to repeat experiments more times, in 
order to ascertain reproducibility.  
 
Current therapeutic strategies generally block T-cells and/or T-cell 
derived cytokines with variable specificity (Di Meglio et al. 2014). Though 
many of these are effective in alleviating symptoms, almost all anti-
psoriatic therapies currently available are broadly immunosuppressive, 
and thus are associated with related averse effects, including increased 
risk of systemic infections and cancer (Di Meglio et al. 2014). The findings 
and hypotheses presented herein provide a novel means of limiting 
inflammation; by developing specific inducers of ACKR2 function, it may 
become possible to limit T-cell entry into the epidermis and thus the 
development of psoriasiform skin lesions. The rationale for such an 
approach is clearly demonstrated by the presented in vivo experiments, in 
which induced ACKR2 expression appeared to protect against psoriasiform 
inflammation. Such a therapeutic strategy would have the benefit of 
leaving the inherent function of T-cells intact (unlike most current 
therapies); instead targeting inflammation through modulating the T-cell 
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positioning in tissues. A topically applied agent capable of enhancing 
ACKR2 function would likely limit this effect largely to the skin, reducing 
potential adverse effects yet further. Such a future therapeutic approach 
would enhance (or at least maintain) the body’s apparent endogenous 
means for limiting the spread of inflammation, that appear to fail at focal 
sites (e.g. through trauma), thus leading to exaggerated inflammation and 
plaque development. 
Together, the presented data support the notion that ACKR2 induction 
may limit psoriasiform inflammation. However, further experimental work 
is required before the therapeutic potential of ACKR2 modulation in this 
context can be fully understood. It is particularly necessary to repeat 
experiments where ACKR2-/- and WT mice are directly compared, with 
further experimental repeats, including larger numbers of mice to 
ascertain reproducibility. Additionally, future experiments need to focus 
on functional effects of differential ACKR2 expression; e.g. data 
presented herein suggest certain microRNAs in vitro downregulate ACKR2 
to a degree, and separate preliminary data also suggest that skin trauma 
in psoriasiform inflammation may downregulate ACKR2. However, these 
particular studies were not functional, and future experiments need to 
ascertain the effect of this downregulation on ACKR2 function in vivo.  
Furthermore, though IFNγ was used as a tool to induce ACKR2 in vivo, 
using IFNγ as a therapeutic strategy in psoriasis is fraught with difficulty 
due to likely pro-inflammatory off§-target effects. Instead, it would be 
necessary to develop an agonist of ACKR2 function (rather than merely 
expression), that is capable of scavenging CC-chemokines in vivo. A high-
throughput screening assay enabling the screening of validated compound 
libraries would be helpful. It would be particularly useful to perform such 
a screen in either primary cells, or in vitro skin equivalents, to better 
replicate the in vivo human situation. Identified compounds would 
subsequently provide a powerful tool for further studying the therapeutic 
potential for ACKR2 modulation both in vitro (e.g. update assays) and in 
vivo.  It is noted however, that differences between mice and humans in 
terms of ACKR2 regulation, which are poorly defined, may provide 
particular challenges. Furthermore, the regulation of ACKR2 function is 
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not well understood and it is difficult to predict the pharmacological 
nature of such an agonist, through a small molecule compound could 
potentially be topically administered to skin, thus limiting systemic side 
effects.  
The data presented herein suggests that ACKR2 may play a role in 
determining the positioning of T-cell in skin, and that this is associated 
with differences in the degree of inflammation. A causative link is 
possible, but has not been proven. Future studies will need to study the 
functional significance of T-cell positioning, both in terms of e.g. 
inflammatory chemokines/cytokines produced, but also in terms of T-cell 
cross-talk with other key psoriasis associated cells, including keratinocytes 
and dendritic cells. Critically also, little is known about what chemokines 
drive the early and chronic phases of psoriasis pathogenesis, and a better 
understanding of the role of chemokines (and in particular CC-chemokine 
ligands of ACKR2) would be pivotal in determining the therapeutic 
potential of ACKR2 modulation. 
The presented data suggest that focal inflammation, modulates 
inflammatory responses in remote skin through modulation of ACKR2 
expression. However, these changes are likely to occur over longer 
periods of time than that studied here; therefore, it would also be 
important to determine whether the differences noted between wild type 
and ACKR null mice are also apparent over a longer period of time. In 
addition, the observed effect of focal inflammation on remote skin needs 
to be studied in greater detail. It would additionally be particularly 
interesting to determine the effect of focal inflammation on resident T-
cell populations in remote skin, and how any such changes may affect 
subsequent inflammatory processes.  
Together, results presented in this thesis provide novel insights into the 
role of ACKR2 in psoriasiform inflammation, which are summarised 
schematically in Figure 7.1. ACKR2 plays a role in restricting epidermal T-
cell entry and thus psoriasiform inflammation. Critically, the data provide 
a mechanism whereby spread of inflammation is restricted; one site of 
skin inflammation, leads to the upregulation of ACKR2 in remote 
unaffected skin, likely through soluble Th1/Th17 cytokines, and in 
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particular circulating IFNγ. This upregulation prevents the spread of 
psoriasiform inflammation to those sites. This upregulation can however 
be overcome by tensile trauma, that leads to a rapid downregulation of 
ACKR2 in keratinocytes. Specifically, microRNAs act as negative regulators 
of ACKR2, with tensile trauma being one factor that leads to the 
upregulation of microRNAs capable of downregulating ACKR2 expression. 
The findings presented provide a rationale for developing specific agonists 
of ACKR2 function, for the treatment and prevention of psoriasiform 
inflammation. 
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Figure 7.1 Schematic summary of main findings. 
1) ACKR2 expression is increased in epidermal keratinocytes (KC) represented in red 
2) Where basal epidermal KC ACKR2 expression is high, this leads to a clearance of 
epidermal-dermal chemotactic CC-chemokine gradients (clearance moss green 
shading). This limits CD3+ T-cell (orange ovals) entry into the epidermis. 
3) Where ACKR2 is deficient (e.g. due to tensile trauma, miR-146), this leads to 
unrestricted chemotactic chemokine gradient formation (dark green) 
4) This leads to enhanced CD3+ migration into the epidermis, release of pro-
inflammatory factors, epidermal hyperproliferation, thickening and typical 
psoriasiform changes. Systemic release of Th1/Th17 cytokines will act to upregulate 
ACKR2 expression at remote skin sites. This in turn, protects such remote sites from 
the spread of psoriasiform inflammation 		
1 3 
4 
2 
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